{"c676aeddbec74ae3fadeeedcfcff34c69d5170b7": [["For Period I, the estimated peak infected cases were smaller than the observed ones, the peak date was earlier than the observed one, and the \u0734 was about 4.66.", [["Period I", "PROTEIN", 4, 12], ["the estimated peak infected cases", "PROBLEM", 14, 47], ["peak", "OBSERVATION_MODIFIER", 28, 32], ["infected", "OBSERVATION", 33, 41], ["smaller", "OBSERVATION_MODIFIER", 53, 60]]], ["For the other two periods, the estimated cases were more, and the peak dates were earlier than the observed ones.", [["the peak dates", "TEST", 62, 76]]], ["TheIntroduction14 (Period III).", [["Period III", "PROTEIN", 19, 29]]], ["The Japanese government gradually enforced more rigorous countermeasure for COVID-19 containment through these three periods.", [["COVID-19 containment", "TREATMENT", 76, 96]]], ["For instance, on Feb 26, large-scale sports and entertainment events were canceled throughout Japan, and organizers of small-scale events were advised to voluntarily cancel events (Prime Minister of Japan and His Cabinet, 2020b).", [["Feb", "TEST", 17, 20], ["entertainment events", "PROBLEM", 48, 68], ["small-scale events", "PROBLEM", 119, 137], ["small", "OBSERVATION_MODIFIER", 119, 124]]], ["On Apr 7, emergency declaration was first declared to seven prefectures by Prime Minister of Japan, and were gradually declared to other prefectures ( Figure 1 ) (Prime Minister of Japan and His Cabinet, 2020b).MethodTo illustrate the effects of NPIs on the dynamics of the epidemic, we developed a simple Susceptible-Infectious-Recovered-Deceased (SIRD) Model (Osemwinyen & Diakhaby, 2015) of COVID-19 transmission.", [["NPIs", "SIMPLE_CHEMICAL", 246, 250], ["COVID-19", "CELL", 394, 402], ["COVID-19", "SPECIES", 394, 402], ["NPIs", "TREATMENT", 246, 250], ["COVID", "TEST", 394, 399], ["Infectious", "OBSERVATION", 318, 328]]], ["This model assumes that the total population of reference is constant.", [["total", "OBSERVATION_MODIFIER", 28, 33], ["population", "OBSERVATION_MODIFIER", 34, 44], ["constant", "OBSERVATION_MODIFIER", 61, 69]]], ["The population is divided into several different compartments (i.e., susceptible, infective, recovered, deceased) and specify how agents move across the separate compartments over time.", [["infective", "PROBLEM", 82, 91], ["population", "OBSERVATION_MODIFIER", 4, 14], ["infective", "OBSERVATION_MODIFIER", 82, 91]]], ["The model assumes that susceptible individuals can become infectious after contact with an infectious individual, and recovered individuals cannot be re-infected.", [["individuals", "ORGANISM", 35, 46], ["susceptible individuals", "PROBLEM", 23, 46], ["infectious", "OBSERVATION_MODIFIER", 58, 68]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 23, 2020. are the rates of infection, recovery, and mortality, respectively.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 288, 297], ["The copyright holder", "TREATMENT", 198, 218], ["infection", "PROBLEM", 288, 297], ["med", "ANATOMY", 102, 105], ["infection", "OBSERVATION", 288, 297]]], ["In addition, a key parameter regulating the dynamics of an epidemic is the basic reproduction number (\u0734 ), which correspondes to the average number of secondary cases generated by an index case in a fully susceptible population (Zhang et al., 2020) .(which was not certified by peer review)Using the SIRD model, we calculated the peak number of existing infected cases and the peak date.", [["infected", "OBSERVATION", 354, 362]]], ["We compared the differences between estimated results and official reports, in order to estimate the effects of NPIs.", [["NPIs", "TREATMENT", 112, 116]]], ["According to the basis of plausible ranges from the recent reports of COVID-19 data (Bhatraju et al., 2020; Geleris et al., 2020; Guan et al., 2020; Li et al., 2020; Mehra, Desai, Kuy, Henry, & Patel, 2020; , we consider that the average incubation period ranges from 2 to 14 days (\u07da = 1/14, 1/2] ), the recovery period ranges from 7 to 28 days (\u07db = [1/28 -1/7] ), and the deceased period ranges from 14 to 60 days (\u07e4 = [1/60 -1/14]).(which was not certified by peer review)For the N, which is the total population of the people who may be exposed to the virus, was assumed to range between a baseline value and a maximum value.", [["people", "ORGANISM", 522, 528], ["people", "SPECIES", 522, 528], ["the virus", "PROBLEM", 551, 560], ["a maximum value", "TEST", 612, 627], ["virus", "OBSERVATION", 555, 560]]], ["The baseline value equals to the number of people who received the reverse transcription polymerase chain reaction (RT-PCR) test in Japan.", [["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49], ["the reverse transcription polymerase chain reaction", "TREATMENT", 63, 114], ["RT-PCR", "TEST", 116, 122]]], ["The maximum value equals to the product of \"the baseline value * the average daily number of contacts per Japanese people\".(which was not certified by peer review)For Period I, no rigorous measures were taken to prevent COVID-19.", [["COVID-19", "CHEMICAL", 220, 228], ["people", "SPECIES", 115, 121], ["COVID", "TEST", 220, 225], ["maximum", "OBSERVATION_MODIFIER", 4, 11]]], ["Most of the laboratory-confirmed cases of COVID-19 were reported in large cities such as Tokyo, Yokohama, and Kyoto (Japan Ministry of Health Labour and Welfare, 2020).", [["COVID", "TEST", 42, 47], ["large", "OBSERVATION_MODIFIER", 68, 73]]], ["Thus, we assume that the daily contacts per people in Japan is 18.8, which is the same as that reported in Shanghai (Zhang et al., 2020) .", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50]]], ["The total number of people who received RT-PCR was 1,846 until Feb 25 (Japan Ministry of Health Labour and Welfare, 2020).", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["RT-PCR", "TEST", 40, 46], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Hence,(which was not certified by peer review)For Period II, voluntary event cancellation, school and workplace closures were carried out throughout Japan.", [["workplace closures", "TREATMENT", 102, 120]]], ["The COVID-19 epidemic has already gradually spread to small cities and towns.", [["The COVID", "TEST", 0, 9], ["epidemic", "PROBLEM", 13, 21], ["small", "OBSERVATION_MODIFIER", 54, 59], ["cities", "OBSERVATION_MODIFIER", 60, 66]]], ["Thus, we assume that the daily contacts per people in Japan is 18.8 * 0.7 * 0.5.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50]]], ["The total number of people who received RT-PCR was 46,172 until Apr 6 (Japan Ministry of Health Labour and Welfare, 2020).", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["RT-PCR", "TEST", 40, 46], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Hence,(which was not certified by peer review)For Period III, emergency declaration was declared, and the Japanese government aimed to reduce the daily contacts per people to 20% compared to that before COVID-19 (Prime Minister of Japan and His Cabinet, 2020a CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.", [["2020a CC", "CHEMICAL", 254, 262], ["people", "SPECIES", 165, 171], ["The copyright holder", "TREATMENT", 458, 478], ["med", "ANATOMY", 362, 365]]], ["For each simulation, we produced 50,000 cases of the SIRD model.", [["the SIRD model", "TREATMENT", 49, 63]]], ["We wrote the code package and run the simulation by Python 3.8.The entire period (Jan 22 to May 14)Based on the official reports (JHU CSSE, 2020), the distribution of total confirmed cases and the existing infected cases were shown in Figure 2 .", [["the existing infected cases", "PROBLEM", 193, 220]]], ["Based on these optimal results, we produced the estimated number of existing infected cases, shown in Figure 3 .", [["existing infected cases", "PROBLEM", 68, 91], ["infected", "OBSERVATION", 77, 85]]], ["Our simulation results displayed that the estimated peak number of existing infected cases would be 17,344 on May 26.", [["existing infected cases", "PROBLEM", 67, 90], ["peak", "OBSERVATION_MODIFIER", 52, 56], ["number", "OBSERVATION_MODIFIER", 57, 63], ["infected", "OBSERVATION", 76, 84]]], ["However, the official reports showed that the peak number of existing infected cases was 11,869 on April 27.", [["infected", "DISEASE", 70, 78], ["infected", "OBSERVATION", 70, 78]]], ["These results indicated that 1) NPIs took in Japan might have reduced more than 52% of the average daily number of contacts per people compared to that before COVID-19; and 2) owing .", [["people", "SPECIES", 128, 134], ["COVID", "TEST", 159, 164]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["05.22.20109660 doi: medRxiv preprint to the effects of NPIs, the Japanese society had avoided collapse of medical service.", [["medRxiv", "TREATMENT", 20, 27], ["NPIs", "TREATMENT", 55, 59], ["collapse", "OBSERVATION", 94, 102]]], ["Nevertheless, 3) the capacity of daily RT-PCR may have restricted the reported confirmed cases; and 4) the official reports may have provided the underestimated figure of COVID-19.Period I (Jan 22 to Feb 25)The optimal results of is 5.41, is 25.22, is 53.66, and N is 34,347.", [["daily RT-PCR", "TEST", 33, 45], ["COVID", "TEST", 171, 176]]], ["Based on these optimal results, we produced the estimated number of existing infected cases, shown in Figure 4 .", [["existing infected cases", "PROBLEM", 68, 91], ["infected", "OBSERVATION", 77, 85]]], ["Our simulation results displayed that the estimated peak number of existing infected cases would be 11,010 on Apr 15.", [["existing infected cases", "PROBLEM", 67, 90], ["peak", "OBSERVATION_MODIFIER", 52, 56], ["number", "OBSERVATION_MODIFIER", 57, 63], ["infected", "OBSERVATION", 76, 84]]], ["Compared to the official reports, which showed that the peak number of existing infected cases was 11,869 on April 27, these results indicated that 1) the capacity of daily RT-PCR obviously restricted the reported confirmed cases; 2) the of Period I was higher than that reported in Wuhan prior to the lockdown on 23 Jan (Tian et al., 2020) ; and 3) rigorous countermeasures were obviously required to contain COVID-19.Period II (Feb 26 to Apr 6)The optimal results of is 6.37, is 15.94, is 40.74, and N is 135,262.", [["COVID-19", "CHEMICAL", 410, 418], ["COVID-19", "DNA", 410, 418], ["daily RT-PCR", "TEST", 167, 179], ["COVID", "TEST", 410, 415], ["infected", "OBSERVATION", 80, 88]]], ["Based on these optimal results, we produced the estimated number of existing infected cases, shown in Figure 5 .Period II (Feb 26 to Apr 6)Our simulation results displayed that the estimated peak number of existing infected cases would be 15,992 on May 25.", [["existing infected cases", "PROBLEM", 68, 91], ["Our simulation", "TEST", 139, 153], ["existing infected cases", "PROBLEM", 206, 229], ["infected", "OBSERVATION", 77, 85], ["peak", "OBSERVATION_MODIFIER", 191, 195], ["number", "OBSERVATION_MODIFIER", 196, 202], ["infected", "OBSERVATION", 215, 223]]], ["Compared to the official reports, which showed that the peak number of existing infected cases was 11,869 on April 27, these results indicated that 1) NPIs took in Period II might reduce more than 50% of the daily contacts per people compared to that before COVID-19; 2) owing to the effects of NPIs, the Japanese society had avoided collapse of medical service, which had been seen in Italy during the same period (Remuzzi & Remuzzi, 2020) ; 3) the of Period II was close to that reported in China before March 2020 (Chinazzi et al., 2020) .", [["NPIs", "DISEASE", 295, 299], ["people", "SPECIES", 227, 233], ["COVID", "TEST", 258, 263], ["NPIs", "TREATMENT", 295, 299], ["Remuzzi & Remuzzi", "TREATMENT", 416, 433], ["infected", "OBSERVATION", 80, 88]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.22.20109660 doi: medRxiv preprint 4) the capacity of daily RT-PCR may have restricted the reported confirmed cases.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv preprint", "TREATMENT", 322, 338], ["daily RT-PCR", "TEST", 358, 370], ["med", "ANATOMY", 102, 105]]], ["Based on these optimal results, we produced the estimated number of existing infected cases, shown in Figure 6 .", [["existing infected cases", "PROBLEM", 68, 91], ["infected", "OBSERVATION", 77, 85]]], ["Our simulation results displayed that the estimated peak number of existing infected cases would be 11,972 on May 15.", [["existing infected cases", "PROBLEM", 67, 90], ["peak", "OBSERVATION_MODIFIER", 52, 56], ["number", "OBSERVATION_MODIFIER", 57, 63], ["infected", "OBSERVATION", 76, 84]]], ["Compared to the official reports, which showed that the peak number of existing infected cases was 11,869 on April 27, these results indicated that 1) NPIs took in Period II might have reduced about 80% of the daily contacts per people compared to that before COVID-19; 2) owing to the effects of NPIs, the epidemic transmission may mainly have occurred through family contacts .", [["infected", "DISEASE", 80, 88], ["NPIs", "CHEMICAL", 297, 301], ["people", "SPECIES", 229, 235], ["COVID", "TEST", 260, 265], ["NPIs", "TREATMENT", 297, 301], ["infected", "OBSERVATION", 80, 88]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 23, 2020 . . https://doi.org/10.1101 other than social contacts such as workplace (Zhang et al., 2020) ; and 3) the \u0734 of Period III was close to that reported throughout the entire period, which means that, the capacity of daily RT-PCR during Period III may have satisfied the required numbers.DiscussionWe developed an SIRD model to estimate the peak number of existing infected COVID-19 cases, the peak date, and the \u0734 in different periods.", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 274, 297], ["The copyright holder", "TREATMENT", 198, 218], ["daily RT", "TREATMENT", 484, 492], ["PCR", "TREATMENT", 493, 496], ["med", "ANATOMY", 102, 105], ["infected", "OBSERVATION", 632, 640]]], ["For an aging society like Japan, the most important prediction is the maximum number of patients who will require medical service.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["This prediction is of crucial importance to design for policies of COVID-19 containment in Japanese hospitals and to calculate the time period in which they need to be available.", [["COVID", "TREATMENT", 67, 72]]], ["Meanwhile, as it is the first time to declare large-scale emergency declarations of infectious disease in Japan, the prediction is of fundamental significance to plan for social countermeasures such as NPIs.DiscussionFor the Monte Carlo Simulation, instead of using the total population of Japan as the N population (Sugishita, Kurita, Sugawara, & Ohkusa, 2020) , we used the number of people who received RT-PCR to estimate the developing trends of epidemic transmission.", [["infectious disease", "DISEASE", 84, 102], ["people", "ORGANISM", 386, 392], ["people", "SPECIES", 386, 392], ["infectious disease", "PROBLEM", 84, 102], ["social countermeasures", "TREATMENT", 171, 193], ["NPIs", "TREATMENT", 202, 206], ["RT", "TREATMENT", 406, 408], ["PCR", "TREATMENT", 409, 412], ["large", "OBSERVATION_MODIFIER", 46, 51], ["infectious", "OBSERVATION_MODIFIER", 84, 94]]], ["This method can generate more reliable predictions of the number of existing infected cases than using other methods.", [["other methods", "TREATMENT", 103, 116], ["infected", "OBSERVATION", 77, 85]]], ["Reasons are that, first, we consider that the total confirmed cases are less challengeable for medical service than the existing infected cases.", [["infected", "OBSERVATION", 129, 137]]], ["Studies have reported that, about 80% of COVID-19 patients did not need medical treatment, and thus do not exert any burdens on medical service (Prime Minister of Japan and His Cabinet, 2020a).", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["COVID", "TEST", 41, 46], ["medical treatment", "TREATMENT", 72, 89]]], ["Second, using the number of RT-PCR receivers to predict the peak incident can display the effectiveness of countermeasure policies.", [["RT-PCR", "TREATMENT", 28, 34], ["countermeasure policies", "TREATMENT", 107, 130]]], ["For instance, in Period II, the estimated peak incident is much more serious than the observed fact, meaning that the capacity of daily RT-PCR in Japan cannot satisfy the required numbers.", [["daily RT", "TREATMENT", 130, 138], ["PCR", "TREATMENT", 139, 142]]], ["For instance, based on estimations of the peak incident by Japanese experts, the total hospital beds for COVID-19 patients have increased from about 2,000 in early February to 31,289 in May 2020 (Japan Ministry of Health Labour and Welfare, 2019).DiscussionOur simulation results showed that despite Period I, the estimated peak date could appear 18 to 29 days later than the observed date.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["COVID", "TEST", 105, 110], ["increased", "OBSERVATION_MODIFIER", 128, 137]]], ["The biggest reason might be because of the capability of daily RT-PCR, which directly defines the observed confirmed cases.", [["daily RT-PCR", "TEST", 57, 69]]], ["On Jan 28, the Japanese government announced that the COVID-19 epidemic has been defined as \"a designated notifiable disease\" according to the Law of Infectious Disease and Patient Treatment, and medical treatment expenses of COVID-19 patients will be covered by the national budget (Prime Minister of Japan and His Cabinet, 2020b).", [["Infectious Disease", "DISEASE", 150, 168], ["patients", "ORGANISM", 235, 243], ["Patient", "SPECIES", 173, 180], ["patients", "SPECIES", 235, 243], ["the COVID", "TEST", 50, 59], ["a designated notifiable disease\"", "PROBLEM", 93, 125], ["Patient Treatment", "TREATMENT", 173, 190], ["medical treatment expenses", "TREATMENT", 196, 222], ["COVID", "TREATMENT", 226, 231], ["Infectious", "OBSERVATION", 150, 160]]], ["Owing to stable and high-qualified medical service, the Japanese society seems to successfully have discharged COVID-19 patients and have avoided collapse of hospital service.DiscussionAccording to our simulation results, \u0734 in Period II is about 2.50, which is similar to that reported by previous studies in China and Italy (Chinazzi et al., 2020; Remuzzi & Remuzzi, 2020; Zhang et al., 2020) .", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["stable", "OBSERVATION_MODIFIER", 9, 15], ["collapse", "OBSERVATION", 146, 154]]], ["Nevertheless, \u0734 throughout the entire period was a smaller number as of 1.79.", [["smaller", "OBSERVATION_MODIFIER", 51, 58]]]], "PMC7320017": [["Critical slowing down ::: IntroductionOur analysis is based on the theory of Critical Slowing Down (CSD) in physical systems and on the use of the instability indicators (in particular, first order autoregressivity (AR1) and variance) employed by Diks Hommes and Wang (2015)37 and others38.", [["IntroductionOur analysis", "TEST", 26, 50], ["Critical Slowing Down (CSD) in physical systems", "PROBLEM", 77, 124], ["the instability indicators", "PROBLEM", 143, 169], ["slowing", "OBSERVATION_MODIFIER", 9, 16], ["Slowing", "OBSERVATION_MODIFIER", 86, 93]]], ["CSD theory is sufficiently general that it can be applied to any time-periodic system comprised of deterministic and stochastic components.", [["deterministic and stochastic components", "PROBLEM", 99, 138], ["stochastic components", "OBSERVATION", 117, 138]]], ["CSD theory has been applied to a wide range of datasets in various fields of research, including Climate Physics41 and Finance37; however, CSD analysis has not been previously used to examine national macro datasets such as GDP.", [["GDP", "CHEMICAL", 224, 227], ["GDP", "CHEMICAL", 224, 227], ["GDP", "SIMPLE_CHEMICAL", 224, 227], ["GDP", "PROTEIN", 224, 227], ["CSD analysis", "TEST", 139, 151]]], ["CSD analysis provides a measure of the change in the characteristics of variability as highlighted by spectral analysis and suggested by the literature18\u201320 (Fig. 1).", [["CSD analysis", "TEST", 0, 12], ["spectral analysis", "TEST", 102, 119]]], ["Preliminary work (by the authors) suggests that CSD behaviour may be present in GDP time-series (Fig. 1).Critical slowing down ::: IntroductionCSD behaviour as outlined by Wiessenfeld (1985)39 and Wisel (1984)40 is best described with an abstract example of an oscillating system.", [["GDP", "CHEMICAL", 80, 83], ["GDP", "SIMPLE_CHEMICAL", 80, 83], ["CSD behaviour", "PROBLEM", 48, 61], ["slowing", "OBSERVATION_MODIFIER", 114, 121]]], ["Consider an object that is suspended between two springs, in a windy environment (the spring-object-spring system; Fig. 2a).", [["object", "OBSERVATION", 12, 18]]], ["If the springs are strong (strong restoring), the oscillations are fast and small.", [["small", "OBSERVATION_MODIFIER", 76, 81]]], ["If the springs are weak (weak restoring), the oscillations are slow and large.", [["weak", "PROBLEM", 19, 23], ["slow", "OBSERVATION_MODIFIER", 63, 67], ["large", "OBSERVATION_MODIFIER", 72, 77]]], ["If the relative strength of the springs becomes weaker over time, then the oscillations of the system transition from small and fast to large and slow (Fig. 2b).", [["small and fast to large and slow (Fig.", "PROBLEM", 118, 156], ["strength", "OBSERVATION_MODIFIER", 16, 24], ["small", "OBSERVATION_MODIFIER", 118, 123], ["large", "OBSERVATION_MODIFIER", 136, 141]]], ["This transition is characteristic of CSD behaviour.", [["CSD behaviour", "PROBLEM", 37, 50], ["CSD", "OBSERVATION", 37, 40]]], ["An additional example is given in Supplementary Material.Critical slowing down ::: IntroductionA premise of our own study is that CSD theory may also be applicable to economic systems.", [["our own study", "TEST", 108, 121], ["slowing", "OBSERVATION_MODIFIER", 66, 73]]], ["In the next section, we describe some of the specific quantitative methods used in the literature to identify CSD.Autocorrelation analysis for CSD ::: IntroductionBefore analysis, time series must be de-trended to isolate variability about the equilibrium growth trend.", [["CSD", "DISEASE", 110, 113], ["CSD", "PROBLEM", 110, 113], ["Autocorrelation analysis", "TEST", 114, 138], ["IntroductionBefore analysis", "TEST", 151, 178]]], ["In our study, data are de-trended using a Hodrick-Prescott filter (HPF) with an averaging windows ranging from 10\u201330 years.", [["our study", "TEST", 3, 12], ["a Hodrick-Prescott filter", "TREATMENT", 40, 65]]], ["The choice of de-trending is discussed further in the methods section.Autocorrelation analysis for CSD ::: IntroductionA widely used indicator of CSD is the AR1 autocorrelation2,42.", [["Autocorrelation analysis", "TEST", 70, 94], ["CSD", "PROBLEM", 99, 102], ["IntroductionA", "TREATMENT", 107, 120]]], ["AR1 is estimated in a moving window as described by Eq.", [["AR1", "GENE_OR_GENE_PRODUCT", 0, 3], ["AR1", "PROTEIN", 0, 3]]], ["A typical window length for estimating AR1 is 15 years.", [["AR1", "DNA", 39, 42], ["window", "OBSERVATION_MODIFIER", 10, 16], ["length", "OBSERVATION_MODIFIER", 17, 23]]], ["The significance of the AR1 indicator is tested using a range of window sizes between 5 to 40 years (see Methods).2", [["AR1", "DNA", 24, 27], ["a range of window sizes", "TREATMENT", 54, 77]]]], "d363ddb638e4e9daf714e45b77c17679ffbee912": [["Based on sequence alignment and homology modeling analysis, we previously predicted that the receptorbinding domain (RBD) of the novel human betacoronavirus 2c EMC/2012 (hCoV-EMC) is located in a region spanning residues 377e662 in hCoV-EMC spike (S) protein.", [["human", "ORGANISM", 135, 140], ["betacoronavirus 2c EMC", "ORGANISM", 141, 163], ["hCoV-EMC", "GENE_OR_GENE_PRODUCT", 170, 178], ["hCoV-EMC spike (S)", "GENE_OR_GENE_PRODUCT", 232, 250], ["receptorbinding domain", "PROTEIN", 93, 115], ["RBD", "PROTEIN", 117, 120], ["hCoV", "PROTEIN", 170, 174], ["hCoV", "PROTEIN", 232, 236], ["EMC spike (S) protein", "PROTEIN", 237, 258], ["human", "SPECIES", 135, 140], ["human betacoronavirus", "SPECIES", 135, 156], ["sequence alignment and homology modeling analysis", "TEST", 9, 58], ["hCoV", "TEST", 232, 236]]], ["1 Similar to the RBD in the S protein of SARS coronavirus (SARSeCoV), the predicted hCoV-EMC S-RBD also contains a core domain consisting of 5 b-sheets (b1-b4, b7) and 3 a-helices (aA-aC).", [["RBD", "DISEASE", 17, 20], ["SARS coronavirus", "DISEASE", 41, 57], ["SARS coronavirus", "ORGANISM", 41, 57], ["SARSeCoV", "CANCER", 59, 67], ["hCoV", "GENE_OR_GENE_PRODUCT", 84, 88], ["b1-b4", "GENE_OR_GENE_PRODUCT", 153, 158], ["aA-aC", "GENE_OR_GENE_PRODUCT", 181, 186], ["RBD", "PROTEIN", 17, 20], ["S protein", "PROTEIN", 28, 37], ["hCoV", "PROTEIN", 84, 88], ["EMC S", "PROTEIN", 89, 94], ["RBD", "PROTEIN", 95, 98], ["b1", "PROTEIN", 153, 155], ["b4", "PROTEIN", 156, 158], ["b7", "PROTEIN", 160, 162], ["a-helices", "PROTEIN", 170, 179], ["aA", "PROTEIN", 181, 183], ["aC", "PROTEIN", 184, 186], ["SARS coronavirus", "SPECIES", 41, 57], ["the RBD", "PROBLEM", 13, 20], ["the S protein", "TEST", 24, 37], ["SARS coronavirus", "PROBLEM", 41, 57], ["SARSeCoV", "TEST", 59, 67], ["the predicted hCoV", "TEST", 70, 88], ["EMC S", "TEST", 89, 94], ["RBD", "PROBLEM", 95, 98], ["b1", "TEST", 153, 155], ["b7", "TEST", 160, 162], ["a-helices", "TEST", 170, 179], ["aA", "TEST", 181, 183], ["RBD", "OBSERVATION", 17, 20]]], ["2,3 However, they have different extended loops between b4 and b7.", [["b4", "GENE_OR_GENE_PRODUCT", 56, 58], ["b7", "GENE_OR_GENE_PRODUCT", 63, 65], ["b4", "PROTEIN", 56, 58], ["b7", "PROTEIN", 63, 65], ["different extended loops between b4 and b7", "PROBLEM", 23, 65], ["different", "OBSERVATION_MODIFIER", 23, 32], ["extended", "OBSERVATION_MODIFIER", 33, 41], ["loops", "OBSERVATION", 42, 47], ["b4", "ANATOMY_MODIFIER", 56, 58], ["b7", "ANATOMY", 63, 65]]], ["SARSeCoV S-RBD has a 71-amino-acid (aa)(residues 424e494) extended loop, including two anti-parallel b-sheets (b5eb6) 2 .", [["71-amino-acid", "CHEMICAL", 21, 34], ["71-amino-acid", "CHEMICAL", 21, 34], ["b5eb6) 2", "GENE_OR_GENE_PRODUCT", 111, 119], ["SARSeCoV S-RBD", "PROTEIN", 0, 14], ["anti-parallel b-sheets", "PROTEIN", 87, 109], ["b5eb6) 2", "PROTEIN", 111, 119], ["RBD", "TEST", 11, 14], ["two anti-parallel b-sheets (b5eb6)", "TREATMENT", 83, 117]]], ["Its receptor-binding motif (RBM) is located in this extended loop, which is responsible for directly contacting the residues in the virus-binding site in the SARSeCoV's receptor, angiotensin-converting enzyme 2 (ACE2) on the target cell.", [["cell", "ANATOMY", 232, 236], ["angiotensin", "CHEMICAL", 179, 190], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 179, 210], ["ACE2", "GENE_OR_GENE_PRODUCT", 212, 216], ["cell", "CELL", 232, 236], ["receptor-binding motif", "PROTEIN", 4, 26], ["RBM", "PROTEIN", 28, 31], ["virus-binding site", "DNA", 132, 150], ["SARSeCoV's receptor", "PROTEIN", 158, 177], ["angiotensin-converting enzyme 2", "PROTEIN", 179, 210], ["ACE2", "PROTEIN", 212, 216], ["target cell", "CELL_TYPE", 225, 236], ["Its receptor-binding motif (RBM", "TREATMENT", 0, 31], ["angiotensin", "TEST", 179, 190], ["converting enzyme", "TEST", 191, 208], ["binding motif", "OBSERVATION", 13, 26], ["loop", "OBSERVATION", 61, 65], ["responsible for", "UNCERTAINTY", 76, 91], ["virus", "OBSERVATION", 132, 137], ["target cell", "OBSERVATION", 225, 236]]], ["2, 3 The hCoV-EMC S-RBD contains a much longer (143-aa: residues 440e582) extended loop, consisting of two anti-parallel b-sheets (b5-b6) as well as three a-helices.", [["b5-b6", "GENE_OR_GENE_PRODUCT", 131, 136], ["hCoV", "PROTEIN", 9, 13], ["EMC S", "PROTEIN", 14, 19], ["RBD", "PROTEIN", 20, 23], ["anti-parallel b-sheets", "PROTEIN", 107, 129], ["b5", "PROTEIN", 131, 133], ["b6", "PROTEIN", 134, 136], ["a-helices", "PROTEIN", 155, 164], ["The hCoV", "TEST", 5, 13], ["RBD", "PROBLEM", 20, 23], ["two anti-parallel b-sheets (b5-b6)", "TREATMENT", 103, 137]]], ["The first two a-helices form a V-shaped structure.", [["V-shaped structure", "PROTEIN", 31, 49], ["shaped", "OBSERVATION_MODIFIER", 33, 39], ["structure", "OBSERVATION", 40, 49]]], ["1 Since the sequence length and conformation of the extended loop in the predicted hCoV-EMC S-RBD significantly differ from those in SARSeCoV S-RBD, we have predicted that hCoV-EMC must have a receptor different from that of SARSeCoV.", [["hCoV", "GENE_OR_GENE_PRODUCT", 83, 87], ["SARSeCoV S-RBD", "GENE_OR_GENE_PRODUCT", 133, 147], ["hCoV", "GENE_OR_GENE_PRODUCT", 172, 176], ["SARSeCoV", "GENE_OR_GENE_PRODUCT", 225, 233], ["hCoV", "PROTEIN", 83, 87], ["EMC S", "PROTEIN", 88, 93], ["RBD", "PROTEIN", 94, 97], ["SARSeCoV S", "PROTEIN", 133, 143], ["RBD", "PROTEIN", 144, 147], ["hCoV", "PROTEIN", 172, 176], ["SARSeCoV", "PROTEIN", 225, 233], ["the sequence length", "TEST", 8, 27], ["the extended loop", "TREATMENT", 48, 65], ["RBD", "PROBLEM", 94, 97], ["RBD", "PROBLEM", 144, 147]]]], "PMC7195380": [["IntroductionClinical and epidemiological evidence has been advanced for human-to-human transmission of the novel coronavirus rampaging the world since late 2019 (see Kamph, 2020; Shereen et al., 2020; Yeo et al., 2020 for an extensive review).", [["human", "ORGANISM", 72, 77], ["human", "ORGANISM", 81, 86], ["coronavirus", "ORGANISM", 113, 124], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 81, 86], ["coronavirus", "SPECIES", 113, 124], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 81, 86], ["an extensive review", "TEST", 222, 241]]], ["The contemporary disease is spreading exponentially around the world, and the pandemic has been felt in at least 185 countries reporting 1,844,863 confirmed cases with 117,021 deaths as at 14th April 2020 (WHO, 2020a, WHO, 2020b).", [["deaths", "DISEASE", 176, 182], ["The contemporary disease", "PROBLEM", 0, 24], ["contemporary", "OBSERVATION_MODIFIER", 4, 16], ["disease", "OBSERVATION", 17, 24], ["spreading", "OBSERVATION_MODIFIER", 28, 37], ["exponentially", "OBSERVATION_MODIFIER", 38, 51]]], ["In this time of the global pandemic, fifty-two (52) African countries have reported one or more confirmed cases of COVID 19 with only Comoros and Lesotho presently with no single confirmed case.", [["COVID", "DISEASE", 115, 120], ["COVID", "TEST", 115, 120]]], ["As a result of changing medical data, Africa at the time of writing has recorded 10,787 confirmed cases, with 501 deaths.", [["deaths", "DISEASE", 114, 120]]], ["Algeria is the most hardly hit nation with 1983 confirmed cases and 313 deaths, although lesser confirmed cases compared to South Africa (2272) with 27 deaths (WHO, 2020a, WHO, 2020b).", [["deaths", "DISEASE", 72, 78], ["deaths", "DISEASE", 152, 158]]], ["In other regions of the world, the United States of America (USA) with 553, 822 confirmed cases and 21,972 deaths remain the hardest-hit nation in America (North and South) and around the world.", [["deaths", "DISEASE", 107, 113]]], ["China, with 83,696 confirmed cases and 3351 deaths, is the hardest hit Asian country.", [["deaths", "DISEASE", 44, 50]]], ["In Europe, Italy, with 159,516 confirmed cases and 20,465 deaths although relatively less compared to confirmed cases in Spain with 169,496 with 17,489 deaths remains the hardest hit because of their superior coronavirus reported death cases.", [["deaths", "DISEASE", 58, 64], ["deaths", "DISEASE", 152, 158], ["coronavirus", "DISEASE", 209, 220], ["death", "DISEASE", 230, 235], ["coronavirus", "ORGANISM", 209, 220]]], ["In the middle east region, Iran, with 73,303 confirmed cases and 4585 deaths is the worst-hit nation.IntroductionIn ascertaining the structures, features, risk factors and severity of the novel coronavirus, clinical and epidemiological evidence has been leaned to human-to-human transmissions (community transmission).", [["deaths", "DISEASE", 70, 76], ["coronavirus", "DISEASE", 194, 205], ["human", "ORGANISM", 264, 269], ["human", "ORGANISM", 273, 278], ["human", "SPECIES", 264, 269], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 264, 269], ["human", "SPECIES", 273, 278], ["risk factors", "PROBLEM", 155, 167], ["the novel coronavirus", "PROBLEM", 184, 205], ["middle", "ANATOMY_MODIFIER", 7, 13]]], ["However, outliers in the human-to-human transmission could be as a result of clusters that are yet to be explored.", [["human", "ORGANISM", 25, 30], ["human", "ORGANISM", 34, 39], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 34, 39]]], ["By advancing arguments for clusters of the novel coronavirus in Africa, we provided a social dimension to abating the spread of coronavirus diseases.", [["coronavirus", "DISEASE", 49, 60], ["coronavirus diseases", "DISEASE", 128, 148], ["coronavirus", "ORGANISM", 49, 60], ["coronavirus", "ORGANISM", 128, 139], ["the novel coronavirus", "PROBLEM", 39, 60], ["coronavirus diseases", "PROBLEM", 128, 148], ["coronavirus diseases", "OBSERVATION", 128, 148]]], ["Africa is predominantly famous for overcrowding their megacities like Pretoria, Lagos, Johannesburg, Cairo and Nairobi.", [["predominantly", "OBSERVATION_MODIFIER", 10, 23], ["famous", "OBSERVATION", 24, 30]]], ["Clustering by people either in public gatherings or residential facilities makes them endangered species.", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20]]], ["Even if social distancing is enforced in the public domain to prevent human-to-human transmission, it may be difficult if not impossible to enforce in an already overcrowded shared resident.", [["human", "ORGANISM", 70, 75], ["human", "ORGANISM", 79, 84], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 79, 84]]], ["By advancing arguments for inevitable human clustering at various residential or sub-groups in Africa, the study provides an econometric analysis of the social dimensions of the spread of coronavirus diseases in Africa.", [["coronavirus diseases", "DISEASE", 188, 208], ["human", "ORGANISM", 38, 43], ["coronavirus", "ORGANISM", 188, 199], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["inevitable human clustering", "PROBLEM", 27, 54], ["the study", "TEST", 103, 112], ["an econometric analysis", "TEST", 122, 145], ["coronavirus diseases", "PROBLEM", 188, 208], ["coronavirus diseases", "OBSERVATION", 188, 208]]], ["Apparently, this study leads the debate on spatial density and statistical credence of how confirmed cases is statistically related to attributable deaths from coronavirus diseases in Africa.", [["deaths", "DISEASE", 148, 154], ["coronavirus diseases", "DISEASE", 160, 180], ["coronavirus", "ORGANISM", 160, 171], ["this study", "TEST", 12, 22], ["coronavirus diseases", "PROBLEM", 160, 180], ["coronavirus diseases", "OBSERVATION", 160, 180]]], ["We build upon the work of Sarkodie and Owusu (2020) to examine the phenomenological influence of outliers in the human-human transmission in Africa.", [["human", "ORGANISM", 113, 118], ["human", "ORGANISM", 119, 124], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 119, 124], ["human-human", "SPECIES", 113, 124]]], ["The intricacies of these unobserved factors in abating human-to-human transmission of coronavirus disease in Africa underpin this study.", [["coronavirus disease", "DISEASE", 86, 105], ["human", "ORGANISM", 55, 60], ["human", "ORGANISM", 64, 69], ["coronavirus", "ORGANISM", 86, 97], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 64, 69], ["coronavirus", "SPECIES", 86, 97], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 64, 69], ["coronavirus disease", "PROBLEM", 86, 105], ["this study", "TEST", 125, 135], ["coronavirus disease", "OBSERVATION", 86, 105]]], ["We rely on publicly available data for Africa countries confirmed and death cases.", [["death", "DISEASE", 70, 75], ["Africa countries", "TREATMENT", 39, 55]]], ["We use a novel estimation method capable of accounting for cross-sectional dependence.", [["a novel estimation method", "TREATMENT", 7, 32], ["cross-sectional dependence", "PROBLEM", 59, 85]]], ["We found a basis for the strict orthogonal relationship among the variable and accounted for unobserved heterogeneity of the human-to-human transmission.Data ::: Materials and methodsWe rely on data obtained from the World Health Organisation (WHO) situation reports 551through to situation reports 852(a time plot of 31-time invariant observations).", [["human", "ORGANISM", 125, 130], ["human", "ORGANISM", 134, 139], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 134, 139]]], ["We transformed the daily observations in conformity with conventional panel data estimation procedure (wide to long) as in Sarkodie and Owusu (2020).", [["conventional panel data", "TEST", 57, 80], ["estimation procedure", "TREATMENT", 81, 101]]], ["We relied on health indicators (number of COVID-19 attributable deaths and number of confirmed cases) across 52 Africa states.3In Fig. I, we presented the spatial density of the number of confirmed cases and the number of deaths from COVID 19 across African states.Model ::: Materials and methodsOur empirical strategy in gauging the statistical relationship between the number of attributable COVID-19 deaths and confirmed cases was to estimate a series of baseline fixed effect estimator by assuming that all explanatory variables are strictly exogenous.", [["deaths", "DISEASE", 64, 70], ["deaths", "DISEASE", 222, 228], ["deaths", "DISEASE", 403, 409], ["COVID", "TEST", 42, 47], ["baseline fixed effect estimator", "PROBLEM", 458, 489]]], ["We proceed to estimate the dynamic panel data system generalised method of moment (GMM) (Arellano and Bover, 1995) and impose (and test) the common factor restrictions to account for the potential endogeneity of the number of COVID-19 attributable deaths and number of confirmed cases across 52 Africa states.", [["deaths", "DISEASE", 248, 254], ["COVID", "TEST", 226, 231]]], ["The functional relationship is expressed as:(1)COVIDdeathsi,t=fConfrmd Casesi,twhere COVIDdeathsi, t is the total number of attributable COVID-19 deaths in country i over period t; Confrmd Casesi, t represent the number of confirmed cases in country i over period t, t defines the time parameters, and i give the cross-sectional domain of the COVID-19 attributable deaths model.Model ::: Materials and methodsWe begin by imposing the assumption of strict exogeneity on the regressors, leading to violations and inconsistency in our fixed-effect model.", [["deaths", "DISEASE", 146, 152], ["deaths", "DISEASE", 365, 371], ["the COVID", "TEST", 339, 348], ["the regressors", "TREATMENT", 469, 483], ["violations", "PROBLEM", 496, 506], ["our fixed-effect model", "TREATMENT", 528, 550]]], ["Our dynamic panel COVID-19 attributable deaths model is specified as:(2)COVIDdeathsi,t=\u03c1+\u03c9COVIDdeathsi,t\u22121+\u03b8Confrmd Casesi,t+\u03bciti=1\u2026n,t=1\u2026T", [["deaths", "DISEASE", 40, 46], ["Our dynamic panel", "TEST", 0, 17], ["COVID", "TEST", 18, 23], ["COVIDdeathsi", "TEST", 72, 84], ["t", "TEST", 85, 86], ["COVIDdeathsi", "TEST", 90, 102], ["Casesi", "TEST", 116, 122], ["\u03bciti", "TEST", 125, 129]]]], "903f8d72ea961ab2c4c0bad918fe78f6aaedf9cf": [["BackgroundVasoactive neuropeptides (VNs) including vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase polypeptide (PACAP) and their receptors exist in the mammalian eye including the sclera, cornea, iris, ciliary body, ciliary process and the retina [1, 2] .", [["eye", "ANATOMY", 182, 185], ["sclera", "ANATOMY", 200, 206], ["cornea", "ANATOMY", 208, 214], ["iris", "ANATOMY", 216, 220], ["ciliary body", "ANATOMY", 222, 234], ["ciliary process", "ANATOMY", 236, 251], ["retina", "ANATOMY", 260, 266], ["BackgroundVasoactive neuropeptides", "GENE_OR_GENE_PRODUCT", 0, 34], ["VNs", "GENE_OR_GENE_PRODUCT", 36, 39], ["vasoactive intestinal peptide", "GENE_OR_GENE_PRODUCT", 51, 80], ["VIP", "GENE_OR_GENE_PRODUCT", 82, 85], ["pituitary adenylate cyclase polypeptide", "GENE_OR_GENE_PRODUCT", 91, 130], ["PACAP", "GENE_OR_GENE_PRODUCT", 132, 137], ["eye", "ORGAN", 182, 185], ["sclera", "TISSUE", 200, 206], ["cornea", "TISSUE", 208, 214], ["iris", "TISSUE", 216, 220], ["ciliary body", "TISSUE", 222, 234], ["ciliary", "MULTI-TISSUE_STRUCTURE", 236, 243], ["retina", "MULTI-TISSUE_STRUCTURE", 260, 266], ["BackgroundVasoactive neuropeptides", "PROTEIN", 0, 34], ["pituitary adenylate cyclase polypeptide", "PROTEIN", 91, 130], ["PACAP", "PROTEIN", 132, 137], ["BackgroundVasoactive neuropeptides (VNs", "TREATMENT", 0, 39], ["vasoactive intestinal peptide", "TREATMENT", 51, 80], ["VIP)", "TREATMENT", 82, 86], ["pituitary adenylate cyclase polypeptide (PACAP)", "TREATMENT", 91, 138], ["iris, ciliary body, ciliary process", "PROBLEM", 216, 251], ["intestinal", "ANATOMY", 62, 72], ["mammalian eye", "ANATOMY", 172, 185], ["sclera", "ANATOMY", 200, 206], ["cornea", "ANATOMY", 208, 214], ["iris", "ANATOMY", 216, 220], ["ciliary body", "ANATOMY", 222, 234], ["ciliary process", "OBSERVATION", 236, 251], ["retina", "ANATOMY", 260, 266]]], ["VNs influence regulatory T cells and are important in maintaining immunological homeostasis [3] .", [["VNs", "ANATOMY", 0, 3], ["T cells", "ANATOMY", 25, 32], ["VNs", "SIMPLE_CHEMICAL", 0, 3], ["regulatory T cells", "CELL", 14, 32], ["VNs", "CELL_TYPE", 0, 3], ["regulatory T cells", "CELL_TYPE", 14, 32], ["VNs influence regulatory T cells", "PROBLEM", 0, 32]]], ["They have significant anti-inflammatory and anti-apoptotic roles particularly in immune privileged sites including the eye.", [["sites", "ANATOMY", 99, 104], ["eye", "ANATOMY", 119, 122], ["eye", "ORGAN", 119, 122], ["anti-apoptotic roles", "TREATMENT", 44, 64], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["anti-inflammatory", "OBSERVATION_MODIFIER", 22, 39], ["anti-apoptotic roles", "OBSERVATION", 44, 64], ["eye", "ANATOMY", 119, 122]]], ["They are potent vasodilators and are essential for the maintenance of blood supply.", [["blood", "ANATOMY", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["potent vasodilators", "TREATMENT", 9, 28], ["blood supply", "TREATMENT", 70, 82]]], ["VN receptors are class II G proteincoupled receptors (GPCRs) which couple primarily to the adenylate cyclase (AC)-cyclic AMP (cAMP) pathway [4] and are present in the retina of different mammalian species [5] .", [["retina", "ANATOMY", 167, 173], ["AMP", "CHEMICAL", 121, 124], ["cAMP", "CHEMICAL", 126, 130], ["adenylate", "CHEMICAL", 91, 100], ["cyclic AMP", "CHEMICAL", 114, 124], ["cAMP", "CHEMICAL", 126, 130], ["VN receptors", "GENE_OR_GENE_PRODUCT", 0, 12], ["class II G proteincoupled receptors", "GENE_OR_GENE_PRODUCT", 17, 52], ["adenylate cyclase (AC)-cyclic AMP", "GENE_OR_GENE_PRODUCT", 91, 124], ["cAMP", "SIMPLE_CHEMICAL", 126, 130], ["retina", "MULTI-TISSUE_STRUCTURE", 167, 173], ["VN receptors", "PROTEIN", 0, 12], ["class II G proteincoupled receptors", "PROTEIN", 17, 52], ["GPCRs", "PROTEIN", 54, 59], ["adenylate cyclase", "PROTEIN", 91, 108], ["the adenylate cyclase", "TEST", 87, 108], ["cyclic AMP (cAMP) pathway", "TEST", 114, 139], ["different mammalian species", "PROBLEM", 177, 204], ["retina", "ANATOMY", 167, 173], ["mammalian species", "OBSERVATION", 187, 204]]], ["VNs activate AC and have a key role in converting ATP to cAMP, hence setting balance levels for ATP and cAMP.", [["ATP", "CHEMICAL", 50, 53], ["cAMP", "CHEMICAL", 57, 61], ["ATP", "CHEMICAL", 96, 99], ["cAMP", "CHEMICAL", 104, 108], ["ATP", "CHEMICAL", 50, 53], ["cAMP", "CHEMICAL", 57, 61], ["ATP", "CHEMICAL", 96, 99], ["cAMP", "CHEMICAL", 104, 108], ["VNs", "SIMPLE_CHEMICAL", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 50, 53], ["cAMP", "SIMPLE_CHEMICAL", 57, 61], ["ATP", "SIMPLE_CHEMICAL", 96, 99], ["cAMP", "SIMPLE_CHEMICAL", 104, 108], ["VNs", "PROTEIN", 0, 3], ["VNs activate AC", "TREATMENT", 0, 15], ["cAMP", "TREATMENT", 57, 61], ["setting balance levels", "TEST", 69, 91], ["ATP", "PROBLEM", 96, 99], ["cAMP", "PROBLEM", 104, 108]]], ["Importantly, ATP is critical for cell survival and cAMP has a central role in neurological metabolism including influencing blood-brain barrier permeability, coordination of neuroregulatory pathways, and protecting against neuronal apoptosis.BackgroundAutoimmunity affecting VNs has been postulated as contributing to certain fatigue-related conditions in humans [6] .", [["cell", "ANATOMY", 33, 37], ["neurological", "ANATOMY", 78, 90], ["blood-brain barrier", "ANATOMY", 124, 143], ["neuronal", "ANATOMY", 223, 231], ["ATP", "CHEMICAL", 13, 16], ["cAMP", "CHEMICAL", 51, 55], ["BackgroundAutoimmunity", "DISEASE", 242, 264], ["fatigue", "DISEASE", 326, 333], ["ATP", "CHEMICAL", 13, 16], ["cAMP", "CHEMICAL", 51, 55], ["ATP", "SIMPLE_CHEMICAL", 13, 16], ["cell", "CELL", 33, 37], ["cAMP", "SIMPLE_CHEMICAL", 51, 55], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 130, 143], ["neuronal", "CELL", 223, 231], ["VNs", "GENE_OR_GENE_PRODUCT", 275, 278], ["humans", "ORGANISM", 356, 362], ["humans", "SPECIES", 356, 362], ["humans", "SPECIES", 356, 362], ["cell survival", "PROBLEM", 33, 46], ["cAMP", "PROBLEM", 51, 55], ["a central role in neurological metabolism", "PROBLEM", 60, 101], ["influencing blood-brain barrier permeability", "PROBLEM", 112, 156], ["neuroregulatory pathways", "TREATMENT", 174, 198], ["neuronal apoptosis", "PROBLEM", 223, 241], ["BackgroundAutoimmunity affecting VNs", "PROBLEM", 242, 278], ["certain fatigue", "PROBLEM", 318, 333], ["cell survival", "OBSERVATION", 33, 46], ["brain", "ANATOMY", 130, 135], ["barrier permeability", "OBSERVATION", 136, 156], ["neuronal apoptosis", "OBSERVATION", 223, 241]]], ["This hypothesis was suggested to account for the multi-faceted and confusing symptomatology of some fatigue-related conditions e.g. chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and fibromyalgia (FM).", [["fatigue", "DISEASE", 100, 107], ["chronic fatigue syndrome", "DISEASE", 132, 156], ["myalgic encephalomyelitis", "DISEASE", 157, 182], ["CFS", "DISEASE", 184, 187], ["ME", "DISEASE", 188, 190], ["fibromyalgia", "DISEASE", 196, 208], ["FM", "DISEASE", 210, 212], ["the multi-faceted and confusing symptomatology", "PROBLEM", 45, 91], ["some fatigue", "PROBLEM", 95, 107], ["related conditions", "PROBLEM", 108, 126], ["chronic fatigue syndrome", "PROBLEM", 132, 156], ["myalgic encephalomyelitis", "PROBLEM", 157, 182], ["CFS/ME)", "PROBLEM", 184, 191], ["fibromyalgia", "PROBLEM", 196, 208], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["fatigue syndrome", "OBSERVATION", 140, 156], ["myalgic encephalomyelitis", "OBSERVATION", 157, 182], ["fibromyalgia", "OBSERVATION", 196, 208]]], ["The constellation of symptoms associated with these conditions is consistent with compromise of receptors associated with VIP and PACAP.", [["VIP", "GENE_OR_GENE_PRODUCT", 122, 125], ["PACAP", "GENE_OR_GENE_PRODUCT", 130, 135], ["symptoms", "PROBLEM", 21, 29], ["these conditions", "PROBLEM", 46, 62], ["compromise of receptors", "PROBLEM", 82, 105], ["VIP and PACAP", "TREATMENT", 122, 135], ["consistent with", "UNCERTAINTY", 66, 81]]], ["This present paper examines the hypothesis that these VNs may also have a role in autoimmune retinal disease.Autoimmunity and retinal pathologyImmune privilege of the internal compartments of the eye is a physiologic mechanism which protects the eye against pathogens, while protecting the visual axis from the sight destroying potential of immunogenic inflammation [7] .", [["retinal", "ANATOMY", 93, 100], ["retinal", "ANATOMY", 126, 133], ["internal compartments", "ANATOMY", 167, 188], ["eye", "ANATOMY", 196, 199], ["eye", "ANATOMY", 246, 249], ["autoimmune retinal disease", "DISEASE", 82, 108], ["Autoimmunity", "DISEASE", 109, 121], ["retinal pathology", "DISEASE", 126, 143], ["inflammation", "DISEASE", 353, 365], ["VNs", "GENE_OR_GENE_PRODUCT", 54, 57], ["retinal", "MULTI-TISSUE_STRUCTURE", 93, 100], ["retinal", "MULTI-TISSUE_STRUCTURE", 126, 133], ["internal compartments", "MULTI-TISSUE_STRUCTURE", 167, 188], ["eye", "ORGAN", 196, 199], ["eye", "ORGAN", 246, 249], ["autoimmune retinal disease", "PROBLEM", 82, 108], ["Autoimmunity", "PROBLEM", 109, 121], ["retinal pathology", "TEST", 126, 143], ["a physiologic mechanism", "PROBLEM", 203, 226], ["pathogens", "PROBLEM", 258, 267], ["immunogenic inflammation", "PROBLEM", 341, 365], ["autoimmune retinal disease", "OBSERVATION", 82, 108], ["retinal", "ANATOMY", 126, 133], ["pathology", "OBSERVATION", 134, 143], ["internal", "ANATOMY_MODIFIER", 167, 175], ["compartments", "ANATOMY_MODIFIER", 176, 188], ["eye", "ANATOMY", 196, 199], ["eye", "ANATOMY", 246, 249], ["immunogenic", "OBSERVATION_MODIFIER", 341, 352], ["inflammation", "OBSERVATION", 353, 365]]], ["Immunological mechanisms in the eye must be tightly regulated to ensure externally mediated injury and infection or internally mediated autoimmunity do not exceed self-defence tolerance.", [["eye", "ANATOMY", 32, 35], ["infection", "DISEASE", 103, 112], ["autoimmunity", "DISEASE", 136, 148], ["eye", "ORGAN", 32, 35], ["Immunological mechanisms in the eye", "PROBLEM", 0, 35], ["externally mediated injury", "PROBLEM", 72, 98], ["infection", "PROBLEM", 103, 112], ["internally mediated autoimmunity", "PROBLEM", 116, 148], ["eye", "ANATOMY", 32, 35], ["injury", "OBSERVATION", 92, 98], ["infection", "OBSERVATION", 103, 112]]], ["Autoimmunity as a cause of retinal pathology has been postulated in patients with peripheral vitreo-chorioretinal dystrophies (PVCRD).", [["retinal", "ANATOMY", 27, 34], ["peripheral vitreo-chorioretinal", "ANATOMY", 82, 113], ["Autoimmunity", "DISEASE", 0, 12], ["retinal pathology", "DISEASE", 27, 44], ["peripheral vitreo-chorioretinal dystrophies", "DISEASE", 82, 125], ["PVCRD", "DISEASE", 127, 132], ["retinal", "MULTI-TISSUE_STRUCTURE", 27, 34], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Autoimmunity", "PROBLEM", 0, 12], ["retinal pathology", "PROBLEM", 27, 44], ["peripheral vitreo-chorioretinal dystrophies", "PROBLEM", 82, 125], ["retinal", "ANATOMY", 27, 34], ["pathology", "OBSERVATION", 35, 44], ["chorioretinal dystrophies", "OBSERVATION", 100, 125]]], ["Self-antibodies were detected in 70% of these cases, although in no cases were circulating immune complexes detected in the blood suggesting that pathology was due to local effects only [8] .Autoimmunity and retinal pathologyRetinal pathology may be mediated through autoantibody-induced apoptosis associated with retinal proteins [9] .", [["blood", "ANATOMY", 124, 129], ["retinal", "ANATOMY", 208, 215], ["Retinal", "ANATOMY", 225, 232], ["retinal", "ANATOMY", 314, 321], ["Autoimmunity", "DISEASE", 191, 203], ["retinal pathology", "DISEASE", 208, 225], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["retinal", "MULTI-TISSUE_STRUCTURE", 208, 215], ["Retinal", "MULTI-TISSUE_STRUCTURE", 225, 232], ["retinal", "MULTI-TISSUE_STRUCTURE", 314, 321], ["Self-antibodies", "PROTEIN", 0, 15], ["circulating immune complexes", "PROTEIN", 79, 107], ["autoantibody", "PROTEIN", 267, 279], ["retinal proteins", "PROTEIN", 314, 330], ["Self-antibodies", "TEST", 0, 15], ["circulating immune complexes", "PROBLEM", 79, 107], ["the blood", "TEST", 120, 129], ["pathology", "TEST", 146, 155], ["Autoimmunity", "PROBLEM", 191, 203], ["retinal pathology", "TEST", 208, 225], ["Retinal pathology", "TEST", 225, 242], ["autoantibody", "PROBLEM", 267, 279], ["apoptosis", "PROBLEM", 288, 297], ["retinal proteins", "PROBLEM", 314, 330], ["retinal", "ANATOMY", 208, 215], ["pathology", "OBSERVATION", 216, 225]]], ["Anti-recoverin antibodies are cytotoxic to retinal cells and induce apoptotic death of retinal photoreceptor cells which leads to the degeneration of the photoreceptor layer and cell death.", [["retinal cells", "ANATOMY", 43, 56], ["retinal photoreceptor cells", "ANATOMY", 87, 114], ["photoreceptor layer", "ANATOMY", 154, 173], ["cell", "ANATOMY", 178, 182], ["death", "DISEASE", 183, 188], ["retinal cells", "CELL", 43, 56], ["retinal photoreceptor cells", "CELL", 87, 114], ["photoreceptor layer", "CELLULAR_COMPONENT", 154, 173], ["cell", "CELL", 178, 182], ["Anti-recoverin antibodies", "PROTEIN", 0, 25], ["retinal cells", "CELL_TYPE", 43, 56], ["retinal photoreceptor cells", "CELL_TYPE", 87, 114], ["Anti-recoverin antibodies", "TREATMENT", 0, 25], ["cytotoxic to retinal cells", "PROBLEM", 30, 56], ["apoptotic death of retinal photoreceptor cells", "PROBLEM", 68, 114], ["the degeneration", "PROBLEM", 130, 146], ["the photoreceptor layer and cell death", "PROBLEM", 150, 188], ["retinal cells", "OBSERVATION", 43, 56], ["apoptotic death", "OBSERVATION", 68, 83], ["retinal photoreceptor cells", "OBSERVATION", 87, 114], ["degeneration", "OBSERVATION", 134, 146], ["photoreceptor", "OBSERVATION_MODIFIER", 154, 167], ["layer", "OBSERVATION_MODIFIER", 168, 173], ["cell death", "OBSERVATION", 178, 188]]], ["Antibodies with other retinal specificities induce their target retinal cell death by activating a caspase 3-dependent apoptotic pathway.", [["retinal", "ANATOMY", 22, 29], ["retinal cell", "ANATOMY", 64, 76], ["retinal", "MULTI-TISSUE_STRUCTURE", 22, 29], ["retinal cell", "CELL", 64, 76], ["caspase 3", "GENE_OR_GENE_PRODUCT", 99, 108], ["caspase 3", "PROTEIN", 99, 108], ["other retinal specificities", "PROBLEM", 16, 43], ["retinal cell death", "PROBLEM", 64, 82], ["a caspase 3-dependent apoptotic pathway", "TREATMENT", 97, 136], ["retinal", "ANATOMY", 22, 29], ["retinal cell death", "OBSERVATION", 64, 82]]], ["Thus autoantibody-induced apoptosis may be a common pathway that leads to retinal death and blindness.", [["retinal", "ANATOMY", 74, 81], ["retinal death", "DISEASE", 74, 87], ["blindness", "DISEASE", 92, 101], ["retinal", "MULTI-TISSUE_STRUCTURE", 74, 81], ["apoptosis", "PROBLEM", 26, 35], ["retinal death", "PROBLEM", 74, 87], ["blindness", "PROBLEM", 92, 101], ["retinal", "ANATOMY", 74, 81], ["death", "OBSERVATION", 82, 87], ["blindness", "OBSERVATION", 92, 101]]], ["Autoimmunity to recoverin has also been suggested in some cases with systemic malignancy [10] .Autoimmunity and retinal pathologyRetinal degeneration is associated with coronavirus infection in murine models and is accompanied by retinal vasculitis and antiretinal antibodies [11] suggesting a role for autoimmunity in the pathogenesis of murine coronavirus induced retinal degeneration.", [["retinal", "ANATOMY", 112, 119], ["Retinal", "ANATOMY", 129, 136], ["retinal", "ANATOMY", 230, 237], ["retinal", "ANATOMY", 366, 373], ["Autoimmunity", "DISEASE", 0, 12], ["malignancy", "DISEASE", 78, 88], ["Autoimmunity", "DISEASE", 95, 107], ["retinal pathology", "DISEASE", 112, 129], ["Retinal degeneration", "DISEASE", 129, 149], ["coronavirus infection", "DISEASE", 169, 190], ["retinal vasculitis", "DISEASE", 230, 248], ["autoimmunity", "DISEASE", 303, 315], ["coronavirus", "DISEASE", 346, 357], ["retinal degeneration", "DISEASE", 366, 386], ["recoverin", "GENE_OR_GENE_PRODUCT", 16, 25], ["retinal", "MULTI-TISSUE_STRUCTURE", 112, 119], ["Retinal", "MULTI-TISSUE_STRUCTURE", 129, 136], ["coronavirus", "ORGANISM", 169, 180], ["murine", "ORGANISM", 194, 200], ["retinal", "MULTI-TISSUE_STRUCTURE", 230, 237], ["antiretinal antibodies", "GENE_OR_GENE_PRODUCT", 253, 275], ["murine", "ORGANISM", 339, 345], ["coronavirus", "ORGANISM", 346, 357], ["retinal", "MULTI-TISSUE_STRUCTURE", 366, 373], ["recoverin", "PROTEIN", 16, 25], ["antiretinal antibodies", "PROTEIN", 253, 275], ["murine", "SPECIES", 194, 200], ["murine", "SPECIES", 339, 345], ["murine coronavirus", "SPECIES", 339, 357], ["systemic malignancy", "PROBLEM", 69, 88], ["Autoimmunity", "PROBLEM", 95, 107], ["retinal pathology", "TEST", 112, 129], ["Retinal degeneration", "PROBLEM", 129, 149], ["coronavirus infection in murine models", "PROBLEM", 169, 207], ["retinal vasculitis", "PROBLEM", 230, 248], ["antiretinal antibodies", "PROBLEM", 253, 275], ["autoimmunity", "PROBLEM", 303, 315], ["murine coronavirus", "PROBLEM", 339, 357], ["retinal degeneration", "PROBLEM", 366, 386], ["systemic", "OBSERVATION_MODIFIER", 69, 77], ["malignancy", "OBSERVATION", 78, 88], ["retinal", "ANATOMY", 112, 119], ["pathology", "OBSERVATION", 120, 129], ["degeneration", "OBSERVATION", 137, 149], ["associated with", "UNCERTAINTY", 153, 168], ["coronavirus", "OBSERVATION_MODIFIER", 169, 180], ["infection", "OBSERVATION", 181, 190], ["retinal", "ANATOMY", 230, 237], ["vasculitis", "OBSERVATION", 238, 248], ["murine coronavirus", "OBSERVATION", 339, 357], ["retinal", "ANATOMY", 366, 373], ["degeneration", "OBSERVATION", 374, 386]]], ["This murine model of retinal degeneration is associated with autoimmune reactivity and breakdown of the blood-retinal barrier [12] .", [["retinal", "ANATOMY", 21, 28], ["blood", "ANATOMY", 104, 109], ["retinal", "ANATOMY", 110, 117], ["retinal degeneration", "DISEASE", 21, 41], ["murine", "ORGANISM", 5, 11], ["retinal", "MULTI-TISSUE_STRUCTURE", 21, 28], ["blood", "ORGANISM_SUBSTANCE", 104, 109], ["retinal barrier", "MULTI-TISSUE_STRUCTURE", 110, 125], ["murine", "SPECIES", 5, 11], ["retinal degeneration", "PROBLEM", 21, 41], ["autoimmune reactivity", "PROBLEM", 61, 82], ["breakdown of the blood", "PROBLEM", 87, 109], ["retinal", "ANATOMY", 21, 28], ["degeneration", "OBSERVATION", 29, 41], ["associated with", "UNCERTAINTY", 45, 60], ["autoimmune reactivity", "OBSERVATION", 61, 82], ["retinal", "ANATOMY", 110, 117]]], ["This finding may be a cardinal feature of postulated VN autoimmune disorders in humans because of the critical role of cyclic AMP in maintaining endothelial integrity in blood-brain barrier (BBB) and blood-retinal barrier (BRB) settings.", [["endothelial", "ANATOMY", 145, 156], ["blood-brain barrier", "ANATOMY", 170, 189], ["BBB", "ANATOMY", 191, 194], ["blood-retinal barrier", "ANATOMY", 200, 221], ["BRB", "ANATOMY", 223, 226], ["autoimmune disorders", "DISEASE", 56, 76], ["AMP", "CHEMICAL", 126, 129], ["cyclic AMP", "CHEMICAL", 119, 129], ["humans", "ORGANISM", 80, 86], ["AMP", "SIMPLE_CHEMICAL", 126, 129], ["endothelial", "CELL", 145, 156], ["blood-", "MULTI-TISSUE_STRUCTURE", 170, 176], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 176, 189], ["BBB", "MULTI-TISSUE_STRUCTURE", 191, 194], ["blood-retinal barrier", "MULTI-TISSUE_STRUCTURE", 200, 221], ["BRB", "MULTI-TISSUE_STRUCTURE", 223, 226], ["humans", "SPECIES", 80, 86], ["humans", "SPECIES", 80, 86], ["postulated VN autoimmune disorders", "PROBLEM", 42, 76], ["cyclic AMP", "TREATMENT", 119, 129], ["blood-retinal barrier (BRB) settings", "TREATMENT", 200, 236], ["may be", "UNCERTAINTY", 13, 19], ["VN", "OBSERVATION_MODIFIER", 53, 55], ["autoimmune", "OBSERVATION", 56, 66], ["endothelial", "ANATOMY", 145, 156], ["brain", "ANATOMY", 176, 181], ["retinal", "ANATOMY", 206, 213]]], ["A sound blood supply is essential for retinal survival and its compromise will have serious consequences [13] .", [["blood", "ANATOMY", 8, 13], ["retinal", "ANATOMY", 38, 45], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["retinal", "MULTI-TISSUE_STRUCTURE", 38, 45], ["A sound blood supply", "TEST", 0, 20], ["retinal survival", "TREATMENT", 38, 54], ["retinal", "ANATOMY", 38, 45]]], ["Retinal vasculitis is a potentially blinding condition with a strong association with systemic inflammatory diseases.", [["Retinal", "ANATOMY", 0, 7], ["Retinal vasculitis", "DISEASE", 0, 18], ["systemic inflammatory diseases", "DISEASE", 86, 116], ["Retinal", "MULTI-TISSUE_STRUCTURE", 0, 7], ["Retinal vasculitis", "PROBLEM", 0, 18], ["a potentially blinding condition", "PROBLEM", 22, 54], ["systemic inflammatory diseases", "PROBLEM", 86, 116], ["vasculitis", "OBSERVATION", 8, 18], ["strong", "OBSERVATION_MODIFIER", 62, 68], ["systemic", "OBSERVATION_MODIFIER", 86, 94], ["inflammatory", "OBSERVATION", 95, 107]]], ["Noninfective retinal vasculitis is likely to be an autoimmune condition although preceding infection and cross reaction to putative autoantigens is suggested [14] .", [["retinal", "ANATOMY", 13, 20], ["retinal vasculitis", "DISEASE", 13, 31], ["infection", "DISEASE", 91, 100], ["retinal", "MULTI-TISSUE_STRUCTURE", 13, 20], ["putative autoantigens", "PROTEIN", 123, 144], ["Noninfective retinal vasculitis", "PROBLEM", 0, 31], ["an autoimmune condition", "PROBLEM", 48, 71], ["preceding infection", "PROBLEM", 81, 100], ["cross reaction", "PROBLEM", 105, 119], ["putative autoantigens", "TEST", 123, 144], ["retinal", "ANATOMY", 13, 20], ["vasculitis", "OBSERVATION", 21, 31], ["likely to be", "UNCERTAINTY", 35, 47], ["autoimmune", "OBSERVATION", 51, 61], ["infection", "OBSERVATION", 91, 100]]], ["Compromise of the endothelial barriers and the BRB may instigate inflammatory responses setting up a chain of events involving VNs in a manner which provokes autoimmunity to them.Autoimmunity and retinal pathologyProtection from BRB and BBB breakdown may be linked to nitric oxide (NO) effects and actions of phosphodiesterase inhibitors [15] and cAMP production.", [["endothelial", "ANATOMY", 18, 29], ["VNs", "ANATOMY", 127, 130], ["retinal", "ANATOMY", 196, 203], ["autoimmunity", "DISEASE", 158, 170], ["Autoimmunity", "DISEASE", 179, 191], ["nitric oxide", "CHEMICAL", 268, 280], ["NO", "CHEMICAL", 282, 284], ["cAMP", "CHEMICAL", 347, 351], ["nitric oxide", "CHEMICAL", 268, 280], ["NO", "CHEMICAL", 282, 284], ["cAMP", "CHEMICAL", 347, 351], ["endothelial", "CELL", 18, 29], ["BRB", "MULTI-TISSUE_STRUCTURE", 47, 50], ["VNs", "GENE_OR_GENE_PRODUCT", 127, 130], ["retinal", "MULTI-TISSUE_STRUCTURE", 196, 203], ["BRB", "MULTI-TISSUE_STRUCTURE", 229, 232], ["BBB", "MULTI-TISSUE_STRUCTURE", 237, 240], ["nitric oxide", "SIMPLE_CHEMICAL", 268, 280], ["NO", "SIMPLE_CHEMICAL", 282, 284], ["phosphodiesterase inhibitors [15]", "SIMPLE_CHEMICAL", 309, 342], ["cAMP", "SIMPLE_CHEMICAL", 347, 351], ["the endothelial barriers", "TREATMENT", 14, 38], ["the BRB", "PROBLEM", 43, 50], ["inflammatory responses", "PROBLEM", 65, 87], ["VNs", "TREATMENT", 127, 130], ["Autoimmunity", "PROBLEM", 179, 191], ["retinal pathologyProtection", "TREATMENT", 196, 223], ["BRB", "PROBLEM", 229, 232], ["BBB breakdown", "PROBLEM", 237, 250], ["nitric oxide", "TREATMENT", 268, 280], ["phosphodiesterase inhibitors", "TREATMENT", 309, 337], ["cAMP production", "PROBLEM", 347, 362], ["endothelial", "ANATOMY", 18, 29], ["inflammatory", "OBSERVATION_MODIFIER", 65, 77], ["retinal", "ANATOMY", 196, 203], ["pathology", "OBSERVATION", 204, 213]]], ["Ocular blood flow is regulated by NO derived from the endothelium and efferent nitrergic neurons.", [["Ocular", "ANATOMY", 0, 6], ["blood", "ANATOMY", 7, 12], ["endothelium", "ANATOMY", 54, 65], ["efferent nitrergic neurons", "ANATOMY", 70, 96], ["NO", "CHEMICAL", 34, 36], ["NO", "CHEMICAL", 34, 36], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["NO", "SIMPLE_CHEMICAL", 34, 36], ["endothelium", "TISSUE", 54, 65], ["efferent nitrergic neurons", "CELL", 70, 96], ["efferent nitrergic neurons", "CELL_TYPE", 70, 96], ["Ocular blood flow", "TEST", 0, 17], ["flow", "OBSERVATION", 13, 17], ["endothelium", "ANATOMY", 54, 65], ["efferent", "OBSERVATION_MODIFIER", 70, 78], ["nitrergic neurons", "OBSERVATION", 79, 96]]], ["However, induced NO expressed under influences of inflammatory mediators evokes neurodegeneration and cell apoptosis and may lead to serious ocular disease including retinal injury [17] .", [["cell", "ANATOMY", 102, 106], ["ocular", "ANATOMY", 141, 147], ["retinal", "ANATOMY", 166, 173], ["NO", "CHEMICAL", 17, 19], ["neurodegeneration", "DISEASE", 80, 97], ["ocular disease", "DISEASE", 141, 155], ["retinal injury", "DISEASE", 166, 180], ["NO", "CHEMICAL", 17, 19], ["NO", "GENE_OR_GENE_PRODUCT", 17, 19], ["cell", "CELL", 102, 106], ["ocular", "ORGAN", 141, 147], ["retinal", "MULTI-TISSUE_STRUCTURE", 166, 173], ["inflammatory mediators", "PROTEIN", 50, 72], ["inflammatory mediators", "PROBLEM", 50, 72], ["neurodegeneration", "PROBLEM", 80, 97], ["cell apoptosis", "PROBLEM", 102, 116], ["serious ocular disease", "PROBLEM", 133, 155], ["retinal injury", "PROBLEM", 166, 180], ["inflammatory", "OBSERVATION_MODIFIER", 50, 62], ["cell apoptosis", "OBSERVATION", 102, 116], ["may lead to", "UNCERTAINTY", 121, 132], ["serious", "OBSERVATION_MODIFIER", 133, 140], ["retinal", "ANATOMY", 166, 173], ["injury", "OBSERVATION", 174, 180]]], ["Other inflammatory mediators also play a role in retinal pathology [18] .", [["retinal", "ANATOMY", 49, 56], ["retinal", "MULTI-TISSUE_STRUCTURE", 49, 56], ["inflammatory mediators", "PROTEIN", 6, 28], ["Other inflammatory mediators", "PROBLEM", 0, 28], ["inflammatory", "OBSERVATION", 6, 18]]], ["Moreover, PACAP and glutamate are co-stored in the retinohypothalamic tract [19] and PACAP attenuates glutamate induced neurotoxicity in cultured retinal neurons [20] suggesting that compromise of this VN would have significant detrimental impact on retinal viability though glutamate toxicity.", [["retinohypothalamic tract", "ANATOMY", 51, 75], ["retinal neurons", "ANATOMY", 146, 161], ["retinal", "ANATOMY", 250, 257], ["glutamate", "CHEMICAL", 20, 29], ["glutamate", "CHEMICAL", 102, 111], ["neurotoxicity", "DISEASE", 120, 133], ["glutamate", "CHEMICAL", 275, 284], ["toxicity", "DISEASE", 285, 293], ["glutamate", "CHEMICAL", 20, 29], ["glutamate", "CHEMICAL", 102, 111], ["glutamate", "CHEMICAL", 275, 284], ["PACAP", "GENE_OR_GENE_PRODUCT", 10, 15], ["glutamate", "SIMPLE_CHEMICAL", 20, 29], ["PACAP", "GENE_OR_GENE_PRODUCT", 85, 90], ["glutamate", "SIMPLE_CHEMICAL", 102, 111], ["retinal neurons [20]", "CELL", 146, 166], ["VN", "GENE_OR_GENE_PRODUCT", 202, 204], ["retinal", "MULTI-TISSUE_STRUCTURE", 250, 257], ["glutamate", "SIMPLE_CHEMICAL", 275, 284], ["cultured retinal neurons", "CELL_LINE", 137, 161], ["VN", "PROTEIN", 202, 204], ["PACAP and glutamate", "TREATMENT", 10, 29], ["PACAP attenuates glutamate induced neurotoxicity", "PROBLEM", 85, 133], ["retinal viability", "PROBLEM", 250, 267], ["glutamate toxicity", "PROBLEM", 275, 293], ["retinohypothalamic tract", "ANATOMY", 51, 75], ["retinal", "ANATOMY", 146, 153], ["retinal", "ANATOMY", 250, 257]]], ["Additional effects of VN compromise would possibly occur through unopposed vasoconstriction and inflammation.Autoimmunity and retinal pathologyResearch data exist on experimental autoimmune conditions such as experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune uveoretinitis (EAU) as models for human autoimmune disorders [21, 22] .", [["retinal", "ANATOMY", 126, 133], ["inflammation", "DISEASE", 96, 108], ["Autoimmunity", "DISEASE", 109, 121], ["retinal pathology", "DISEASE", 126, 143], ["autoimmune encephalomyelitis", "DISEASE", 222, 250], ["EAE", "DISEASE", 252, 255], ["autoimmune uveoretinitis", "DISEASE", 274, 298], ["EAU", "DISEASE", 300, 303], ["autoimmune disorders", "DISEASE", 325, 345], ["VN", "GENE_OR_GENE_PRODUCT", 22, 24], ["retinal", "MULTI-TISSUE_STRUCTURE", 126, 133], ["human", "ORGANISM", 319, 324], ["human", "SPECIES", 319, 324], ["human", "SPECIES", 319, 324], ["VN compromise", "PROBLEM", 22, 35], ["unopposed vasoconstriction", "PROBLEM", 65, 91], ["inflammation", "PROBLEM", 96, 108], ["Autoimmunity", "PROBLEM", 109, 121], ["retinal pathology", "TEST", 126, 143], ["Research data", "TEST", 143, 156], ["experimental autoimmune conditions", "PROBLEM", 166, 200], ["experimental autoimmune encephalomyelitis", "PROBLEM", 209, 250], ["experimental autoimmune uveoretinitis", "PROBLEM", 261, 298], ["human autoimmune disorders", "PROBLEM", 319, 345], ["vasoconstriction", "OBSERVATION", 75, 91], ["inflammation", "OBSERVATION", 96, 108], ["retinal", "ANATOMY", 126, 133], ["pathology", "OBSERVATION", 134, 143], ["autoimmune", "OBSERVATION", 179, 189], ["autoimmune encephalomyelitis", "OBSERVATION", 222, 250], ["autoimmune uveoretinitis", "OBSERVATION", 274, 298]]], ["Importantly, regulatory T cells suppress EAU [23] and VIP generates regulatory T cells in EAE [24] suggesting that VNs may have an important role in therapies.", [["regulatory T cells", "ANATOMY", 13, 31], ["regulatory T cells", "ANATOMY", 68, 86], ["EAE", "DISEASE", 90, 93], ["T cells", "CELL", 24, 31], ["VIP", "GENE_OR_GENE_PRODUCT", 54, 57], ["T cells", "CELL", 79, 86], ["VNs", "GENE_OR_GENE_PRODUCT", 115, 118], ["regulatory T cells", "CELL_TYPE", 13, 31], ["regulatory T cells", "CELL_TYPE", 68, 86], ["VNs", "TREATMENT", 115, 118]]], ["While a role for VIP in the treatment of EAU has not been established [25] some supportive evidence is encouraging [26, 27] .", [["EAU", "DISEASE", 41, 44], ["VIP", "GENE_OR_GENE_PRODUCT", 17, 20], ["VIP", "TREATMENT", 17, 20]]], ["Nevertheless, the question to be posed is could autoimmune or other dysfunction of VNs contribute to retinal disease by failing to provide proper immune regulation?Postulated vasoactive neuropeptide autoimmunity in retinal diseaseWhy VNs should participate in induction of autoimmunity, not just protecting from it, is unclear given their key role usually in protecting physiological systems from infection and inflammatory responses.", [["VNs", "ANATOMY", 83, 86], ["retinal", "ANATOMY", 101, 108], ["retinal", "ANATOMY", 215, 222], ["VNs", "ANATOMY", 234, 237], ["VNs", "DISEASE", 83, 86], ["retinal disease", "DISEASE", 101, 116], ["autoimmunity", "DISEASE", 199, 211], ["retinal disease", "DISEASE", 215, 230], ["autoimmunity", "DISEASE", 273, 285], ["infection", "DISEASE", 397, 406], ["VNs", "GENE_OR_GENE_PRODUCT", 83, 86], ["retinal", "MULTI-TISSUE_STRUCTURE", 101, 108], ["vasoactive neuropeptide", "GENE_OR_GENE_PRODUCT", 175, 198], ["retinal", "MULTI-TISSUE_STRUCTURE", 215, 222], ["VNs", "GENE_OR_GENE_PRODUCT", 234, 237], ["autoimmune", "PROBLEM", 48, 58], ["other dysfunction of VNs", "PROBLEM", 62, 86], ["retinal disease", "PROBLEM", 101, 116], ["retinal disease", "PROBLEM", 215, 230], ["autoimmunity", "PROBLEM", 273, 285], ["infection", "PROBLEM", 397, 406], ["inflammatory responses", "PROBLEM", 411, 433], ["retinal", "ANATOMY", 101, 108], ["disease", "OBSERVATION", 109, 116], ["vasoactive neuropeptide autoimmunity", "OBSERVATION", 175, 211], ["retinal", "ANATOMY", 215, 222], ["disease", "OBSERVATION", 223, 230], ["infection", "OBSERVATION", 397, 406], ["inflammatory", "OBSERVATION_MODIFIER", 411, 423]]], ["Promoter regions of some VN receptor genes have CpG fragments which might promote autoimmunity if exposed to apoptotic or necrotic circumstances and become recognised by the immune system as foreign immune complexes [28] .", [["immune system", "ANATOMY", 174, 187], ["autoimmunity", "DISEASE", 82, 94], ["necrotic", "DISEASE", 122, 130], ["CpG", "CHEMICAL", 48, 51], ["VN receptor", "GENE_OR_GENE_PRODUCT", 25, 36], ["Promoter regions", "DNA", 0, 16], ["VN receptor genes", "DNA", 25, 42], ["CpG fragments", "DNA", 48, 61], ["foreign immune complexes", "PROTEIN", 191, 215], ["CpG fragments", "PROBLEM", 48, 61], ["apoptotic or necrotic circumstances", "PROBLEM", 109, 144], ["CpG fragments", "OBSERVATION", 48, 61], ["necrotic", "OBSERVATION_MODIFIER", 122, 130]]], ["Also as their receptors are members of the GPCR family they may be susceptible to autoimmunity as are other members of the GPCR family [29] .Postulated vasoactive neuropeptide autoimmunity in retinal diseaseThe hypothesis that VN autoimmunity causes retinal disease requires definitive evidence.", [["retinal", "ANATOMY", 192, 199], ["retinal", "ANATOMY", 250, 257], ["autoimmunity", "DISEASE", 82, 94], ["autoimmunity", "DISEASE", 176, 188], ["retinal disease", "DISEASE", 192, 207], ["autoimmunity", "DISEASE", 230, 242], ["retinal disease", "DISEASE", 250, 265], ["GPCR", "GENE_OR_GENE_PRODUCT", 43, 47], ["vasoactive neuropeptide", "GENE_OR_GENE_PRODUCT", 152, 175], ["retinal", "MULTI-TISSUE_STRUCTURE", 192, 199], ["VN", "GENE_OR_GENE_PRODUCT", 227, 229], ["retinal", "MULTI-TISSUE_STRUCTURE", 250, 257], ["GPCR family", "PROTEIN", 43, 54], ["GPCR family", "PROTEIN", 123, 134], ["retinal disease", "PROBLEM", 192, 207], ["retinal disease", "PROBLEM", 250, 265], ["vasoactive neuropeptide autoimmunity", "OBSERVATION", 152, 188], ["retinal", "ANATOMY", 192, 199], ["disease", "OBSERVATION", 200, 207], ["retinal", "ANATOMY", 250, 257], ["disease", "OBSERVATION", 258, 265]]], ["However, there may be an association between retinal pathology and postulated VN fatigue-related conditions.", [["retinal", "ANATOMY", 45, 52], ["retinal pathology", "DISEASE", 45, 62], ["fatigue", "DISEASE", 81, 88], ["retinal", "MULTI-TISSUE_STRUCTURE", 45, 52], ["an association between retinal pathology", "PROBLEM", 22, 62], ["postulated VN fatigue", "PROBLEM", 67, 88], ["may be", "UNCERTAINTY", 15, 21], ["retinal", "ANATOMY", 45, 52], ["pathology", "OBSERVATION", 53, 62], ["VN fatigue", "OBSERVATION", 78, 88]]], ["Some limited evidence exists that retinal disease occurs in patients with CFS/ME [30] .", [["retinal", "ANATOMY", 34, 41], ["retinal disease", "DISEASE", 34, 49], ["CFS", "DISEASE", 74, 77], ["retinal", "MULTI-TISSUE_STRUCTURE", 34, 41], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["retinal disease", "PROBLEM", 34, 49], ["retinal", "ANATOMY", 34, 41], ["disease", "OBSERVATION", 42, 49]]], ["Evidence is now also available that abnormalities in VN receptor genes cause immunological disturbance in T cells of patients with multiple sclerosis MS resulting in Th1 skewed profiles and consequent pathology [31] .", [["T cells", "ANATOMY", 106, 113], ["multiple sclerosis MS", "DISEASE", 131, 152], ["VN receptor", "GENE_OR_GENE_PRODUCT", 53, 64], ["T cells", "CELL", 106, 113], ["patients", "ORGANISM", 117, 125], ["VN receptor genes", "DNA", 53, 70], ["T cells", "CELL_TYPE", 106, 113], ["patients", "SPECIES", 117, 125], ["abnormalities in VN receptor genes", "PROBLEM", 36, 70], ["immunological disturbance in T cells", "PROBLEM", 77, 113], ["multiple sclerosis MS", "PROBLEM", 131, 152], ["Th1 skewed profiles", "PROBLEM", 166, 185], ["consequent pathology", "PROBLEM", 190, 210], ["multiple", "OBSERVATION_MODIFIER", 131, 139], ["sclerosis", "OBSERVATION", 140, 149]]], ["This latter finding provides support for the case that VN disturbance does have demonstrable effects on downstream immunological function.Postulated vasoactive neuropeptide autoimmunity in retinal diseaseProof of this hypothesis has important implications for treatment and prevention of autoimmune retinopathy and blindness as a number of therapeutic pathways may be opened.", [["retinal", "ANATOMY", 189, 196], ["VN disturbance", "DISEASE", 55, 69], ["autoimmunity", "DISEASE", 173, 185], ["autoimmune retinopathy", "DISEASE", 288, 310], ["blindness", "DISEASE", 315, 324], ["VN", "GENE_OR_GENE_PRODUCT", 55, 57], ["vasoactive neuropeptide", "GENE_OR_GENE_PRODUCT", 149, 172], ["retinal", "MULTI-TISSUE_STRUCTURE", 189, 196], ["VN disturbance", "PROBLEM", 55, 69], ["treatment", "TREATMENT", 260, 269], ["autoimmune retinopathy", "PROBLEM", 288, 310], ["blindness", "PROBLEM", 315, 324], ["vasoactive neuropeptide autoimmunity", "OBSERVATION", 149, 185], ["retinal", "ANATOMY", 189, 196], ["autoimmune retinopathy", "OBSERVATION", 288, 310], ["blindness", "OBSERVATION", 315, 324]]], ["Importantly for therapeutic contexts cAMP effects are maintained by phosphodiesterase (PDE) inhibitors which could be used in VN autoimmune disorders.", [["cAMP", "CHEMICAL", 37, 41], ["autoimmune disorders", "DISEASE", 129, 149], ["cAMP", "CHEMICAL", 37, 41], ["cAMP", "SIMPLE_CHEMICAL", 37, 41], ["phosphodiesterase (PDE", "GENE_OR_GENE_PRODUCT", 68, 90], ["therapeutic contexts cAMP effects", "TREATMENT", 16, 49], ["phosphodiesterase (PDE) inhibitors", "TREATMENT", 68, 102], ["VN autoimmune disorders", "PROBLEM", 126, 149]]], ["PDE inhibitors have subsets which are highly specific and may constitute appropriately targeted interventions in cAMP disorders [32] [33] [34] .", [["cAMP", "CHEMICAL", 113, 117], ["cAMP", "CHEMICAL", 113, 117], ["PDE", "GENE_OR_GENE_PRODUCT", 0, 3], ["cAMP", "SIMPLE_CHEMICAL", 113, 117], ["PDE inhibitors", "TREATMENT", 0, 14], ["cAMP disorders", "PROBLEM", 113, 127]]], ["A case may exist to undertake a therapeutic trial of VN replacement, PDE inhibitors and other agents in autoimmune retinopathies resulting from possible VN autoimmunity.ConclusionAutoimmunity of VNs is not yet proven although evidence now exists implicating VNs in human autoimmune disorders such as MS. VNs not only protect against retinal pathology, but may themselves undergo autoimmune disruption to affect normally immune privileged regions of the eye.", [["retinal", "ANATOMY", 333, 340], ["eye", "ANATOMY", 453, 456], ["autoimmune retinopathies", "DISEASE", 104, 128], ["autoimmunity", "DISEASE", 156, 168], ["autoimmune disorders", "DISEASE", 271, 291], ["MS", "DISEASE", 300, 302], ["VN", "SIMPLE_CHEMICAL", 53, 55], ["PDE", "SIMPLE_CHEMICAL", 69, 72], ["VN", "GENE_OR_GENE_PRODUCT", 153, 155], ["VNs", "CANCER", 195, 198], ["VNs", "GENE_OR_GENE_PRODUCT", 258, 261], ["human", "ORGANISM", 265, 270], ["VNs", "SIMPLE_CHEMICAL", 304, 307], ["retinal", "MULTI-TISSUE_STRUCTURE", 333, 340], ["eye", "ORGAN", 453, 456], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 265, 270], ["VN replacement", "TREATMENT", 53, 67], ["PDE inhibitors", "TREATMENT", 69, 83], ["other agents", "TREATMENT", 88, 100], ["autoimmune retinopathies", "PROBLEM", 104, 128], ["VN autoimmunity", "PROBLEM", 153, 168], ["VNs", "PROBLEM", 195, 198], ["VNs", "PROBLEM", 258, 261], ["human autoimmune disorders", "PROBLEM", 265, 291], ["MS", "PROBLEM", 300, 302], ["VNs", "TREATMENT", 304, 307], ["retinal pathology", "PROBLEM", 333, 350], ["autoimmune disruption", "PROBLEM", 379, 400], ["retinal", "ANATOMY", 333, 340], ["pathology", "OBSERVATION", 341, 350], ["autoimmune", "OBSERVATION", 379, 389], ["eye", "ANATOMY", 453, 456]]], ["An association of VN autoimmunity with retinopathy in humans should be investigated as preventive and treatment opportunities may already exist.", [["autoimmunity", "DISEASE", 21, 33], ["retinopathy", "DISEASE", 39, 50], ["VN", "GENE_OR_GENE_PRODUCT", 18, 20], ["humans", "ORGANISM", 54, 60], ["humans", "SPECIES", 54, 60], ["humans", "SPECIES", 54, 60], ["VN autoimmunity", "PROBLEM", 18, 33], ["retinopathy", "PROBLEM", 39, 50], ["VN autoimmunity", "OBSERVATION", 18, 33], ["retinopathy", "OBSERVATION", 39, 50]]], ["Clinical trials for VN replacement, PDE inhibitors and other interventions may then be considered for the treatment of autoimmune eye conditions and potentially the prevention of blindness in them.", [["eye", "ANATOMY", 130, 133], ["autoimmune eye conditions", "DISEASE", 119, 144], ["blindness", "DISEASE", 179, 188], ["PDE", "SIMPLE_CHEMICAL", 36, 39], ["eye", "ORGAN", 130, 133], ["Clinical trials", "TREATMENT", 0, 15], ["VN replacement", "TREATMENT", 20, 34], ["PDE inhibitors", "TREATMENT", 36, 50], ["other interventions", "TREATMENT", 55, 74], ["autoimmune eye conditions", "PROBLEM", 119, 144], ["blindness", "PROBLEM", 179, 188], ["blindness", "OBSERVATION", 179, 188]]]], "ae7d48fde4968d045abed72cd1335b86e3c4ca06": [["IntroductionMucopolysaccharidosis type I (MPS-1) is an autosomal recessive metabolic storage disease caused by the deficiency of a-L-iduronidase, resulting in accumulation of heparan and dermatan sulfate substrates (glycosaminoglycans) in various tissues.", [["tissues", "ANATOMY", 247, 254], ["Mucopolysaccharidosis type I", "DISEASE", 12, 40], ["autosomal recessive metabolic storage disease", "DISEASE", 55, 100], ["-L-iduronidase", "CHEMICAL", 130, 144], ["dermatan sulfate", "CHEMICAL", 187, 203], ["dermatan sulfate", "CHEMICAL", 187, 203], ["Mucopolysaccharidosis type I", "GENE_OR_GENE_PRODUCT", 12, 40], ["MPS-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["-L-iduronidase", "GENE_OR_GENE_PRODUCT", 130, 144], ["heparan", "SIMPLE_CHEMICAL", 175, 182], ["dermatan sulfate substrates", "SIMPLE_CHEMICAL", 187, 214], ["glycosaminoglycans", "SIMPLE_CHEMICAL", 216, 234], ["tissues", "TISSUE", 247, 254], ["-L-iduronidase", "PROTEIN", 130, 144], ["Mucopolysaccharidosis type I (MPS-1", "SPECIES", 12, 47], ["IntroductionMucopolysaccharidosis type I", "PROBLEM", 0, 40], ["MPS", "TEST", 42, 45], ["an autosomal recessive metabolic storage disease", "PROBLEM", 52, 100], ["the deficiency", "PROBLEM", 111, 125], ["a-L-iduronidase", "TREATMENT", 129, 144], ["heparan", "TREATMENT", 175, 182], ["dermatan sulfate substrates (glycosaminoglycans", "TREATMENT", 187, 234], ["Mucopolysaccharidosis", "OBSERVATION", 12, 33], ["autosomal", "OBSERVATION_MODIFIER", 55, 64], ["recessive", "OBSERVATION_MODIFIER", 65, 74], ["metabolic storage disease", "OBSERVATION", 75, 100], ["various tissues", "ANATOMY", 239, 254]]], ["1 Hurler's syndrome (HS) is the most severe phenotype, with symptoms appearing shortly after birth, characterized by upper airway obstruction and recurrent chest infections, hepatosplenomegaly, corneal clouding, cardiac dysfunction, skeletal abnormalities, progressive deterioration of the central nervous system and death in early childhood.", [["airway", "ANATOMY", 123, 129], ["chest", "ANATOMY", 156, 161], ["corneal", "ANATOMY", 194, 201], ["cardiac", "ANATOMY", 212, 219], ["skeletal", "ANATOMY", 233, 241], ["central nervous system", "ANATOMY", 290, 312], ["Hurler's syndrome", "DISEASE", 2, 19], ["HS", "DISEASE", 21, 23], ["airway obstruction", "DISEASE", 123, 141], ["chest infections", "DISEASE", 156, 172], ["hepatosplenomegaly", "DISEASE", 174, 192], ["corneal clouding", "DISEASE", 194, 210], ["cardiac dysfunction", "DISEASE", 212, 231], ["skeletal abnormalities", "DISEASE", 233, 255], ["deterioration of the central nervous system", "DISEASE", 269, 312], ["death", "DISEASE", 317, 322], ["upper airway", "ORGANISM_SUBDIVISION", 117, 129], ["chest", "ORGANISM_SUBDIVISION", 156, 161], ["corneal", "TISSUE", 194, 201], ["cardiac", "ORGAN", 212, 219], ["skeletal", "ORGAN", 233, 241], ["central nervous system", "ANATOMICAL_SYSTEM", 290, 312], ["Hurler's syndrome", "PROBLEM", 2, 19], ["the most severe phenotype", "PROBLEM", 28, 53], ["symptoms", "PROBLEM", 60, 68], ["upper airway obstruction", "PROBLEM", 117, 141], ["recurrent chest infections", "PROBLEM", 146, 172], ["hepatosplenomegaly", "PROBLEM", 174, 192], ["corneal clouding", "PROBLEM", 194, 210], ["cardiac dysfunction", "PROBLEM", 212, 231], ["skeletal abnormalities", "PROBLEM", 233, 255], ["progressive deterioration of the central nervous system", "PROBLEM", 257, 312], ["death", "PROBLEM", 317, 322], ["most severe", "OBSERVATION_MODIFIER", 32, 43], ["upper", "ANATOMY_MODIFIER", 117, 122], ["airway", "ANATOMY", 123, 129], ["obstruction", "OBSERVATION", 130, 141], ["recurrent", "OBSERVATION_MODIFIER", 146, 155], ["chest", "ANATOMY", 156, 161], ["infections", "OBSERVATION", 162, 172], ["hepatosplenomegaly", "OBSERVATION", 174, 192], ["corneal", "ANATOMY", 194, 201], ["clouding", "OBSERVATION", 202, 210], ["cardiac", "ANATOMY", 212, 219], ["dysfunction", "OBSERVATION", 220, 231], ["skeletal", "ANATOMY", 233, 241], ["abnormalities", "OBSERVATION", 242, 255], ["progressive", "OBSERVATION_MODIFIER", 257, 268], ["deterioration", "OBSERVATION", 269, 282], ["central", "ANATOMY_MODIFIER", 290, 297], ["nervous system", "ANATOMY", 298, 312], ["early", "OBSERVATION_MODIFIER", 326, 331]]], ["[1] [2] [3] [4] [5] [6] [7] Hematopoietic stem cell transplantation (SCT) can prevent the progression of HS and provides maximal benefit when performed early in life.", [["Hematopoietic stem cell", "ANATOMY", 28, 51], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 23], ["stem cell", "CELL", 42, 51], ["Hematopoietic stem cell transplantation", "TREATMENT", 28, 67], ["the progression of HS", "PROBLEM", 86, 107], ["stem cell transplantation", "OBSERVATION", 42, 67]]], ["6, 8 Enzyme replacement therapy (ERT; Aldurazyme) became recently available for the treatment of MPS-1.", [["Aldurazyme", "CHEMICAL", 38, 48], ["MPS", "DISEASE", 97, 100], ["Aldurazyme", "CHEMICAL", 38, 48], ["Aldurazyme", "SIMPLE_CHEMICAL", 38, 48], ["MPS-1", "GENE_OR_GENE_PRODUCT", 97, 102], ["8 Enzyme replacement therapy", "TREATMENT", 3, 31], ["ERT", "TREATMENT", 33, 36], ["Aldurazyme", "TREATMENT", 38, 48], ["MPS", "TEST", 97, 100]]], ["However, intravenously administered enzyme will not cross the blood-brain barrier; therefore, SCT remains the treatment of choice in children with HS.IntroductionThe estimated number of HS patients who underwent SCT worldwide, since the early 1980s, is more than 400 (based on European Blood and Marrow Transplantation (EBMT)-and Center for International Blood and Marrow Transplant Research databases).", [["intravenously", "ANATOMY", 9, 22], ["blood-brain barrier", "ANATOMY", 62, 81], ["Blood", "ANATOMY", 286, 291], ["Marrow", "ANATOMY", 296, 302], ["Blood", "ANATOMY", 355, 360], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 9, 22], ["blood-", "MULTI-TISSUE_STRUCTURE", 62, 68], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 68, 81], ["children", "ORGANISM", 133, 141], ["patients", "ORGANISM", 189, 197], ["Marrow", "TISSUE", 296, 302], ["children", "SPECIES", 133, 141], ["patients", "SPECIES", 189, 197], ["intravenously administered enzyme", "TEST", 9, 42], ["SCT", "TREATMENT", 94, 97], ["European Blood and Marrow Transplantation", "TREATMENT", 277, 318], ["International Blood", "TEST", 341, 360], ["brain", "ANATOMY", 68, 73], ["Marrow", "ANATOMY", 296, 302], ["Marrow", "ANATOMY", 365, 371]]], ["Donor engraftment after SCT leads to a rapid reduction of obstructive airway symptoms, hepatosplenomegaly and corneal clouding.", [["airway", "ANATOMY", 70, 76], ["corneal", "ANATOMY", 110, 117], ["obstructive airway symptoms", "DISEASE", 58, 85], ["hepatosplenomegaly", "DISEASE", 87, 105], ["corneal clouding", "DISEASE", 110, 126], ["airway", "MULTI-TISSUE_STRUCTURE", 70, 76], ["corneal", "TISSUE", 110, 117], ["Donor engraftment", "TREATMENT", 0, 17], ["SCT", "TREATMENT", 24, 27], ["obstructive airway symptoms", "PROBLEM", 58, 85], ["hepatosplenomegaly", "PROBLEM", 87, 105], ["corneal clouding", "PROBLEM", 110, 126], ["engraftment", "OBSERVATION", 6, 17], ["obstructive", "OBSERVATION_MODIFIER", 58, 69], ["airway", "ANATOMY", 70, 76], ["hepatosplenomegaly", "OBSERVATION", 87, 105], ["corneal", "ANATOMY", 110, 117], ["clouding", "OBSERVATION", 118, 126]]], ["Hydrocephalus is either prevented or stabilized and hearing impairment improves in many children.", [["Hydrocephalus", "DISEASE", 0, 13], ["hearing impairment", "DISEASE", 52, 70], ["children", "ORGANISM", 88, 96], ["children", "SPECIES", 88, 96], ["Hydrocephalus", "PROBLEM", 0, 13], ["hearing impairment", "PROBLEM", 52, 70], ["stabilized", "OBSERVATION_MODIFIER", 37, 47]]], ["[9] [10] [11] [12] [13] Additionally, successful SCT averts death from cardiac dysfunction 2,5 improves growth and psychomotor development, and prolongs survival.", [["cardiac", "ANATOMY", 71, 78], ["death", "DISEASE", 60, 65], ["cardiac dysfunction", "DISEASE", 71, 90], ["[9] [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 0, 23], ["cardiac", "ORGAN", 71, 78], ["successful SCT averts death", "PROBLEM", 38, 65], ["cardiac dysfunction", "PROBLEM", 71, 90], ["psychomotor development", "PROBLEM", 115, 138], ["cardiac", "ANATOMY", 71, 78], ["dysfunction", "OBSERVATION", 79, 90]]], ["4, 6, 7, 11, 12, 14 Significant and often progressive orthopedic anomalies persist however, despite successful SCT, often needing additional interventions.", [["orthopedic anomalies", "DISEASE", 54, 74], ["often progressive orthopedic anomalies", "PROBLEM", 36, 74], ["successful SCT", "TREATMENT", 100, 114], ["additional interventions", "TREATMENT", 130, 154], ["Significant", "OBSERVATION_MODIFIER", 20, 31], ["often", "OBSERVATION_MODIFIER", 36, 41], ["progressive", "OBSERVATION_MODIFIER", 42, 53], ["orthopedic", "OBSERVATION_MODIFIER", 54, 64], ["anomalies", "OBSERVATION", 65, 74]]], ["6, 11, 12 While the quality of life of successfully transplanted children seems encouraging, the relatively high rates of graft failure (15-75%) [9] [10] [11] [12] and 'transplant-related morbidity' limit its success.", [["graft", "ANATOMY", 122, 127], ["children", "ORGANISM", 65, 73], ["graft", "TISSUE", 122, 127], ["children", "SPECIES", 65, 73], ["graft failure", "PROBLEM", 122, 135], ["'transplant", "TREATMENT", 168, 179], ["morbidity'", "PROBLEM", 188, 198], ["graft failure", "OBSERVATION", 122, 135]]], ["9, 10, 15 Optimizing transplantation techniques resulting in less graft failure and less 'transplant-related morbidity/mortality' could improve the outcome of HS patients.IntroductionWe now report data on 146 patients with HS transplanted in Europe between 1994 and 2004.", [["graft", "ANATOMY", 66, 71], ["graft", "TISSUE", 66, 71], ["patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 209, 217], ["Optimizing transplantation techniques", "TREATMENT", 10, 47], ["less graft failure", "PROBLEM", 61, 79], ["mortality'", "PROBLEM", 119, 129], ["less", "OBSERVATION_MODIFIER", 61, 65], ["graft failure", "OBSERVATION", 66, 79], ["less", "OBSERVATION_MODIFIER", 84, 88]]], ["We studied different conditioning regimens, donor types and cell sources to identify factors associated with graft failure and morbidity after SCT.Collection of dataAll HS patients reported to the EBMT-registry between January 1994 and September 2004 were included.", [["cell", "ANATOMY", 60, 64], ["graft", "ANATOMY", 109, 114], ["graft failure", "DISEASE", 109, 122], ["cell", "CELL", 60, 64], ["graft", "TISSUE", 109, 114], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["different conditioning regimens", "TREATMENT", 11, 42], ["donor types and cell sources", "PROBLEM", 44, 72], ["graft failure", "PROBLEM", 109, 122], ["morbidity", "PROBLEM", 127, 136], ["SCT", "TEST", 143, 146], ["graft failure", "OBSERVATION", 109, 122]]], ["Since the follow-up of these patients was incomplete, an additional 'simple questionnaire' was prepared and sent to the various centers that transplanted these patients to complete the data set on (1) basic patient characteristics, (2) basic donor information (cell source, donor relationship, human leukocyte antigen (HLA)-matching and, in the case of cord blood (CB), cell count of the product, pre-transplant ERT), (3) conditioning regimen used, (4) survival and engraftment including chimerism and enzyme activity and (5) transplant-related morbidity and mortality with particular reference to graft-versus-host disease (GvHD), veno-occlusive disease (VOD), pulmonary complications (infection, idiopathic pneumonia syndrome/diffuse alveolar hemorrhage (IPS/DAH)).PatientsFrom a total of 154 patients entered in the EBMT registry, questionnaires were completed in 146 patients (82 male/64 female).", [["cell", "ANATOMY", 261, 265], ["cord blood", "ANATOMY", 353, 363], ["CB", "ANATOMY", 365, 367], ["cell", "ANATOMY", 370, 374], ["graft", "ANATOMY", 598, 603], ["pulmonary", "ANATOMY", 662, 671], ["alveolar", "ANATOMY", 736, 744], ["graft-versus-host disease", "DISEASE", 598, 623], ["GvHD", "DISEASE", 625, 629], ["veno-occlusive disease", "DISEASE", 632, 654], ["VOD", "DISEASE", 656, 659], ["pulmonary complications", "DISEASE", 662, 685], ["infection", "DISEASE", 687, 696], ["idiopathic pneumonia syndrome", "DISEASE", 698, 727], ["alveolar hemorrhage", "DISEASE", 736, 755], ["DAH", "DISEASE", 761, 764], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 160, 168], ["patient", "ORGANISM", 207, 214], ["cell", "CELL", 261, 265], ["human leukocyte antigen", "GENE_OR_GENE_PRODUCT", 294, 317], ["cord", "ORGANISM_SUBSTANCE", 353, 357], ["blood", "ORGANISM_SUBSTANCE", 358, 363], ["CB", "CELL", 365, 367], ["cell", "CELL", 370, 374], ["graft", "TISSUE", 598, 603], ["pulmonary", "ORGAN", 662, 671], ["alveolar", "MULTI-TISSUE_STRUCTURE", 736, 744], ["Patients", "ORGANISM", 767, 775], ["patients", "ORGANISM", 795, 803], ["patients", "ORGANISM", 871, 879], ["human leukocyte antigen", "PROTEIN", 294, 317], ["HLA", "PROTEIN", 319, 322], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 160, 168], ["patient", "SPECIES", 207, 214], ["human", "SPECIES", 294, 299], ["Patients", "SPECIES", 767, 775], ["patients", "SPECIES", 795, 803], ["patients", "SPECIES", 871, 879], ["human", "SPECIES", 294, 299], ["human leukocyte antigen", "TEST", 294, 317], ["cord blood", "TEST", 353, 363], ["cell count", "TEST", 370, 380], ["pre-transplant ERT", "TREATMENT", 397, 415], ["conditioning regimen", "TREATMENT", 422, 442], ["survival", "TREATMENT", 453, 461], ["engraftment", "TREATMENT", 466, 477], ["chimerism and enzyme activity", "TREATMENT", 488, 517], ["transplant", "TREATMENT", 526, 536], ["graft", "TREATMENT", 598, 603], ["host disease", "PROBLEM", 611, 623], ["GvHD", "PROBLEM", 625, 629], ["veno-occlusive disease (VOD)", "PROBLEM", 632, 660], ["pulmonary complications (infection", "PROBLEM", 662, 696], ["idiopathic pneumonia syndrome", "PROBLEM", 698, 727], ["diffuse alveolar hemorrhage", "PROBLEM", 728, 755], ["IPS/DAH)", "TREATMENT", 757, 765], ["cord blood", "ANATOMY", 353, 363], ["graft", "OBSERVATION", 598, 603], ["host disease", "OBSERVATION", 611, 623], ["GvHD", "OBSERVATION", 625, 629], ["veno-occlusive", "OBSERVATION_MODIFIER", 632, 646], ["disease", "OBSERVATION", 647, 654], ["VOD", "OBSERVATION", 656, 659], ["pulmonary", "ANATOMY", 662, 671], ["complications", "OBSERVATION", 672, 685], ["infection", "OBSERVATION", 687, 696], ["idiopathic", "OBSERVATION_MODIFIER", 698, 708], ["pneumonia", "OBSERVATION", 709, 718], ["diffuse", "OBSERVATION_MODIFIER", 728, 735], ["alveolar", "ANATOMY_MODIFIER", 736, 744], ["hemorrhage", "OBSERVATION", 745, 755]]], ["The diagnosis of HS was confirmed on the basis of the a-L-iduronidase activity in peripheral blood leukocytes, increased excretion of glycosaminoglycans in the urine and the clinical phenotype.", [["peripheral blood leukocytes", "ANATOMY", 82, 109], ["urine", "ANATOMY", 160, 165], ["-L-iduronidase", "CHEMICAL", 55, 69], ["-L-iduronidase", "SIMPLE_CHEMICAL", 55, 69], ["peripheral blood leukocytes", "ORGANISM_SUBSTANCE", 82, 109], ["glycosaminoglycans", "SIMPLE_CHEMICAL", 134, 152], ["urine", "ORGANISM_SUBSTANCE", 160, 165], ["iduronidase", "PROTEIN", 58, 69], ["peripheral blood leukocytes", "CELL_TYPE", 82, 109], ["HS", "PROBLEM", 17, 19], ["peripheral blood leukocytes", "PROBLEM", 82, 109], ["increased excretion of glycosaminoglycans in the urine", "PROBLEM", 111, 165], ["the clinical phenotype", "PROBLEM", 170, 192], ["peripheral", "ANATOMY_MODIFIER", 82, 92], ["blood leukocytes", "ANATOMY", 93, 109], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["excretion", "OBSERVATION_MODIFIER", 121, 130], ["glycosaminoglycans", "OBSERVATION_MODIFIER", 134, 152]]], ["The median age of diagnosis was 10.5 (range 0-55) months, while the median age at transplantation was 18 (range 1-96) months.", [["diagnosis", "TEST", 18, 27]]], ["Patients were transplanted in 16 centers: Manchester (39) , Lyon (20) , Dublin (20) , London (15) , Paris (12) , Utrecht (8), Monza (6), Hannover (5), Prague (5), Vienna (4), Zurich (4), Ghent (4), Padua (1), Jena (1), Leiden (1) and Nancy (1).PatientsGroups to be analyzed: grafts and conditioning HLA matching was based on high-resolution (HR) typing for class I and class II (10 antigens) for bone marrow (BM) and peripheral blood stem cell (PBSC) donors, and for CB donors lower resolution criteria were used (loci A and B by serology and DRB1 by HR typing).", [["grafts", "ANATOMY", 275, 281], ["bone marrow", "ANATOMY", 396, 407], ["BM", "ANATOMY", 409, 411], ["peripheral blood stem cell", "ANATOMY", 417, 443], ["PBSC", "ANATOMY", 445, 449], ["Patients", "ORGANISM", 0, 8], ["Patients", "ORGANISM", 244, 252], ["grafts", "TISSUE", 275, 281], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 396, 407], ["BM", "CELL", 409, 411], ["peripheral blood stem cell", "CELL", 417, 443], ["PBSC", "CELL", 445, 449], ["donors", "ORGANISM", 451, 457], ["peripheral blood stem cell", "CELL_TYPE", 417, 443], ["PBSC", "CELL_TYPE", 445, 449], ["Patients", "SPECIES", 0, 8], ["Patients", "SPECIES", 244, 252], ["class I", "SPECIES", 357, 364], ["Monza", "TREATMENT", 126, 131], ["grafts and conditioning HLA matching", "TREATMENT", 275, 311], ["bone marrow (BM", "TEST", 396, 411], ["peripheral blood stem cell", "PROBLEM", 417, 443], ["PBSC) donors", "TEST", 445, 457], ["CB donors lower resolution criteria", "TEST", 467, 502], ["serology", "TEST", 530, 538], ["DRB1", "TEST", 543, 547], ["HR typing", "TEST", 551, 560], ["grafts", "OBSERVATION", 275, 281], ["bone marrow", "ANATOMY", 396, 407], ["peripheral", "ANATOMY_MODIFIER", 417, 427], ["blood", "ANATOMY", 428, 433], ["stem cell", "OBSERVATION", 434, 443]]], ["A DPB1 mismatch was not taken into account.", [["DPB1", "GENE_OR_GENE_PRODUCT", 2, 6], ["DPB1", "DNA", 2, 6], ["A DPB1 mismatch", "TREATMENT", 0, 15]]], ["Mainly due to retrospective HR typing in some centers, the number of patients transplanted with X2 mismatches is relatively high.", [["patients", "ORGANISM", 69, 77], ["X2 mismatches", "DNA", 96, 109], ["patients", "SPECIES", 69, 77], ["retrospective HR typing", "TEST", 14, 37], ["X2 mismatches", "TREATMENT", 96, 109], ["high", "OBSERVATION_MODIFIER", 124, 128]]], ["For the analyses, patients were simply divided into matched or mismatched group.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["CB grafts identical according to the lower resolution criteria mentioned above were regarded as matched.", [["CB grafts", "ANATOMY", 0, 9], ["CB grafts", "TISSUE", 0, 9], ["CB grafts", "TREATMENT", 0, 9], ["grafts", "OBSERVATION", 3, 9]]], ["Other factors analyzed included (a) cell source (BM, PBSC, CB), (b) donor relationship and (c) T-cell depletion (TCD).PatientsConditioning regimens were grouped as follows: busulfan-cyclophosphamide 200 mg/kg, busulfan with high-dose cyclophosphamide (240-260 mg/kg), busulfan-targeting, fludarabine-based myeloablative (Flud-MA) and reducedintensity conditioning (RIC).", [["cell", "ANATOMY", 36, 40], ["BM", "ANATOMY", 49, 51], ["PBSC", "ANATOMY", 53, 57], ["CB", "ANATOMY", 59, 61], ["T-cell", "ANATOMY", 95, 101], ["busulfan", "CHEMICAL", 173, 181], ["cyclophosphamide", "CHEMICAL", 182, 198], ["busulfan", "CHEMICAL", 210, 218], ["cyclophosphamide", "CHEMICAL", 234, 250], ["busulfan", "CHEMICAL", 268, 276], ["fludarabine", "CHEMICAL", 288, 299], ["Flud-MA", "CHEMICAL", 321, 328], ["busulfan", "CHEMICAL", 173, 181], ["cyclophosphamide", "CHEMICAL", 182, 198], ["busulfan", "CHEMICAL", 210, 218], ["cyclophosphamide", "CHEMICAL", 234, 250], ["busulfan", "CHEMICAL", 268, 276], ["fludarabine", "CHEMICAL", 288, 299], ["cell", "CELL", 36, 40], ["BM", "TISSUE", 49, 51], ["T-cell", "CELL", 95, 101], ["Patients", "ORGANISM", 118, 126], ["busulfan", "SIMPLE_CHEMICAL", 173, 181], ["cyclophosphamide", "SIMPLE_CHEMICAL", 182, 198], ["busulfan", "SIMPLE_CHEMICAL", 210, 218], ["cyclophosphamide", "SIMPLE_CHEMICAL", 234, 250], ["busulfan", "SIMPLE_CHEMICAL", 268, 276], ["fludarabine", "SIMPLE_CHEMICAL", 288, 299], ["Flud-MA", "SIMPLE_CHEMICAL", 321, 328], ["PBSC", "CELL_TYPE", 53, 57], ["Patients", "SPECIES", 118, 126], ["PBSC", "TEST", 53, 57], ["(c) T-cell depletion", "PROBLEM", 91, 111], ["PatientsConditioning regimens", "TREATMENT", 118, 147], ["busulfan", "TREATMENT", 173, 181], ["cyclophosphamide", "TREATMENT", 182, 198], ["busulfan", "TREATMENT", 210, 218], ["high-dose cyclophosphamide", "TREATMENT", 224, 250], ["busulfan", "TREATMENT", 268, 276], ["fludarabine", "TREATMENT", 288, 299], ["myeloablative (Flud-MA", "TREATMENT", 306, 328], ["reducedintensity conditioning", "TREATMENT", 334, 363], ["cell depletion", "OBSERVATION", 97, 111]]], ["The various subgroups within the main groups are described (in the legend of Table 2 ).PatientsDonor chimerism was determined by various standard procedures (cytogenetic/molecular/X-Y FISH), depending on the center and grouped as follows: 495, 75-95, 50-75, 25-50 and 11-25%.", [["Patients", "ORGANISM", 87, 95], ["Patients", "SPECIES", 87, 95], ["various", "OBSERVATION_MODIFIER", 4, 11], ["subgroups", "OBSERVATION_MODIFIER", 12, 21], ["main", "OBSERVATION_MODIFIER", 33, 37], ["groups", "OBSERVATION_MODIFIER", 38, 44], ["Donor chimerism", "OBSERVATION", 95, 110]]], ["A donor chimerism of 495% was regarded as having full donor chimerism (410 and o95% as mixed chimerism).PatientsEnzyme levels in leukocytes were measured (locally) by various standard procedures and grouped as follows: normal, high heterozygote for heterozygote individuals (15-25 nmol/h/mg) and low heterozygote for heterozygote individuals (4.5-15 nmol/h/mg).PatientsProphylaxis against GvHD consisted of cyclosporin (aiming at 100-200mg/l) for all patients, 7addition of methylprednisolone (1-2 mg/kg/day) in the case of a CB donors and plus methotrexate (MTX) in the case of a unrelated donor (UD).", [["leukocytes", "ANATOMY", 129, 139], ["GvHD", "DISEASE", 389, 393], ["cyclosporin", "CHEMICAL", 407, 418], ["methylprednisolone", "CHEMICAL", 474, 492], ["methotrexate", "CHEMICAL", 545, 557], ["MTX", "CHEMICAL", 559, 562], ["cyclosporin", "CHEMICAL", 407, 418], ["methylprednisolone", "CHEMICAL", 474, 492], ["methotrexate", "CHEMICAL", 545, 557], ["MTX", "CHEMICAL", 559, 562], ["Patients", "ORGANISM", 104, 112], ["leukocytes", "CELL", 129, 139], ["Patients", "ORGANISM", 361, 369], ["cyclosporin", "SIMPLE_CHEMICAL", 407, 418], ["patients", "ORGANISM", 451, 459], ["methylprednisolone", "SIMPLE_CHEMICAL", 474, 492], ["methotrexate", "SIMPLE_CHEMICAL", 545, 557], ["MTX", "SIMPLE_CHEMICAL", 559, 562], ["leukocytes", "CELL_TYPE", 129, 139], ["Patients", "SPECIES", 104, 112], ["Patients", "SPECIES", 361, 369], ["patients", "SPECIES", 451, 459], ["A donor chimerism", "TEST", 0, 17], ["full donor chimerism", "PROBLEM", 49, 69], ["PatientsEnzyme levels", "TEST", 104, 125], ["leukocytes", "TEST", 129, 139], ["high heterozygote", "PROBLEM", 227, 244], ["heterozygote individuals", "PROBLEM", 249, 273], ["low heterozygote", "PROBLEM", 296, 312], ["heterozygote individuals", "PROBLEM", 317, 341], ["PatientsProphylaxis", "TREATMENT", 361, 380], ["GvHD", "PROBLEM", 389, 393], ["cyclosporin", "TREATMENT", 407, 418], ["methylprednisolone", "TREATMENT", 474, 492], ["a CB donors", "TREATMENT", 524, 535], ["methotrexate (MTX", "TREATMENT", 545, 562], ["a unrelated donor (UD", "TREATMENT", 579, 600], ["donor chimerism", "OBSERVATION", 2, 17], ["chimerism", "OBSERVATION", 60, 69], ["normal", "OBSERVATION", 219, 225]]], ["In the case of a sibling donor, the use of MTX was based on institutional protocols.", [["MTX", "CHEMICAL", 43, 46], ["MTX", "CHEMICAL", 43, 46], ["MTX", "SIMPLE_CHEMICAL", 43, 46], ["a sibling donor", "TREATMENT", 15, 30], ["MTX", "TREATMENT", 43, 46], ["institutional protocols", "TREATMENT", 60, 83]]], ["When in the case of TCD (by any method: for example, using antibodies, CD34 \u00fe selection), the number of cells was reduced o50 000 CD3 \u00fe /kg, no GvHD prophylaxis was given.End pointsPrimary end points were the 'alive and engrafted' rate and 'survival' after the first SCT at the latest follow-up time point (at least 46 months).", [["cells", "ANATOMY", 104, 109], ["GvHD", "DISEASE", 144, 148], ["CD34", "GENE_OR_GENE_PRODUCT", 71, 75], ["cells", "CELL", 104, 109], ["TCD", "PROTEIN", 20, 23], ["antibodies", "PROTEIN", 59, 69], ["CD34", "PROTEIN", 71, 75], ["CD3", "PROTEIN", 130, 133], ["GvHD prophylaxis", "TREATMENT", 144, 160], ["the first SCT", "TEST", 257, 270], ["no", "UNCERTAINTY", 141, 143], ["GvHD prophylaxis", "OBSERVATION", 144, 160]]], ["'Engraftment' was defined as a donor chimerism of 410% and an a-L-iduronidase level of more than the lower limit of normal for the heterozygote individuals (44.5 nmol/h/mg).", [["-L-iduronidase", "GENE_OR_GENE_PRODUCT", 63, 77], ["a donor chimerism", "TEST", 29, 46], ["an a-L-iduronidase level", "TEST", 59, 83], ["the heterozygote individuals", "PROBLEM", 127, 155]]], ["Patients receiving successful 'donor lymphocyte infusions (DLI)' (defined as subsequent increase of donor chimerism) because of mixed chimerism were regarded as successful transplants.End pointsSecondary end points were transplantation-associated morbidity defined as acute GvHD or chronic GvHD, VOD and IPS/DAH.", [["lymphocyte", "ANATOMY", 37, 47], ["GvHD", "DISEASE", 274, 278], ["GvHD", "DISEASE", 290, 294], ["VOD", "DISEASE", 296, 299], ["DAH", "DISEASE", 308, 311], ["Patients", "ORGANISM", 0, 8], ["lymphocyte", "CELL", 37, 47], ["Patients", "SPECIES", 0, 8], ["successful 'donor lymphocyte infusions (DLI)", "TREATMENT", 19, 63], ["donor chimerism", "TREATMENT", 100, 115], ["mixed chimerism", "PROBLEM", 128, 143], ["successful transplants", "TREATMENT", 161, 183], ["Secondary end points", "PROBLEM", 194, 214], ["transplantation", "TREATMENT", 220, 235], ["morbidity", "PROBLEM", 247, 256], ["acute GvHD", "PROBLEM", 268, 278], ["chronic GvHD", "PROBLEM", 282, 294], ["VOD", "PROBLEM", 296, 299], ["IPS", "PROBLEM", 304, 307], ["DAH", "PROBLEM", 308, 311], ["donor chimerism", "OBSERVATION", 100, 115], ["mixed chimerism", "OBSERVATION", 128, 143], ["acute", "OBSERVATION_MODIFIER", 268, 273], ["GvHD", "OBSERVATION", 274, 278], ["chronic", "OBSERVATION_MODIFIER", 282, 289], ["GvHD", "OBSERVATION", 290, 294], ["VOD", "OBSERVATION", 296, 299], ["DAH", "OBSERVATION", 308, 311]]], ["Acute GvHD was diagnosed and graded according to Glucksberg et al. 16 Severity of chronic GvHD was graded according to Shulman et al. 17 The diagnosis of VOD was made according to the Seattle or Baltimore criteria.", [["GvHD", "DISEASE", 6, 10], ["GvHD", "DISEASE", 90, 94], ["VOD", "DISEASE", 154, 157], ["Acute GvHD", "PROBLEM", 0, 10], ["chronic GvHD", "PROBLEM", 82, 94], ["VOD", "PROBLEM", 154, 157], ["GvHD", "OBSERVATION", 6, 10], ["chronic", "OBSERVATION_MODIFIER", 82, 89], ["GvHD", "OBSERVATION", 90, 94], ["VOD", "OBSERVATION", 154, 157]]], ["18 Other secondary end points were as follows: the effect of DLI given on mixed chimerism, 'alive and engrafted' and 'survival' after second and third SCTs, the effect of cell source (CB vs the combined group BM \u00fe PBSC) on mixed chimerism and the influence of period (1994-1998 vs 1999-2004) of transplantation on 'alive and engrafted' and 'survival' rate.Statistical analysisThe associations between age, sex, donor relationship, heterozygote donor, stem cell source, HLA disparity, conditioning regimen used and TCD and the primary and secondary end points were analyzed in univariable and multivariable logistic regression analyses.", [["cell", "ANATOMY", 171, 175], ["BM", "ANATOMY", 209, 211], ["PBSC", "ANATOMY", 214, 218], ["stem cell", "ANATOMY", 451, 460], ["cell", "CELL", 171, 175], ["stem cell", "CELL", 451, 460], ["PBSC", "CELL_TYPE", 214, 218], ["DLI", "PROBLEM", 61, 64], ["third SCTs", "PROBLEM", 145, 155], ["cell source", "PROBLEM", 171, 182], ["the combined group BM \u00fe PBSC", "TREATMENT", 190, 218], ["mixed chimerism", "PROBLEM", 223, 238], ["transplantation", "TREATMENT", 295, 310], ["Statistical analysis", "TEST", 356, 376], ["heterozygote donor", "PROBLEM", 431, 449], ["stem cell source", "PROBLEM", 451, 467], ["HLA disparity", "PROBLEM", 469, 482], ["conditioning regimen", "TREATMENT", 484, 504], ["TCD", "TREATMENT", 514, 517], ["multivariable logistic regression analyses", "TEST", 592, 634], ["stem cell", "OBSERVATION", 451, 460]]], ["Univariable predictors of outcome that were statistically significant (Po0.10) were selected for multivariable logistic regression analysis.", [["multivariable logistic regression analysis", "TEST", 97, 139]]], ["CI not including 1 (P-valueso0.05) were considered statistically significant.", [["CI", "TEST", 0, 2], ["significant", "OBSERVATION_MODIFIER", 65, 76]]], ["The time to event (graft failure and dead) in association to the primary end point 'alive and engrafted' was expressed in Kaplan-Meier curves.", [["graft", "ANATOMY", 19, 24], ["graft", "TISSUE", 19, 24], ["graft failure", "PROBLEM", 19, 32], ["dead", "PROBLEM", 37, 41]]], ["Statistical analysis was performed using SPSS 12.1 (SPSS Inc., Chicago, IL, USA).Survival and 'alive and engrafted' rateThe 'survival' and 'alive and engrafted' rate after first transplantation was 124/146 (85%) and 82/146 (56%), respectively.", [["Statistical analysis", "TEST", 0, 20], ["SPSS", "TEST", 41, 45], ["SPSS Inc.", "TEST", 52, 61]]], ["The overall 'alive and engrafted' rate after one to three transplantations was 111/146 (76%) with a survival rate of 118/146 (81%).", [["a survival rate", "TEST", 98, 113]]], ["At the time of analysis, some patients were awaiting a second graft.", [["patients", "ORGANISM", 30, 38], ["graft", "TISSUE", 62, 67], ["patients", "SPECIES", 30, 38], ["analysis", "TEST", 15, 23], ["a second graft", "TREATMENT", 53, 67], ["graft", "OBSERVATION", 62, 67]]], ["Twenty-two patients (15%) died after initial transplant, 19 from transplantationrelated causes (Table 1) .", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["initial transplant", "TREATMENT", 37, 55], ["transplant", "OBSERVATION", 45, 55]]], ["Infection, mainly viral, was the most prevalent cause of death.Survival and 'alive and engrafted' rateThe association between the various variables and the primary end points are shown in Table 2 .", [["Infection", "DISEASE", 0, 9], ["death", "DISEASE", 57, 62], ["Infection", "PROBLEM", 0, 9], ["mainly viral", "PROBLEM", 11, 23], ["death", "PROBLEM", 57, 62], ["engrafted' rate", "TREATMENT", 87, 102], ["viral", "OBSERVATION", 18, 23], ["most prevalent", "OBSERVATION_MODIFIER", 33, 47]]], ["Data for this analysis were complete for all variables.", [["this analysis", "TEST", 9, 22]]], ["RIC (P \u00bc 0.005), TCD (P \u00bc 0.001) and HLA disparity (P \u00bc 0.014) were found to be predictors for lower rates of being 'alive and engrafted'.", [["RIC", "TEST", 0, 3], ["TCD", "TEST", 17, 20], ["HLA disparity", "TEST", 37, 50]]], ["Within the CB group, HLA disparity was not found to be a predictor for a lower 'alive and engrafted' rate (OR 0.88; 95% CI 0.16-4.87; P \u00bc 0.88): after first CB transplant, 8/12 (6/6 match), 5/8 (5/6 match) and 2/3 (4/6 match) were successful.", [["CB", "ANATOMY", 11, 13], ["CB", "CANCER", 11, 13], ["HLA", "GENE_OR_GENE_PRODUCT", 21, 24], ["CI", "TEST", 120, 122], ["P", "TEST", 134, 135], ["first CB transplant", "TREATMENT", 151, 170]]], ["Busulfan targeting was a predictor for a higher rate of being 'alive and engrafted' (P \u00bc 0.028).", [["Busulfan", "CHEMICAL", 0, 8], ["Busulfan", "CHEMICAL", 0, 8], ["Busulfan", "SIMPLE_CHEMICAL", 0, 8], ["Busulfan", "TREATMENT", 0, 8]]], ["None of the characteristics clearly predicted survival and, therefore, predictors of the primary end point 'alive and engrafted' may be taken to be the predominant predictors of graft failure.", [["graft", "ANATOMY", 178, 183], ["graft", "TISSUE", 178, 183], ["graft failure", "PROBLEM", 178, 191], ["graft failure", "OBSERVATION", 178, 191]]], ["In addition, Kaplan-Meier curves, showing the influence of conditioning, TCD and cell source on the end point 'alive and engrafted' over time are shown in Figure 1 .Survival and 'alive and engrafted' rateThe multivariable analyses on the primary end point 'alive and engrafted' showed similar results to those of the univariable analysis (Figure 2) , except that the Flud-MA regimens were found to protect against graft failure in this analysis (univariable analysis P \u00bc 0.", [["cell", "ANATOMY", 81, 85], ["graft", "ANATOMY", 414, 419], ["graft failure", "DISEASE", 414, 427], ["cell", "CELL", 81, 85], ["Flud-MA", "SIMPLE_CHEMICAL", 367, 374], ["graft", "TISSUE", 414, 419], ["Meier curves", "TEST", 20, 32], ["TCD", "TREATMENT", 73, 76], ["engrafted' rate", "TREATMENT", 189, 204], ["The multivariable analyses", "TEST", 204, 230], ["the univariable analysis", "TEST", 313, 337], ["the Flud-MA regimens", "TREATMENT", 363, 383], ["graft failure", "PROBLEM", 414, 427], ["this analysis", "TEST", 431, 444], ["univariable analysis", "TEST", 446, 466], ["graft failure", "OBSERVATION", 414, 427]]], ["After deleting the three patients who received successful DLI, Flud-MA regimen was no longer a predictor for a higher 'alive and engrafted' rate.Survival and 'alive and engrafted' rateThere was no difference in outcome between the periods 1994-1998 and 1999-2004, although almost all TCD and RIC transplantations were performed in the second period (Table 3 ).", [["Flud-MA", "CHEMICAL", 63, 70], ["patients", "ORGANISM", 25, 33], ["Flud-MA", "SIMPLE_CHEMICAL", 63, 70], ["patients", "SPECIES", 25, 33], ["successful DLI", "TREATMENT", 47, 61], ["Flud-MA regimen", "TREATMENT", 63, 78], ["RIC transplantations", "TREATMENT", 292, 312], ["no", "UNCERTAINTY", 194, 196], ["difference", "OBSERVATION_MODIFIER", 197, 207]]], ["In the earlier period, unrelated donor and mismatched donors were risk factors, but not in the later period.Survival and 'alive and engrafted' rateMorbidity associated with SCT Acute GvHD (Xgrade 2) was noted in 16% of patients ( Table 1) and was found to be independent of sex, age at transplantation, matching, conditioning, cell source and donor relationship.", [["cell", "ANATOMY", 327, 331], ["GvHD", "DISEASE", 183, 187], ["donors", "ORGANISM", 54, 60], ["patients", "ORGANISM", 219, 227], ["cell", "CELL", 327, 331], ["patients", "SPECIES", 219, 227], ["engrafted' rateMorbidity", "TREATMENT", 132, 156], ["SCT Acute GvHD", "PROBLEM", 173, 187], ["transplantation", "TREATMENT", 286, 301], ["Acute", "OBSERVATION_MODIFIER", 177, 182], ["GvHD", "OBSERVATION", 183, 187]]], ["A similar analysis for VOD showed, for every month older in age, 12% less chance of developing VOD (OR 0.88; 95% CI 0.81-0.97; P \u00bc 0.009), while Bu/Cy hi (OR 5.25; 95% CI 1.22-22.69; P \u00bc 0.026) was a predictor for VOD.", [["VOD", "DISEASE", 23, 26], ["VOD", "DISEASE", 95, 98], ["VOD", "DISEASE", 214, 217], ["A similar analysis", "TEST", 0, 18], ["VOD", "PROBLEM", 23, 26], ["developing VOD", "PROBLEM", 84, 98], ["CI", "TEST", 113, 115], ["P", "TEST", 127, 128], ["CI", "TEST", 168, 170], ["P", "TEST", 183, 184], ["VOD", "PROBLEM", 214, 217], ["VOD", "OBSERVATION", 95, 98]]], ["The median age of patients with a VOD was 9 (range 4-18) months.", [["VOD", "DISEASE", 34, 37], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["a VOD", "PROBLEM", 32, 37]]], ["The multivariable analyses suggested only older age (9% less chance for every month older in age) to be a protector (OR 0.91; 95% CI 0.83-1.01; P \u00bc 0.063) against VOD.", [["VOD", "DISEASE", 163, 166], ["The multivariable analyses", "TEST", 0, 26], ["CI", "TEST", 130, 132], ["VOD", "PROBLEM", 163, 166]]], ["Additionally, there was a nonsignificant trend to more pulmonary complications (n \u00bc 11) in the mismatched group (OR 2.96; 95% CI 0.89-9.87; Effect of DLI and outcome of second (and third) SCT Because of progressive mixed chimerism (progressive donor signal decrease in at least two chimerism measurements), 10 patients received DLI.", [["pulmonary", "ANATOMY", 55, 64], ["pulmonary complications", "DISEASE", 55, 78], ["pulmonary", "ORGAN", 55, 64], ["patients", "ORGANISM", 310, 318], ["patients", "SPECIES", 310, 318], ["a nonsignificant trend to more pulmonary complications", "PROBLEM", 24, 78], ["CI", "TEST", 126, 128], ["DLI", "TEST", 150, 153], ["progressive mixed chimerism", "PROBLEM", 203, 230], ["progressive donor signal decrease", "PROBLEM", 232, 265], ["DLI", "TREATMENT", 328, 331], ["nonsignificant", "OBSERVATION_MODIFIER", 26, 40], ["pulmonary", "ANATOMY", 55, 64], ["complications", "OBSERVATION", 65, 78], ["progressive", "OBSERVATION_MODIFIER", 203, 214], ["mixed chimerism", "OBSERVATION", 215, 230], ["decrease", "OBSERVATION_MODIFIER", 257, 265]]], ["The number of DLI given per patient varied from 1 to 17.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["DLI", "TREATMENT", 14, 17], ["DLI", "OBSERVATION", 14, 17]]], ["The amount of CD3 \u00fe cells in the DLI varied from 2.5 \u00c2 10 4 to 10 7 /kg.", [["CD3 \u00fe cells", "ANATOMY", 14, 25], ["CD3", "GENE_OR_GENE_PRODUCT", 14, 17], ["CD3 \u00fe cells", "CELL_TYPE", 14, 25], ["CD3 \u00fe cells", "PROBLEM", 14, 25], ["the DLI", "TREATMENT", 29, 36], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["CD3 \u00fe cells", "OBSERVATION", 14, 25], ["DLI", "ANATOMY", 33, 36]]], ["In three patients, a conversion in the mixed chimerism was seen.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["a conversion in the mixed chimerism", "TREATMENT", 19, 54], ["mixed chimerism", "OBSERVATION", 39, 54]]], ["All other patients, with the exception of one who had a stable low level (16%) of donor chimerism, were re-transplanted.Survival and 'alive and engrafted' rateNo toxicity was seen in any of the patients who received DLI.", [["toxicity", "DISEASE", 162, 170], ["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 194, 202], ["donor chimerism", "TREATMENT", 82, 97], ["engrafted' rateNo toxicity", "PROBLEM", 144, 170], ["DLI", "TREATMENT", 216, 219], ["stable", "OBSERVATION_MODIFIER", 56, 62], ["donor chimerism", "OBSERVATION", 82, 97]]], ["Thirty-three patients were re-transplanted, three of whom received a third transplant.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["a third transplant", "TREATMENT", 67, 85], ["transplant", "OBSERVATION", 75, 85]]], ["The 'alive and engrafted' rate for the second SCT was 79% (median follow-up 12; range 7-50 months): 16/21 (76.2%) using the same donor, 10/12 (83.3%) using a different donor, 16/19 after myeloablative conditioning and 10/14 after RIC.", [["the second SCT", "TEST", 35, 49], ["a different donor", "TREATMENT", 156, 173], ["myeloablative conditioning", "TREATMENT", 187, 213], ["RIC", "TREATMENT", 230, 233]]], ["Two of three patients who received a third-SCT (20 and 28 months of follow-up) are alive with a functioning graft.DiscussionIn this European retrospective study on the outcome of SCT, HS, TCD and RIC were found to be risk factors for graft failure.", [["graft", "ANATOMY", 108, 113], ["graft", "ANATOMY", 234, 239], ["patients", "ORGANISM", 13, 21], ["graft", "TISSUE", 108, 113], ["graft", "TISSUE", 234, 239], ["patients", "SPECIES", 13, 21], ["a third-SCT", "TREATMENT", 35, 46], ["a functioning graft", "TREATMENT", 94, 113], ["SCT", "TEST", 179, 182], ["TCD", "TEST", 188, 191], ["RIC", "TREATMENT", 196, 199], ["graft failure", "PROBLEM", 234, 247], ["graft", "OBSERVATION", 108, 113], ["graft failure", "OBSERVATION", 234, 247]]], ["Busulfan targeting influenced engraftment positively, while cell source used (BM, PBSC or CB) did not influence the end point.", [["cell", "ANATOMY", 60, 64], ["BM", "ANATOMY", 78, 80], ["PBSC", "ANATOMY", 82, 86], ["CB", "ANATOMY", 90, 92], ["Busulfan", "CHEMICAL", 0, 8], ["Busulfan", "CHEMICAL", 0, 8], ["Busulfan", "SIMPLE_CHEMICAL", 0, 8], ["cell", "CELL", 60, 64], ["BM", "CELL", 78, 80], ["PBSC", "CELL", 82, 86], ["PBSC", "CELL_TYPE", 82, 86], ["Busulfan", "TREATMENT", 0, 8]]], ["CB; however, was found to be a predictor for achieving full donor chimerism associated with normal enzyme levels.DiscussionSince the first published report of SCT for HS, 3 no large series has been published analyzing the risk factors for graft failure.", [["graft", "ANATOMY", 239, 244], ["graft failure", "DISEASE", 239, 252], ["CB", "CELL", 0, 2], ["graft", "TISSUE", 239, 244], ["full donor chimerism", "PROBLEM", 55, 75], ["large series", "PROBLEM", 176, 188], ["graft failure", "PROBLEM", 239, 252], ["chimerism", "OBSERVATION", 66, 75], ["graft failure", "OBSERVATION", 239, 252]]], ["Improved supportive care (for example, firmer GvHD prophylaxis) is probably an important factor in this observation.", [["GvHD", "DISEASE", 46, 50], ["firmer GvHD prophylaxis", "TREATMENT", 39, 62]]], ["Additionally, the use of (mismatch) CB (mainly used after 1998) might have influenced the observation that mismatching was not associated with a higher incidence of graft failure after 1998, since mismatches in CB vs BM/PBSC are not biologically equivalent.", [["graft", "ANATOMY", 165, 170], ["CB", "ANATOMY", 211, 213], ["BM", "ANATOMY", 217, 219], ["PBSC", "ANATOMY", 220, 224], ["graft", "TISSUE", 165, 170], ["CB", "CELL", 211, 213], ["BM", "CELL", 217, 219], ["PBSC", "CELL", 220, 224], ["CB", "CELL_TYPE", 211, 213], ["BM", "CELL_TYPE", 217, 219], ["PBSC", "CELL_TYPE", 220, 224], ["graft failure", "PROBLEM", 165, 178], ["mismatches in CB", "PROBLEM", 197, 213], ["BM/PBSC", "TREATMENT", 217, 224], ["graft failure", "OBSERVATION", 165, 178], ["CB", "ANATOMY", 211, 213], ["PBSC", "OBSERVATION", 220, 224]]], ["12, 20, 21 Cell source (PBSC, BM or CB) was not found to influence the end point 'alive and engrafted'.", [["Cell", "ANATOMY", 11, 15], ["PBSC", "ANATOMY", 24, 28], ["BM", "ANATOMY", 30, 32], ["CB", "ANATOMY", 36, 38], ["Cell", "CELL", 11, 15], ["PBSC", "CELL", 24, 28], ["BM", "CELL", 30, 32], ["PBSC", "CELL_TYPE", 24, 28], ["PBSC", "TEST", 24, 28]]], ["An interesting observation, however, is that after first SCT, significantly more patients receiving CB achieved full donor chimerism in comparison with patients receiving PBSC/BM.", [["PBSC", "ANATOMY", 171, 175], ["BM", "ANATOMY", 176, 178], ["patients", "ORGANISM", 81, 89], ["CB", "CELL", 100, 102], ["patients", "ORGANISM", 152, 160], ["PBSC", "CELL", 171, 175], ["BM", "CELL", 176, 178], ["PBSC", "CELL_TYPE", 171, 175], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 152, 160], ["An interesting observation", "TEST", 0, 26], ["first SCT", "TEST", 51, 60], ["full donor chimerism", "TREATMENT", 112, 132], ["PBSC/BM", "TREATMENT", 171, 178], ["BM", "OBSERVATION", 176, 178]]], ["Similar results have been observed in the above-mentioned studies and mixed chimerism was not seen.", [["mixed chimerism", "PROBLEM", 70, 85], ["mixed chimerism", "OBSERVATION", 70, 85], ["not seen", "UNCERTAINTY", 90, 98]]], ["12, 21 Mixed chimerism was associated with lower enzyme levels in this study as in previous studies.", [["Mixed chimerism", "PROBLEM", 7, 22], ["lower enzyme levels", "PROBLEM", 43, 62], ["this study", "TEST", 66, 76], ["previous studies", "TEST", 83, 99], ["chimerism", "OBSERVATION", 13, 22]]], ["10, 11 Although no large-scale studies have examined the impact of enzyme levels after SCT on longterm outcome, recent data appear to suggest that low levels may negatively influence neurocognitive outcome.", [["large-scale studies", "TEST", 19, 38], ["enzyme levels", "TEST", 67, 80], ["low levels", "PROBLEM", 147, 157]]], ["22 Future studies are eagerly awaited.DiscussionThe observation of less mixed chimerism in patients receiving CB is intriguing.", [["patients", "ORGANISM", 91, 99], ["CB", "CELL", 110, 112], ["patients", "SPECIES", 91, 99], ["Future studies", "TEST", 3, 17], ["less mixed chimerism", "PROBLEM", 67, 87], ["less mixed", "OBSERVATION_MODIFIER", 67, 77], ["chimerism", "OBSERVATION", 78, 87]]], ["It might be that the higher degree of HLA mismatch 23 exerts a stronger graft-versusmarrow (GvM) effect.", [["graft", "ANATOMY", 72, 77], ["graft", "TISSUE", 72, 77], ["HLA mismatch", "PROBLEM", 38, 50], ["a stronger graft", "TREATMENT", 61, 77], ["HLA mismatch", "OBSERVATION", 38, 50]]], ["The fact that this GvM effect is associated with subclinical GvHD might be due to the fact that CB cells have a more naive phenotype.", [["CB cells", "ANATOMY", 96, 104], ["GvHD", "DISEASE", 61, 65], ["GvM", "GENE_OR_GENE_PRODUCT", 19, 22], ["CB cells", "CELL", 96, 104], ["CB cells", "CELL_LINE", 96, 104], ["this GvM effect", "PROBLEM", 14, 29], ["subclinical GvHD", "PROBLEM", 49, 65], ["CB cells", "PROBLEM", 96, 104]]], ["This might make the marrow more sensitive to GvM in comparison to the known target organs of GvHD.", [["marrow", "ANATOMY", 20, 26], ["organs", "ANATOMY", 83, 89], ["GvHD", "DISEASE", 93, 97], ["marrow", "TISSUE", 20, 26], ["GvM", "GENE_OR_GENE_PRODUCT", 45, 48], ["organs", "ORGAN", 83, 89], ["GvHD", "PROBLEM", 93, 97], ["GvHD", "OBSERVATION", 93, 97]]], ["Another explanation might be the increased pluripotential capability of the CB stem cell, relative to adult stem cell, with higher proliferative potentials in comparison to BM.", [["CB stem cell", "ANATOMY", 76, 88], ["adult stem cell", "ANATOMY", 102, 117], ["BM", "ANATOMY", 173, 175], ["CB stem cell", "CELL", 76, 88], ["adult stem cell", "CELL", 102, 117], ["BM", "CELL", 173, 175], ["CB stem cell", "CELL_LINE", 76, 88], ["adult stem cell", "CELL_TYPE", 102, 117], ["BM", "CELL_TYPE", 173, 175], ["the increased pluripotential capability of the CB stem cell", "PROBLEM", 29, 88], ["adult stem cell", "PROBLEM", 102, 117], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["pluripotential capability", "OBSERVATION", 43, 68], ["CB stem cell", "OBSERVATION", 76, 88], ["stem cell", "OBSERVATION", 108, 117], ["higher proliferative", "OBSERVATION_MODIFIER", 124, 144]]], ["[24] [25] [26] We are aware from animal studies that the addition of mesenchymal stem cells to the SCT product results in less graft rejection, due to the immunomodulating potential of these cells.", [["mesenchymal stem cells", "ANATOMY", 69, 91], ["graft", "ANATOMY", 127, 132], ["cells", "ANATOMY", 191, 196], ["mesenchymal stem cells", "CELL", 69, 91], ["graft", "TISSUE", 127, 132], ["cells", "CELL", 191, 196], ["mesenchymal stem cells", "CELL_TYPE", 69, 91], ["animal studies", "TEST", 33, 47], ["mesenchymal stem cells", "TREATMENT", 69, 91], ["the SCT product", "TEST", 95, 110], ["less graft rejection", "PROBLEM", 122, 142], ["these cells", "PROBLEM", 185, 196], ["mesenchymal stem cells", "OBSERVATION", 69, 91], ["less", "OBSERVATION_MODIFIER", 122, 126], ["graft rejection", "OBSERVATION", 127, 142]]], ["27, 28 Other advantages of CB include (1) lower rates for acute GvHD and extensive chronic GvHD in comparison to unrelated donors, [29] [30] [31] [32] (2) immediate availability, 23 reducing the period between diagnosis and SCT (in this study 7.5 months), which might improve the long-term outcome, (3) reduced likelihood of transmitting infection (viral) and (4) the suggestion that a more primitive stem cell population might have a greater capacity for transdifferentiation.", [["stem cell", "ANATOMY", 401, 410], ["GvHD", "DISEASE", 64, 68], ["GvHD", "DISEASE", 91, 95], ["infection", "DISEASE", 338, 347], ["donors", "ORGANISM", 123, 129], ["stem cell", "CELL", 401, 410], ["primitive stem cell population", "CELL_LINE", 391, 421], ["acute GvHD", "PROBLEM", 58, 68], ["extensive chronic GvHD", "PROBLEM", 73, 95], ["SCT", "TEST", 224, 227], ["this study", "TEST", 232, 242], ["transmitting infection (viral)", "PROBLEM", 325, 355], ["a more primitive stem cell population", "PROBLEM", 384, 421], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["GvHD", "OBSERVATION", 64, 68], ["extensive", "OBSERVATION_MODIFIER", 73, 82], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["GvHD", "OBSERVATION", 91, 95], ["long-term outcome", "OBSERVATION_MODIFIER", 280, 297], ["infection", "OBSERVATION", 338, 347], ["stem cell population", "OBSERVATION", 401, 421]]], ["[24] [25] [26] This latter capability might be particularly important in SCT for inborn errors of metabolism, by theoretically improving delivery of enzyme to bone, cartilage and brain tissue.", [["bone", "ANATOMY", 159, 163], ["cartilage", "ANATOMY", 165, 174], ["brain tissue", "ANATOMY", 179, 191], ["inborn errors of metabolism", "DISEASE", 81, 108], ["bone", "TISSUE", 159, 163], ["cartilage", "TISSUE", 165, 174], ["brain tissue", "TISSUE", 179, 191], ["inborn errors of metabolism", "PROBLEM", 81, 108], ["enzyme to bone, cartilage and brain tissue", "PROBLEM", 149, 191], ["bone", "ANATOMY", 159, 163], ["cartilage", "ANATOMY", 165, 174], ["brain tissue", "ANATOMY", 179, 191]]], ["More research is warranted to study this hypothesis.DiscussionInevitably, in the absence of international standardized conditioning protocols, various regimens have been challenged to improve the engraftment in SCT for HS: Souillet et al., 11 as well as the Dublin group (unpublished data), have used higher doses of cyclophosphamide (240-260 mg/ kg) with the aim of increasing myeloablation and immunosuppression/ablation, which failed to influence engraftment.", [["cyclophosphamide", "CHEMICAL", 317, 333], ["cyclophosphamide", "CHEMICAL", 317, 333], ["cyclophosphamide", "SIMPLE_CHEMICAL", 317, 333], ["international standardized conditioning protocols", "TREATMENT", 92, 141], ["various regimens", "TREATMENT", 143, 159], ["cyclophosphamide", "TREATMENT", 317, 333], ["increasing myeloablation", "TREATMENT", 367, 391], ["immunosuppression", "TREATMENT", 396, 413], ["ablation", "TREATMENT", 414, 422]]], ["Other groups have increased immunosuppression by adding fludarabine to a myelo-ablative regimen (Flud-MA) which, in the multivariable analysis, was found to be a predictor for a higher 'alive and engrafted' rate, in contrast to the results from the univariable analysis (P \u00bc 0.", [["fludarabine", "CHEMICAL", 56, 67], ["Flud-MA", "CHEMICAL", 97, 104], ["fludarabine", "CHEMICAL", 56, 67], ["fludarabine", "SIMPLE_CHEMICAL", 56, 67], ["Flud-MA", "SIMPLE_CHEMICAL", 97, 104], ["increased immunosuppression", "TREATMENT", 18, 45], ["fludarabine", "TREATMENT", 56, 67], ["a myelo-ablative regimen", "TREATMENT", 71, 95], ["the multivariable analysis", "TEST", 116, 142], ["the univariable analysis", "TEST", 245, 269], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["immunosuppression", "OBSERVATION", 28, 45]]], ["Any improvement may have been partly offset due to the fact that this group contained relatively more patients receiving a TCD and HLA mismatch graft (three of whom received successful DLI), both being identified as risk factors for graft failure.", [["graft", "ANATOMY", 233, 238], ["graft failure", "DISEASE", 233, 246], ["patients", "ORGANISM", 102, 110], ["graft", "TISSUE", 144, 149], ["graft", "TISSUE", 233, 238], ["patients", "SPECIES", 102, 110], ["a TCD and HLA mismatch graft", "TREATMENT", 121, 149], ["successful DLI", "TREATMENT", 174, 188], ["graft failure", "PROBLEM", 233, 246], ["mismatch graft", "OBSERVATION", 135, 149], ["graft failure", "OBSERVATION", 233, 246]]], ["Additionally, the Flud-MA group (n \u00bc 17) consisted of three different regimens, including four patients receiving busulfan \u00fe melphalan.", [["busulfan", "CHEMICAL", 114, 122], ["melphalan", "CHEMICAL", 125, 134], ["busulfan", "CHEMICAL", 114, 122], ["melphalan", "CHEMICAL", 125, 134], ["patients", "ORGANISM", 95, 103], ["busulfan", "SIMPLE_CHEMICAL", 114, 122], ["melphalan", "SIMPLE_CHEMICAL", 125, 134], ["patients", "SPECIES", 95, 103], ["three different regimens", "TREATMENT", 54, 78], ["busulfan \u00fe melphalan", "TREATMENT", 114, 134]]], ["This combination is more myeloablative than busulfan alone.DiscussionTargeting the busulfan dose by pharmacokinetic monitoring has been shown to optimize myeloablation, reduce toxicity and increase engraftment rates, because of the known narrow therapeutic range and wide variability in busulfan exposure in children receiving oral busulfan.", [["oral", "ANATOMY", 327, 331], ["busulfan", "CHEMICAL", 44, 52], ["busulfan", "CHEMICAL", 83, 91], ["toxicity", "DISEASE", 176, 184], ["busulfan", "CHEMICAL", 287, 295], ["busulfan", "CHEMICAL", 332, 340], ["busulfan", "CHEMICAL", 44, 52], ["busulfan", "CHEMICAL", 83, 91], ["busulfan", "CHEMICAL", 287, 295], ["busulfan", "CHEMICAL", 332, 340], ["busulfan", "SIMPLE_CHEMICAL", 44, 52], ["busulfan", "SIMPLE_CHEMICAL", 83, 91], ["busulfan", "SIMPLE_CHEMICAL", 287, 295], ["children", "ORGANISM", 308, 316], ["oral", "ORGANISM_SUBDIVISION", 327, 331], ["busulfan", "SIMPLE_CHEMICAL", 332, 340], ["children", "SPECIES", 308, 316], ["busulfan alone", "TREATMENT", 44, 58], ["the busulfan dose", "TREATMENT", 79, 96], ["pharmacokinetic monitoring", "TEST", 100, 126], ["myeloablation", "TREATMENT", 154, 167], ["reduce toxicity", "PROBLEM", 169, 184], ["increase engraftment rates", "TREATMENT", 189, 215], ["the known narrow therapeutic range", "PROBLEM", 228, 262], ["busulfan exposure", "TREATMENT", 287, 304], ["oral busulfan", "TREATMENT", 327, 340], ["narrow", "OBSERVATION_MODIFIER", 238, 244], ["wide", "OBSERVATION_MODIFIER", 267, 271], ["variability", "OBSERVATION_MODIFIER", 272, 283]]], ["[33] [34] [35] In this study, busulfan targeting was associated with better engraftment.", [["busulfan", "CHEMICAL", 30, 38], ["busulfan", "CHEMICAL", 30, 38], ["busulfan", "SIMPLE_CHEMICAL", 30, 38], ["this study", "TEST", 18, 28], ["busulfan targeting", "TREATMENT", 30, 48]]], ["The optimized myeloablation might be required to overcome the effect of abundance of 'glycosaminoglycans' in the BM matrix, which has been suggested to negatively influence stem cell homing.", [["BM matrix", "ANATOMY", 113, 122], ["stem cell", "ANATOMY", 173, 182], ["glycosaminoglycans", "GENE_OR_GENE_PRODUCT", 86, 104], ["BM matrix", "CELLULAR_COMPONENT", 113, 122], ["stem cell", "CELL", 173, 182], ["The optimized myeloablation", "TREATMENT", 0, 27], ["'glycosaminoglycans' in the BM matrix", "TREATMENT", 85, 122], ["BM", "ANATOMY", 113, 115], ["stem cell homing", "OBSERVATION", 173, 189]]], ["36 In line with this, we found RIC to be a risk factor for graft failure.", [["graft", "ANATOMY", 59, 64], ["graft failure", "DISEASE", 59, 72], ["graft", "TISSUE", 59, 64], ["a risk factor", "PROBLEM", 41, 54], ["graft failure", "PROBLEM", 59, 72], ["graft failure", "OBSERVATION", 59, 72]]], ["Although for malignant and some nonmalignant diseases RIC is feasible 37, 38 for genetic diseases (for example; HS, Thalassemia-major) RIC is associated with graft failure.", [["malignant", "ANATOMY", 13, 22], ["nonmalignant", "ANATOMY", 32, 44], ["graft", "ANATOMY", 158, 163], ["genetic diseases", "DISEASE", 81, 97], ["Thalassemia-major) RIC", "DISEASE", 116, 138], ["graft", "TISSUE", 158, 163], ["malignant", "PROBLEM", 13, 22], ["some nonmalignant diseases RIC", "PROBLEM", 27, 57], ["genetic diseases", "PROBLEM", 81, 97], ["HS", "TEST", 112, 114], ["Thalassemia", "PROBLEM", 116, 127], ["graft failure", "PROBLEM", 158, 171], ["malignant", "OBSERVATION_MODIFIER", 13, 22], ["some", "OBSERVATION_MODIFIER", 27, 31], ["nonmalignant", "OBSERVATION_MODIFIER", 32, 44], ["associated with", "UNCERTAINTY", 142, 157], ["graft failure", "OBSERVATION", 158, 171]]], ["39 The incidence of GvHD and 'IPS/DAH' using BM/ PBSCs reported by Peters et al. 9,10 was considerably higher than that observed in this series.", [["BM", "ANATOMY", 45, 47], ["GvHD", "DISEASE", 20, 24], ["DAH", "DISEASE", 34, 37], ["BM", "CELL", 45, 47], ["GvHD", "PROBLEM", 20, 24], ["'IPS/DAH'", "TREATMENT", 29, 38], ["BM/ PBSCs", "TREATMENT", 45, 54], ["GvHD", "OBSERVATION", 20, 24]]], ["While no obvious explanation is apparent, alternative conditioning and GVHD prophylaxis regimens may well be a factor.DiscussionSurvival after second transplant was better in this study than reported by others (80 vs 50%), 40 and two of three patients achieved sustained engraftment following a third graft.", [["GVHD", "DISEASE", 71, 75], ["patients", "ORGANISM", 243, 251], ["graft", "TISSUE", 301, 306], ["patients", "SPECIES", 243, 251], ["alternative conditioning", "TREATMENT", 42, 66], ["GVHD prophylaxis regimens", "TREATMENT", 71, 96], ["second transplant", "TREATMENT", 143, 160], ["this study", "TEST", 175, 185], ["sustained engraftment", "TREATMENT", 261, 282], ["a third graft", "TREATMENT", 293, 306], ["no obvious", "UNCERTAINTY", 6, 16], ["engraftment", "OBSERVATION", 271, 282], ["graft", "OBSERVATION", 301, 306]]], ["There was no difference observed between patients Table 4 Donor chimerism and enzyme activity in leucocytes (a-iduronidase in nmol/h/mg) in leukocytes receiving either a myeloablative or RIC second SCT and whether the same or an alternative donor was chosen.", [["leucocytes", "ANATOMY", 97, 107], ["leukocytes", "ANATOMY", 140, 150], ["patients", "ORGANISM", 41, 49], ["leucocytes", "CELL", 97, 107], ["a-iduronidase", "SIMPLE_CHEMICAL", 109, 122], ["leukocytes", "CELL", 140, 150], ["leucocytes", "CELL_TYPE", 97, 107], ["leukocytes", "CELL_TYPE", 140, 150], ["patients", "SPECIES", 41, 49], ["Donor chimerism", "TEST", 58, 73], ["enzyme activity", "TEST", 78, 93], ["leucocytes", "TEST", 97, 107], ["leukocytes", "PROBLEM", 140, 150], ["a myeloablative", "TREATMENT", 168, 183], ["RIC second SCT", "TREATMENT", 187, 201], ["an alternative donor", "TREATMENT", 226, 246], ["no", "UNCERTAINTY", 10, 12], ["leucocytes", "ANATOMY", 97, 107]]], ["These data indicate that after an unsuccessful first SCT, a second SCT is a feasible option.DiscussionIn conclusion, TCD and RIC were associated, in this series, with increased incidence of graft failure, while busulfan targeting (therapeutic drug monitoring) increased the likelihood of sustained engraftment.", [["graft", "ANATOMY", 190, 195], ["graft failure", "DISEASE", 190, 203], ["busulfan", "CHEMICAL", 211, 219], ["busulfan", "CHEMICAL", 211, 219], ["graft", "TISSUE", 190, 195], ["busulfan", "SIMPLE_CHEMICAL", 211, 219], ["an unsuccessful first SCT", "TREATMENT", 31, 56], ["a second SCT", "TREATMENT", 58, 70], ["a feasible option", "TREATMENT", 74, 91], ["graft failure", "PROBLEM", 190, 203], ["busulfan targeting", "TREATMENT", 211, 229], ["therapeutic drug monitoring", "TEST", 231, 258], ["sustained engraftment", "PROBLEM", 288, 309], ["graft failure", "OBSERVATION", 190, 203], ["sustained", "OBSERVATION_MODIFIER", 288, 297], ["engraftment", "OBSERVATION", 298, 309]]], ["The same criteria may apply in relation to other inborn errors of metabolism and hemoglobinopathies.", [["inborn errors of metabolism", "DISEASE", 49, 76], ["hemoglobinopathies", "DISEASE", 81, 99], ["other inborn errors of metabolism", "PROBLEM", 43, 76], ["hemoglobinopathies", "PROBLEM", 81, 99], ["hemoglobinopathies", "OBSERVATION", 81, 99]]], ["CB increased the likelihood of sustained engraftment associated with normal enzyme levels and could therefore be considered as a preferential stem cell source.", [["stem cell", "ANATOMY", 142, 151], ["CB", "CELL", 0, 2], ["stem cell", "CELL", 142, 151], ["sustained engraftment", "PROBLEM", 31, 52], ["a preferential stem cell source", "PROBLEM", 127, 158], ["sustained", "OBSERVATION_MODIFIER", 31, 40], ["engraftment", "OBSERVATION", 41, 52], ["preferential stem cell source", "OBSERVATION", 129, 158]]], ["A further study of long-term outcome on successfully transplanted patients is now proposed.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["A further study", "TEST", 0, 15], ["long-term", "OBSERVATION_MODIFIER", 19, 28]]]], "PMC7252009": [], "948732920b2f1825951182ce460230e3ffb60f23": [["The work of the brain would be easy if we knew what we needed to remember or understand in the future.", [["brain", "ANATOMY", 16, 21], ["brain", "ORGAN", 16, 21], ["brain", "ANATOMY", 16, 21]]], ["Life is full of surprises -new people whom we need to know, names we have to remember, problems we try to solve.", [["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37]]]], "deff731c9ab79995d16c839ae35d771d49af62f9": [["262 with DENV, we tested the secretion properties of ZIKV and YFV NS1 in infected C6/36 and Vero-263 E6 cells.", [["C6/36", "ANATOMY", 82, 87], ["Vero-263 E6 cells", "ANATOMY", 92, 109], ["ZIKV", "ORGANISM", 53, 57], ["YFV NS1", "ORGANISM", 62, 69], ["C6/36", "CELL", 82, 87], ["Vero-263 E6 cells", "CELL", 92, 109], ["ZIKV", "PROTEIN", 53, 57], ["YFV NS1", "PROTEIN", 62, 69], ["Vero-263 E6 cells", "CELL_LINE", 92, 109], ["DENV", "SPECIES", 9, 13], ["ZIKV", "SPECIES", 53, 57], ["YFV", "SPECIES", 62, 65], ["Vero-263 E6", "SPECIES", 92, 103], ["DENV", "PROBLEM", 9, 13], ["the secretion properties", "TEST", 25, 49], ["ZIKV", "PROBLEM", 53, 57], ["YFV NS1", "TEST", 62, 69], ["Vero", "TEST", 92, 96], ["DENV", "OBSERVATION", 9, 13], ["E6 cells", "OBSERVATION", 101, 109]]], ["The presence of ZIKV NS1 was detected by ELISA in the cell supernatants of both cell 264 lines at 48 hpi, whereas YFV NS1 was detected at 72 hpi, by western blot assay (Fig 9A) .", [["cell supernatants", "ANATOMY", 54, 71], ["cell 264 lines", "ANATOMY", 80, 94], ["ZIKV NS1", "ORGANISM", 16, 24], ["cell", "CELL", 54, 58], ["cell 264 lines", "CELL", 80, 94], ["YFV NS1", "ORGANISM", 114, 121], ["ZIKV NS1", "PROTEIN", 16, 24], ["cell 264 lines", "CELL_LINE", 80, 94], ["YFV NS1", "PROTEIN", 114, 121], ["ZIKV", "SPECIES", 16, 20], ["YFV", "SPECIES", 114, 117], ["ZIKV NS1", "PROBLEM", 16, 24], ["ELISA", "TEST", 41, 46], ["YFV NS1", "TEST", 114, 121], ["ZIKV NS1", "OBSERVATION", 16, 24], ["both", "ANATOMY_MODIFIER", 75, 79], ["cell", "OBSERVATION", 80, 84], ["264 lines", "OBSERVATION", 85, 94]]], ["Vero-265 E6 cells were used as vertebrate cells in these experiments since very low levels of infection 13 266 were detected in BHK-21 cells with ZIKV and YFV (data not shown).", [["Vero-265 E6 cells", "ANATOMY", 0, 17], ["cells", "ANATOMY", 42, 47], ["BHK-21 cells", "ANATOMY", 128, 140], ["infection", "DISEASE", 94, 103], ["Vero-265 E6 cells", "CELL", 0, 17], ["cells", "CELL", 42, 47], ["BHK-21 cells", "CELL", 128, 140], ["ZIKV", "CELL", 146, 150], ["YFV", "ORGANISM", 155, 158], ["Vero-265 E6 cells", "CELL_LINE", 0, 17], ["vertebrate cells", "CELL_TYPE", 31, 47], ["BHK-21 cells", "CELL_LINE", 128, 140], ["Vero-265 E6", "SPECIES", 0, 11], ["BHK-21", "SPECIES", 128, 134], ["ZIKV", "SPECIES", 146, 150], ["YFV", "SPECIES", 155, 158], ["Vero", "TEST", 0, 4], ["E6 cells", "TEST", 9, 17], ["vertebrate cells", "PROBLEM", 31, 47], ["these experiments", "TEST", 51, 68], ["very low levels of infection", "PROBLEM", 75, 103], ["BHK", "TEST", 128, 131], ["ZIKV", "PROBLEM", 146, 150], ["YFV (data", "TEST", 155, 164], ["E6 cells", "OBSERVATION", 9, 17], ["very", "OBSERVATION_MODIFIER", 75, 79], ["low levels", "OBSERVATION_MODIFIER", 80, 90], ["infection", "OBSERVATION", 94, 103]]], ["The secretion of YFV NS1 267 was found to be sensitive to BFA treatment in both mosquito and vertebrate cells (Fig. 9A) .", [["cells", "ANATOMY", 104, 109], ["BFA", "CHEMICAL", 58, 61], ["BFA", "CHEMICAL", 58, 61], ["YFV NS1 267", "ORGANISM", 17, 28], ["BFA", "SIMPLE_CHEMICAL", 58, 61], ["vertebrate cells", "CELL", 93, 109], ["Fig. 9A", "CELL", 111, 118], ["YFV NS1 267", "PROTEIN", 17, 28], ["mosquito and vertebrate cells", "CELL_TYPE", 80, 109], ["YFV NS1 267", "SPECIES", 17, 28], ["The secretion of YFV NS1", "TEST", 0, 24], ["BFA treatment", "TREATMENT", 58, 71], ["vertebrate cells", "OBSERVATION", 93, 109]]], ["In 268 contrast, the secretion of ZIKV NS1 was found to be insensitive to BFA and GCA treatment in 269 infected mosquito, but not in infected vertebrate cells (Fig 9B) .", [["cells", "ANATOMY", 153, 158], ["BFA", "CHEMICAL", 74, 77], ["GCA", "CHEMICAL", 82, 85], ["BFA", "CHEMICAL", 74, 77], ["ZIKV NS1", "ORGANISM", 34, 42], ["BFA", "SIMPLE_CHEMICAL", 74, 77], ["GCA", "SIMPLE_CHEMICAL", 82, 85], ["cells", "CELL", 153, 158], ["Fig 9B", "CELL", 160, 166], ["ZIKV NS1", "PROTEIN", 34, 42], ["infected vertebrate cells", "CELL_TYPE", 133, 158], ["ZIKV", "SPECIES", 34, 38], ["ZIKV NS1", "PROBLEM", 34, 42], ["BFA", "TEST", 74, 77], ["GCA treatment", "TREATMENT", 82, 95], ["infected vertebrate cells", "OBSERVATION", 133, 158]]], ["In addition, the secretion of ZIKV 270 NS1 was reduced in mosquito, but not in vertebrate cells, treated with the CyA inhibitor CsA (Fig 271 9C ).", [["cells", "ANATOMY", 90, 95], ["CyA", "CHEMICAL", 114, 117], ["CsA", "CHEMICAL", 128, 131], ["CyA", "CHEMICAL", 114, 117], ["CsA", "CHEMICAL", 128, 131], ["ZIKV", "GENE_OR_GENE_PRODUCT", 30, 34], ["NS1", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 90, 95], ["CyA", "SIMPLE_CHEMICAL", 114, 117], ["CsA", "SIMPLE_CHEMICAL", 128, 131], ["ZIKV 270 NS1", "PROTEIN", 30, 42], ["vertebrate cells", "CELL_TYPE", 79, 95], ["ZIKV", "SPECIES", 30, 34], ["ZIKV", "PROBLEM", 30, 34], ["NS1", "PROBLEM", 39, 42], ["the CyA inhibitor CsA", "TREATMENT", 110, 131], ["vertebrate cells", "OBSERVATION", 79, 95]]], ["Co-localizations experiments carried out in C6/36, Aag2 and Vero-E6 cells infected with 272 ZIKV and YFV, showed a stronger, and a significantly different, co-localization between ZIKV 273 NS1 and CAV-1 than between YFV NS1 and CAV-1, in both mosquito cell lines.", [["C6/36", "ANATOMY", 44, 49], ["Aag2", "ANATOMY", 51, 55], ["Vero-E6 cells", "ANATOMY", 60, 73], ["cell lines", "ANATOMY", 252, 262], ["C6/36", "CELL", 44, 49], ["Aag2", "CELL", 51, 55], ["Vero-E6 cells", "CELL", 60, 73], ["YFV", "ORGANISM", 101, 104], ["ZIKV 273 NS1", "ORGANISM", 180, 192], ["CAV-1", "GENE_OR_GENE_PRODUCT", 197, 202], ["YFV NS1", "ORGANISM", 216, 223], ["CAV-1", "ORGANISM", 228, 233], ["mosquito cell lines", "CELL", 243, 262], ["C6/36", "CELL_LINE", 44, 49], ["Aag2", "CELL_LINE", 51, 55], ["Vero-E6 cells", "CELL_LINE", 60, 73], ["NS1", "PROTEIN", 189, 192], ["YFV NS1", "PROTEIN", 216, 223], ["CAV", "PROTEIN", 228, 231], ["mosquito cell lines", "CELL_LINE", 243, 262], ["Vero-E6", "SPECIES", 60, 67], ["ZIKV", "SPECIES", 92, 96], ["YFV", "SPECIES", 101, 104], ["CAV-1", "SPECIES", 197, 202], ["YFV NS1", "SPECIES", 216, 223], ["CAV-1", "SPECIES", 228, 233], ["Co-localizations experiments", "TEST", 0, 28], ["C6", "TEST", 44, 46], ["Aag2", "TEST", 51, 55], ["Vero", "TEST", 60, 64], ["ZIKV", "PROBLEM", 92, 96], ["ZIKV", "TEST", 180, 184], ["NS1", "TEST", 189, 192], ["CAV", "TEST", 197, 200], ["YFV NS1", "TEST", 216, 223], ["CAV", "TEST", 228, 231], ["CAV", "ANATOMY", 197, 200], ["CAV", "ANATOMY", 228, 231], ["both", "ANATOMY_MODIFIER", 238, 242], ["mosquito cell lines", "OBSERVATION", 243, 262]]], ["No co-274 localization of ZIKV or YFV NS1 with CAV-1 was observed in vertebrate cell line ( Fig 9D and 275 9E).", [["cell line", "ANATOMY", 80, 89], ["ZIKV", "GENE_OR_GENE_PRODUCT", 26, 30], ["YFV NS1", "ORGANISM", 34, 41], ["CAV-1", "GENE_OR_GENE_PRODUCT", 47, 52], ["vertebrate cell line", "CELL", 69, 89], ["Fig 9D", "CELL", 92, 98], ["275 9E", "CELL", 103, 109], ["ZIKV", "PROTEIN", 26, 30], ["YFV NS1", "PROTEIN", 34, 41], ["CAV-1", "DNA", 47, 52], ["vertebrate cell line", "CELL_LINE", 69, 89], ["275 9E", "CELL_LINE", 103, 109], ["ZIKV", "SPECIES", 26, 30], ["YFV", "SPECIES", 34, 37], ["ZIKV", "PROBLEM", 26, 30], ["CAV", "TEST", 47, 50], ["CAV", "ANATOMY", 47, 50], ["vertebrate cell line", "OBSERVATION", 69, 89]]], ["Of note, the co-localization data support the predictions derived from the presence of a 276 conserved caveolin binding (CBD) domain in ZIKV (and DENV) but not in YFV NS1 (Fig 9F) .DISCUSSION304 Our previous work demonstrated that DENV NS1 secretion in mosquito cell lines follows a BFA-305 insensitivity secretion pathway that depends on CAV-1; moreover, NS1 was found to interact 306 directly with CAV-1 [10].", [["cell lines", "ANATOMY", 262, 272], ["BFA-305", "CHEMICAL", 283, 290], ["BFA-305", "CHEMICAL", 283, 290], ["caveolin", "GENE_OR_GENE_PRODUCT", 103, 111], ["ZIKV", "GENE_OR_GENE_PRODUCT", 136, 140], ["YFV NS1", "ORGANISM", 163, 170], ["DENV", "ORGANISM", 231, 235], ["NS1", "GENE_OR_GENE_PRODUCT", 236, 239], ["mosquito cell lines", "CELL", 253, 272], ["BFA-305", "SIMPLE_CHEMICAL", 283, 290], ["CAV-1", "GENE_OR_GENE_PRODUCT", 339, 344], ["NS1", "GENE_OR_GENE_PRODUCT", 356, 359], ["276 conserved caveolin binding (CBD) domain", "PROTEIN", 89, 132], ["ZIKV", "PROTEIN", 136, 140], ["YFV NS1", "PROTEIN", 163, 170], ["Fig 9F", "PROTEIN", 172, 178], ["NS1", "PROTEIN", 236, 239], ["mosquito cell lines", "CELL_LINE", 253, 272], ["NS1", "PROTEIN", 356, 359], ["DENV", "SPECIES", 146, 150], ["YFV", "SPECIES", 163, 166], ["DENV", "SPECIES", 231, 235], ["ZIKV", "PROBLEM", 136, 140], ["DENV", "PROBLEM", 146, 150], ["DENV NS1 secretion", "PROBLEM", 231, 249], ["mosquito cell lines", "TREATMENT", 253, 272], ["a BFA", "TEST", 281, 286], ["insensitivity secretion pathway", "PROBLEM", 291, 322], ["NS1", "PROBLEM", 356, 359], ["CAV", "TEST", 400, 403], ["caveolin binding", "OBSERVATION", 103, 119], ["CBD", "ANATOMY", 121, 124], ["NS1 secretion", "OBSERVATION", 236, 249], ["cell lines", "OBSERVATION", 262, 272]]], ["Therefore, in the present work, we explored the association of NS1 with 307 proteins involved, together with CAV-1, in the intracellular transport of cholesterol and the 308 dependence of NS1 secretion on such association.", [["intracellular", "ANATOMY", 123, 136], ["cholesterol", "CHEMICAL", 150, 161], ["cholesterol", "CHEMICAL", 150, 161], ["NS1", "GENE_OR_GENE_PRODUCT", 63, 66], ["CAV-1", "GENE_OR_GENE_PRODUCT", 109, 114], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 136], ["cholesterol", "SIMPLE_CHEMICAL", 150, 161], ["NS1", "GENE_OR_GENE_PRODUCT", 188, 191], ["NS1", "PROTEIN", 63, 66], ["307 proteins", "PROTEIN", 72, 84], ["NS1", "PROTEIN", 188, 191], ["NS1", "PROBLEM", 63, 66], ["NS1 secretion", "PROBLEM", 188, 201], ["NS1 secretion", "OBSERVATION", 188, 201]]], ["The results revealed that NS1 is associated 309 to the chaperone caveolin complex (CAV-1, Cy40, FKBP52 and CyA) and that the integrity of 310 this complex is necessary for the secretion of NS1 in mosquito infected cells.", [["cells", "ANATOMY", 214, 219], ["CyA", "CHEMICAL", 107, 110], ["NS1", "GENE_OR_GENE_PRODUCT", 26, 29], ["caveolin", "GENE_OR_GENE_PRODUCT", 65, 73], ["CAV-1", "GENE_OR_GENE_PRODUCT", 83, 88], ["Cy40", "GENE_OR_GENE_PRODUCT", 90, 94], ["FKBP52", "GENE_OR_GENE_PRODUCT", 96, 102], ["CyA", "SIMPLE_CHEMICAL", 107, 110], ["NS1", "GENE_OR_GENE_PRODUCT", 189, 192], ["cells", "CELL", 214, 219], ["NS1", "PROTEIN", 26, 29], ["chaperone caveolin complex", "PROTEIN", 55, 81], ["CAV", "PROTEIN", 83, 86], ["Cy40", "PROTEIN", 90, 94], ["FKBP52", "PROTEIN", 96, 102], ["CyA", "PROTEIN", 107, 110], ["NS1", "PROTEIN", 189, 192], ["mosquito infected cells", "CELL_TYPE", 196, 219], ["NS1", "PROBLEM", 26, 29], ["CAV", "TEST", 83, 86], ["Cy40", "TEST", 90, 94], ["FKBP52", "TEST", 96, 102], ["CyA", "TEST", 107, 110], ["the secretion of NS1 in mosquito infected cells", "PROBLEM", 172, 219], ["NS1", "OBSERVATION", 26, 29], ["infected cells", "OBSERVATION", 205, 219]]], ["Additional data 311 suggest that in virus infected mosquito cells, ZIKV NS1, but not yellow fever virus NS1, also 312 associates with CAV-1 and usurps the cholesterol traffic pathways for secretion.", [["cells", "ANATOMY", 60, 65], ["yellow fever", "DISEASE", 85, 97], ["cholesterol", "CHEMICAL", 155, 166], ["cholesterol", "CHEMICAL", 155, 166], ["mosquito cells", "CELL", 51, 65], ["ZIKV NS1", "ORGANISM", 67, 75], ["yellow fever virus", "ORGANISM", 85, 103], ["NS1", "ORGANISM", 104, 107], ["CAV-1", "GENE_OR_GENE_PRODUCT", 134, 139], ["cholesterol", "SIMPLE_CHEMICAL", 155, 166], ["mosquito cells", "CELL_TYPE", 51, 65], ["ZIKV NS1", "PROTEIN", 67, 75], ["NS1", "PROTEIN", 104, 107], ["yellow fever virus", "SPECIES", 85, 103], ["ZIKV", "SPECIES", 67, 71], ["yellow fever virus", "SPECIES", 85, 103], ["CAV-1", "SPECIES", 134, 139], ["Additional data", "TEST", 0, 15], ["virus infected mosquito cells", "PROBLEM", 36, 65], ["ZIKV NS1", "PROBLEM", 67, 75], ["yellow fever virus NS1", "PROBLEM", 85, 107], ["CAV", "TEST", 134, 137], ["secretion", "PROBLEM", 188, 197]]], ["Thus, the lipid 313 content or molecular structure of the DENV NS1 seems to have taken advantage of mosquito 314 cell cholesterol transport to guarantee the efficient NS1 secretion in the mosquito vector.", [["cell", "ANATOMY", 113, 117], ["lipid 313", "CHEMICAL", 10, 19], ["cholesterol", "CHEMICAL", 118, 129], ["cholesterol", "CHEMICAL", 118, 129], ["DENV NS1", "ORGANISM", 58, 66], ["mosquito 314 cell", "CELL", 100, 117], ["cholesterol", "SIMPLE_CHEMICAL", 118, 129], ["NS1", "GENE_OR_GENE_PRODUCT", 167, 170], ["DENV NS1", "PROTEIN", 58, 66], ["NS1", "PROTEIN", 167, 170], ["DENV", "SPECIES", 58, 62], ["the DENV NS1", "PROBLEM", 54, 66], ["mosquito 314 cell cholesterol transport", "TREATMENT", 100, 139], ["DENV NS1", "OBSERVATION", 58, 66], ["NS1 secretion", "OBSERVATION", 167, 180]]], ["However, the model predicts all these proteins interacting at the same 374 domain in NS1 (data not shown), which seems unlikely, due to steric effects.", [["NS1", "GENE_OR_GENE_PRODUCT", 85, 88], ["374 domain", "PROTEIN", 71, 81], ["NS1", "PROTEIN", 85, 88], ["steric effects", "PROBLEM", 136, 150], ["steric effects", "OBSERVATION", 136, 150]]], ["Thus, we favor an 375 alternative molecular docking model, based on interaction energies, in which NS1 is bound 376 directly to CAV-1, and in turn FKBP52, CyA and Cy40 are bound to CAV-1 (Fig. 10D ).", [["CyA", "CHEMICAL", 155, 158], ["CyA", "CHEMICAL", 155, 158], ["NS1", "GENE_OR_GENE_PRODUCT", 99, 102], ["CAV-1", "GENE_OR_GENE_PRODUCT", 128, 133], ["FKBP52", "GENE_OR_GENE_PRODUCT", 147, 153], ["CyA", "SIMPLE_CHEMICAL", 155, 158], ["Cy40", "GENE_OR_GENE_PRODUCT", 163, 167], ["CAV-1", "GENE_OR_GENE_PRODUCT", 181, 186], ["NS1", "PROTEIN", 99, 102], ["CAV-1", "DNA", 128, 133], ["FKBP52", "PROTEIN", 147, 153], ["Cy40", "PROTEIN", 163, 167], ["CAV-1", "DNA", 181, 186], ["CAV", "TEST", 128, 131], ["FKBP52", "TEST", 147, 153], ["CyA", "TEST", 155, 158], ["CAV", "TEST", 181, 184]]], ["This 377 model still allowed interaction of NS1 with the CCC through membranes.", [["membranes", "ANATOMY", 69, 78], ["NS1", "GENE_OR_GENE_PRODUCT", 44, 47], ["membranes", "CELLULAR_COMPONENT", 69, 78], ["NS1", "PROTEIN", 44, 47], ["CCC", "PROTEIN", 57, 60], ["NS1 with the CCC through membranes", "TREATMENT", 44, 78]]], ["However, if the NS1-378 CCC complex will traffic to the plasma membrane as a free-cytosolic complex or membrane 379 associated is totally unknown.", [["plasma membrane", "ANATOMY", 56, 71], ["cytosolic", "ANATOMY", 82, 91], ["membrane", "ANATOMY", 103, 111], ["NS1", "GENE_OR_GENE_PRODUCT", 16, 19], ["CCC", "GENE_OR_GENE_PRODUCT", 24, 27], ["plasma membrane", "CELLULAR_COMPONENT", 56, 71], ["membrane 379", "CELLULAR_COMPONENT", 103, 115], ["NS1", "PROTEIN", 16, 19], ["CCC complex", "PROTEIN", 24, 35], ["cytosolic complex", "PROTEIN", 82, 99], ["membrane 379", "PROTEIN", 103, 115], ["the NS1", "TEST", 12, 19]]], ["576 Lipid droplets were numbered in maximum projection images obtained by LSM 700 confocal", [["Lipid droplets", "ANATOMY", 4, 18], ["Lipid droplets", "TEST", 4, 18]]]], "PMC1197287": [["IntroductionThe genus Coronavirus belongs to the plus-strand RNA virus family of the Coronaviridae and currently contains about 25 species that are classified into three groups according to their genetic and serological relationships [1\u20134].", [["The genus Coronavirus", "PROBLEM", 12, 33], ["the Coronaviridae", "TREATMENT", 81, 98], ["genus Coronavirus", "OBSERVATION", 16, 33]]], ["Coronaviruses (CoVs) infect humans and multiple species of animals, causing a variety of highly prevalent and severe diseases [1,5].", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["CoVs", "GENE_OR_GENE_PRODUCT", 15, 19], ["humans", "ORGANISM", 28, 34], ["humans", "SPECIES", 28, 34], ["humans", "SPECIES", 28, 34], ["Coronaviruses (CoVs) infect humans", "PROBLEM", 0, 34], ["multiple species of animals", "PROBLEM", 39, 66], ["severe diseases", "PROBLEM", 110, 125], ["multiple", "OBSERVATION_MODIFIER", 39, 47], ["species", "OBSERVATION_MODIFIER", 48, 55], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["diseases", "OBSERVATION", 117, 125]]], ["For example, human coronavirus (HCoV) strains 229E (HCoV-229E), NL63 (HCoV-NL63), OC43 (HCoV-OC43), and HKU1 (HCoV-HKU1) cause a significant portion of upper and lower respiratory tract infections in humans, including common colds, bronchiolitis, and pneumonia.", [["lower respiratory tract", "ANATOMY", 162, 185], ["respiratory tract infections", "DISEASE", 168, 196], ["colds", "DISEASE", 225, 230], ["bronchiolitis", "DISEASE", 232, 245], ["pneumonia", "DISEASE", 251, 260], ["human coronavirus (HCoV) strains 229E", "ORGANISM", 13, 50], ["HCoV-229E", "ORGANISM", 52, 61], ["NL63", "GENE_OR_GENE_PRODUCT", 64, 68], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 70, 79], ["OC43", "GENE_OR_GENE_PRODUCT", 82, 86], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 88, 97], ["HKU1", "GENE_OR_GENE_PRODUCT", 104, 108], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 110, 119], ["upper", "ORGANISM_SUBDIVISION", 152, 157], ["lower", "ORGANISM_SUBDIVISION", 162, 167], ["respiratory tract", "ORGANISM_SUBDIVISION", 168, 185], ["humans", "ORGANISM", 200, 206], ["human", "SPECIES", 13, 18], ["coronavirus", "SPECIES", 19, 30], ["humans", "SPECIES", 200, 206], ["human coronavirus", "SPECIES", 13, 30], ["HCoV", "SPECIES", 32, 36], ["humans", "SPECIES", 200, 206], ["human coronavirus", "TEST", 13, 30], ["HCoV", "TEST", 32, 36], ["strains", "TEST", 38, 45], ["HCoV", "TEST", 52, 56], ["NL63", "TEST", 64, 68], ["HCoV", "TEST", 70, 74], ["OC43", "TEST", 82, 86], ["HCoV", "TEST", 88, 92], ["OC43", "TEST", 93, 97], ["HKU1", "TEST", 104, 108], ["HCoV", "TEST", 110, 114], ["upper and lower respiratory tract infections", "PROBLEM", 152, 196], ["common colds", "PROBLEM", 218, 230], ["bronchiolitis", "PROBLEM", 232, 245], ["pneumonia", "PROBLEM", 251, 260], ["significant", "OBSERVATION_MODIFIER", 129, 140], ["portion", "OBSERVATION_MODIFIER", 141, 148], ["upper", "ANATOMY_MODIFIER", 152, 157], ["lower", "ANATOMY_MODIFIER", 162, 167], ["respiratory tract", "ANATOMY", 168, 185], ["infections", "OBSERVATION", 186, 196], ["common", "OBSERVATION_MODIFIER", 218, 224], ["colds", "OBSERVATION", 225, 230], ["bronchiolitis", "OBSERVATION", 232, 245], ["pneumonia", "OBSERVATION", 251, 260]]], ["They have also been implicated in otitis media, exacerbations of asthma, diarrhea, myocarditis, and neurological disease [2,3,6\u20139].", [["neurological", "ANATOMY", 100, 112], ["otitis media", "DISEASE", 34, 46], ["asthma", "DISEASE", 65, 71], ["diarrhea", "DISEASE", 73, 81], ["myocarditis", "DISEASE", 83, 94], ["neurological disease", "DISEASE", 100, 120], ["otitis media", "PROBLEM", 34, 46], ["asthma", "PROBLEM", 65, 71], ["diarrhea", "PROBLEM", 73, 81], ["myocarditis", "PROBLEM", 83, 94], ["neurological disease", "PROBLEM", 100, 120], ["otitis", "OBSERVATION", 34, 40], ["asthma", "OBSERVATION", 65, 71], ["diarrhea", "OBSERVATION", 73, 81], ["myocarditis", "OBSERVATION", 83, 94], ["neurological disease", "OBSERVATION", 100, 120]]], ["A previously unknown HCoV, severe acute respiratory syndrome coronavirus (SARS-CoV), which is most closely related to the group II CoVs [10], proved to be the etiological agent of a global outbreak of a life-threatening form of pneumonia called severe acute respiratory syndrome (SARS), which, in 2003, was the cause of more than 800 fatalities worldwide [11\u201314].", [["acute respiratory syndrome coronavirus", "DISEASE", 34, 72], ["SARS-CoV)", "DISEASE", 74, 83], ["pneumonia", "DISEASE", 228, 237], ["acute respiratory syndrome", "DISEASE", 252, 278], ["SARS", "DISEASE", 280, 284], ["fatalities", "DISEASE", 334, 344], ["HCoV", "ORGANISM", 21, 25], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 27, 72], ["SARS-CoV", "ORGANISM", 74, 82], ["HCoV", "SPECIES", 21, 25], ["severe acute respiratory syndrome coronavirus", "SPECIES", 27, 72], ["SARS-CoV", "SPECIES", 74, 82], ["A previously unknown HCoV", "PROBLEM", 0, 25], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 27, 72], ["pneumonia", "PROBLEM", 228, 237], ["severe acute respiratory syndrome", "PROBLEM", 245, 278], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["respiratory syndrome coronavirus", "OBSERVATION", 40, 72], ["pneumonia", "OBSERVATION", 228, 237], ["severe", "OBSERVATION_MODIFIER", 245, 251], ["acute", "OBSERVATION_MODIFIER", 252, 257], ["respiratory syndrome", "OBSERVATION", 258, 278]]], ["Animal CoVs are mainly associated with enteric and respiratory diseases in livestock and domestic animals.", [["respiratory", "ANATOMY", 51, 62], ["enteric and respiratory diseases", "DISEASE", 39, 71], ["CoVs", "GENE_OR_GENE_PRODUCT", 7, 11], ["Animal CoVs", "PROBLEM", 0, 11], ["enteric and respiratory diseases", "PROBLEM", 39, 71], ["CoVs", "OBSERVATION", 7, 11], ["respiratory diseases", "OBSERVATION", 51, 71]]], ["Most of the viruses are highly contagious with significant mortality in young animals, resulting in considerable economic losses worldwide [5,9].IntroductionAlthough vaccines have been developed against avian infectious bronchitis virus (IBV), canine CoV, and porcine transmissible gastroenteritis virus (TGEV) to help prevent serious diseases, several potential problems remain.", [["avian infectious bronchitis virus", "DISEASE", 203, 236], ["transmissible gastroenteritis", "DISEASE", 268, 297], ["TGEV", "DISEASE", 305, 309], ["avian infectious bronchitis virus", "ORGANISM", 203, 236], ["IBV", "ORGANISM", 238, 241], ["canine CoV", "ORGANISM", 244, 254], ["porcine transmissible gastroenteritis virus", "ORGANISM", 260, 303], ["TGEV", "ORGANISM", 305, 309], ["avian infectious bronchitis virus", "SPECIES", 203, 236], ["canine", "SPECIES", 244, 250], ["porcine transmissible gastroenteritis virus", "SPECIES", 260, 303], ["avian infectious bronchitis virus", "SPECIES", 203, 236], ["IBV", "SPECIES", 238, 241], ["canine CoV", "SPECIES", 244, 254], ["porcine transmissible gastroenteritis virus", "SPECIES", 260, 303], ["TGEV", "SPECIES", 305, 309], ["the viruses", "PROBLEM", 8, 19], ["considerable economic losses worldwide", "PROBLEM", 100, 138], ["vaccines", "TREATMENT", 166, 174], ["avian infectious bronchitis virus", "PROBLEM", 203, 236], ["canine CoV", "PROBLEM", 244, 254], ["porcine transmissible gastroenteritis virus", "PROBLEM", 260, 303], ["serious diseases", "PROBLEM", 327, 343], ["several potential problems", "PROBLEM", 345, 371], ["viruses", "OBSERVATION", 12, 19], ["highly", "OBSERVATION_MODIFIER", 24, 30], ["contagious", "OBSERVATION_MODIFIER", 31, 41], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["mortality", "OBSERVATION", 59, 68], ["considerable", "OBSERVATION_MODIFIER", 100, 112], ["economic losses", "OBSERVATION", 113, 128], ["serious", "OBSERVATION_MODIFIER", 327, 334], ["diseases", "OBSERVATION", 335, 343]]], ["Vaccination against IBV is only partially successful due to the continual emergence of new serotypes and recombination events between field and vaccine strains.", [["IBV", "ORGANISM", 20, 23], ["IBV", "SPECIES", 20, 23], ["Vaccination", "TREATMENT", 0, 11], ["IBV", "PROBLEM", 20, 23], ["new serotypes", "TREATMENT", 87, 100], ["vaccine strains", "TREATMENT", 144, 159], ["new", "OBSERVATION_MODIFIER", 87, 90], ["serotypes", "OBSERVATION", 91, 100]]], ["The development of vaccines against feline infectious peritonitis virus (FIPV) has been frustrated by the phenomenon of antibody-dependent enhancement.", [["feline infectious peritonitis", "DISEASE", 36, 65], ["feline infectious peritonitis virus", "ORGANISM", 36, 71], ["feline infectious peritonitis virus", "SPECIES", 36, 71], ["feline infectious peritonitis virus", "SPECIES", 36, 71], ["FIPV", "SPECIES", 73, 77], ["vaccines", "TREATMENT", 19, 27], ["feline infectious peritonitis virus", "PROBLEM", 36, 71], ["antibody-dependent enhancement", "PROBLEM", 120, 150], ["infectious", "OBSERVATION_MODIFIER", 43, 53], ["peritonitis", "OBSERVATION", 54, 65], ["antibody", "OBSERVATION", 120, 128], ["dependent", "OBSERVATION_MODIFIER", 129, 138], ["enhancement", "OBSERVATION_MODIFIER", 139, 150]]], ["No licensed vaccines or specific drugs are available to prevent HCoV infection [6,9].", [["infection", "DISEASE", 69, 78], ["HCoV", "SIMPLE_CHEMICAL", 64, 68], ["HCoV", "SPECIES", 64, 68], ["licensed vaccines", "TREATMENT", 3, 20], ["specific drugs", "TREATMENT", 24, 38], ["HCoV infection", "PROBLEM", 64, 78], ["infection", "OBSERVATION", 69, 78]]], ["Following the SARS outbreak, a series of inhibitors was reported against the helicase and main protease (Mpro) of SARS-CoV to prevent viral replication [15\u201320].", [["SARS", "DISEASE", 14, 18], ["SARS-CoV", "ORGANISM", 114, 122], ["helicase", "PROTEIN", 77, 85], ["protease", "PROTEIN", 95, 103], ["Mpro", "PROTEIN", 105, 109], ["SARS-CoV", "SPECIES", 114, 122], ["the SARS outbreak", "PROBLEM", 10, 27], ["a series of inhibitors", "TREATMENT", 29, 51], ["the helicase", "TREATMENT", 73, 85], ["SARS", "PROBLEM", 114, 118], ["viral replication", "TREATMENT", 134, 151]]], ["However, previous research has only placed emphasis on SARS-CoV, and no structural data are available to confirm the direct interaction between these inhibitors and their targets, or for the further modification of these compounds.IntroductionIn common with other RNA viruses employing RNA-dependent RNA polymerases for genome replication, CoVs are generally thought to mutate at a high frequency [21], although this phenomenon remains to be studied in detail.", [["SARS", "DISEASE", 55, 59], ["SARS-CoV", "ORGANISM", 55, 63], ["CoVs", "GENE_OR_GENE_PRODUCT", 340, 344], ["RNA-dependent RNA polymerases", "PROTEIN", 286, 315], ["CoVs", "DNA", 340, 344], ["SARS-CoV", "SPECIES", 55, 63], ["SARS-CoV", "TEST", 55, 63], ["these inhibitors", "TREATMENT", 144, 160], ["IntroductionIn", "TREATMENT", 231, 245], ["other RNA viruses", "PROBLEM", 258, 275], ["RNA-dependent RNA polymerases", "TREATMENT", 286, 315], ["genome replication", "PROBLEM", 320, 338], ["CoVs", "PROBLEM", 340, 344], ["this phenomenon", "PROBLEM", 412, 427]]], ["During the SARS epidemic in China, the emergence of SARS-CoV suggested an animal\u2013human interspecies transmission [22,23].", [["SARS", "DISEASE", 11, 15], ["SARS", "DISEASE", 52, 56], ["SARS-CoV", "ORGANISM", 52, 60], ["SARS-CoV", "SPECIES", 52, 60], ["SARS", "PROBLEM", 52, 56]]], ["The virus continued evolving to adapt to the human host during the course of the outbreak [22] with about one-third the mutation rate of human immunodeficiency virus [24].", [["human immunodeficiency virus", "DISEASE", 137, 165], ["human", "ORGANISM", 45, 50], ["human immunodeficiency virus", "ORGANISM", 137, 165], ["human", "SPECIES", 45, 50], ["human immunodeficiency virus", "SPECIES", 137, 165], ["human", "SPECIES", 45, 50], ["human immunodeficiency virus", "SPECIES", 137, 165], ["The virus", "PROBLEM", 0, 9], ["human immunodeficiency virus", "PROBLEM", 137, 165], ["virus", "OBSERVATION", 4, 9]]], ["The high degree of similarity between genome sequences of bovine CoV and the recently sequenced HCoV-OC43 suggested an earlier animal-to-human interspecies transmission than SARS-CoV [25].", [["SARS", "DISEASE", 174, 178], ["bovine CoV", "ORGANISM", 58, 68], ["HCoV-OC43", "ORGANISM", 96, 105], ["human", "ORGANISM", 137, 142], ["SARS-CoV", "ORGANISM", 174, 182], ["HCoV", "DNA", 96, 100], ["OC43", "DNA", 101, 105], ["bovine", "SPECIES", 58, 64], ["human", "SPECIES", 137, 142], ["bovine CoV", "SPECIES", 58, 68], ["human", "SPECIES", 137, 142], ["SARS-CoV", "SPECIES", 174, 182], ["bovine CoV", "TEST", 58, 68], ["high degree", "OBSERVATION_MODIFIER", 4, 15], ["bovine CoV", "OBSERVATION", 58, 68]]], ["Moreover, a high frequency of RNA recombination is a common feature of CoV genetics and has been demonstrated for representative viruses from all CoV groups, including murine hepatitis virus (MHV), TGEV, and IBV [9,26].", [["murine hepatitis virus", "DISEASE", 168, 190], ["CoV", "ORGANISM", 71, 74], ["CoV", "ORGANISM", 146, 149], ["murine hepatitis virus", "ORGANISM", 168, 190], ["MHV", "ORGANISM", 192, 195], ["TGEV", "ORGANISM", 198, 202], ["IBV", "ORGANISM", 208, 211], ["murine hepatitis virus", "SPECIES", 168, 190], ["murine hepatitis virus", "SPECIES", 168, 190], ["MHV", "SPECIES", 192, 195], ["TGEV", "SPECIES", 198, 202], ["IBV", "SPECIES", 208, 211], ["a high frequency of RNA recombination", "PROBLEM", 10, 47], ["representative viruses", "PROBLEM", 114, 136], ["all CoV groups", "TREATMENT", 142, 156], ["murine hepatitis virus", "PROBLEM", 168, 190], ["TGEV", "PROBLEM", 198, 202], ["IBV", "PROBLEM", 208, 211], ["viruses", "OBSERVATION", 129, 136]]], ["For instance, the outbreaks caused by variant strains of IBV that arose from recombination of vaccine and wild-type virulent strains in chicken flocks limit the usage of vaccines against IBV [27,28].", [["IBV", "ORGANISM", 57, 60], ["wild-type virulent strains", "ORGANISM", 106, 132], ["chicken", "ORGANISM", 136, 143], ["IBV", "ORGANISM", 187, 190], ["chicken", "SPECIES", 136, 143], ["IBV", "SPECIES", 57, 60], ["chicken", "SPECIES", 136, 143], ["IBV", "SPECIES", 187, 190], ["IBV", "PROBLEM", 57, 60], ["vaccine", "TREATMENT", 94, 101], ["type virulent strains", "PROBLEM", 111, 132], ["vaccines", "TREATMENT", 170, 178], ["IBV", "PROBLEM", 187, 190]]], ["Consequently, it is of concern whether current vaccines or drugs in development will be effective against the next wave of attacks by altered SARS-CoV [22].IntroductionIn view of the issues posed above, the development of wide-spectrum drugs against the existing pathogenic CoVs is a more reasonable and attractive prospect than individual strategies for drug design, and thereby could provide an effective first line of defense against future emerging CoV-related diseases such as SARS.", [["SARS", "DISEASE", 482, 486], ["CoVs", "MULTI-TISSUE_STRUCTURE", 274, 278], ["CoV", "ORGANISM", 453, 456], ["SARS-CoV", "SPECIES", 142, 150], ["current vaccines", "TREATMENT", 39, 55], ["drugs", "TREATMENT", 59, 64], ["attacks", "PROBLEM", 123, 130], ["altered SARS", "PROBLEM", 134, 146], ["wide-spectrum drugs", "TREATMENT", 222, 241], ["the existing pathogenic CoVs", "PROBLEM", 250, 278], ["related diseases", "PROBLEM", 457, 473], ["SARS", "PROBLEM", 482, 486], ["pathogenic CoVs", "OBSERVATION", 263, 278]]], ["However, some of the key factors controlling the host spectrum and viral pathogenicity are highly variable among CoVs.", [["CoVs", "CANCER", 113, 117], ["viral pathogenicity", "PROBLEM", 67, 86], ["host spectrum", "OBSERVATION_MODIFIER", 49, 62], ["viral pathogenicity", "OBSERVATION", 67, 86]]], ["For instance, CoVs use different host receptors for cellular entry, have poorly conserved structural proteins (antigens), and encode diverse accessory genes in their 3'-terminal genome regions that probably contribute to the pathogenicity of CoVs in specific hosts [1\u20133,29\u201334].", [["cellular", "ANATOMY", 52, 60], ["CoVs", "GENE_OR_GENE_PRODUCT", 14, 18], ["cellular", "CELL", 52, 60], ["CoVs", "GENE_OR_GENE_PRODUCT", 242, 246], ["CoVs", "PROTEIN", 14, 18], ["structural proteins", "PROTEIN", 90, 109], ["antigens", "PROTEIN", 111, 119], ["accessory genes", "DNA", 141, 156], ["3'-terminal genome regions", "DNA", 166, 192], ["CoVs", "DNA", 242, 246], ["CoVs", "PROBLEM", 14, 18], ["cellular entry", "PROBLEM", 52, 66], ["the pathogenicity of CoVs", "PROBLEM", 221, 246], ["diverse", "OBSERVATION_MODIFIER", 133, 140], ["accessory genes", "OBSERVATION", 141, 156], ["probably contribute to", "UNCERTAINTY", 198, 220]]], ["Clearly, this structural and functional diversity presents a significant obstacle for designing a versatile compound against all CoVs unless a highly conserved target that is comparatively stable during evolution is identified within the genus Coronavirus.", [["CoVs", "GENE_OR_GENE_PRODUCT", 129, 133], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 244, 255], ["this structural and functional diversity", "PROBLEM", 9, 49], ["all CoVs", "PROBLEM", 125, 133], ["the genus Coronavirus", "PROBLEM", 234, 255], ["functional diversity", "OBSERVATION", 29, 49], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["comparatively", "OBSERVATION_MODIFIER", 175, 188], ["stable", "OBSERVATION_MODIFIER", 189, 195], ["genus Coronavirus", "OBSERVATION", 238, 255]]], ["Here we report the discovery of a highly conserved region based on four crystal structures and one homology model of Mpro representing all three genetic clusters of the genus Coronavirus, and a uniform inhibition mechanism revealed from the structures of Mpro-inhibitor complexes from SARS-CoV and TGEV.", [["Mpro", "GENE_OR_GENE_PRODUCT", 117, 121], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 175, 186], ["Mpro-inhibitor", "GENE_OR_GENE_PRODUCT", 255, 269], ["SARS-CoV", "ORGANISM", 285, 293], ["TGEV", "ORGANISM", 298, 302], ["Mpro", "PROTEIN", 117, 121], ["Mpro-inhibitor complexes", "PROTEIN", 255, 279], ["TGEV", "SPECIES", 298, 302], ["SARS-CoV", "SPECIES", 285, 293], ["TGEV", "SPECIES", 298, 302], ["the genus Coronavirus", "PROBLEM", 165, 186], ["a uniform inhibition mechanism", "TEST", 192, 222], ["SARS", "PROBLEM", 285, 289], ["TGEV", "PROBLEM", 298, 302], ["genus Coronavirus", "OBSERVATION", 169, 186]]], ["A structure-assisted optimization program has yielded compounds with fast in vitro inactivation of multiple CoV Mpros, potent antiviral activity, and extremely low cellular toxicity in cell-based assays.", [["cellular", "ANATOMY", 164, 172], ["cell", "ANATOMY", 185, 189], ["toxicity", "DISEASE", 173, 181], ["CoV", "ORGANISM", 108, 111], ["Mpros", "SIMPLE_CHEMICAL", 112, 117], ["cellular", "CELL", 164, 172], ["cell", "CELL", 185, 189], ["A structure-assisted optimization program", "TREATMENT", 0, 41], ["multiple CoV Mpros", "TREATMENT", 99, 117], ["potent antiviral activity", "PROBLEM", 119, 144], ["extremely low cellular toxicity", "PROBLEM", 150, 181], ["multiple", "OBSERVATION_MODIFIER", 99, 107], ["CoV Mpros", "OBSERVATION", 108, 117], ["antiviral activity", "OBSERVATION", 126, 144], ["low cellular", "OBSERVATION_MODIFIER", 160, 172], ["toxicity", "OBSERVATION", 173, 181]]], ["Further modification could rapidly lead to the discovery of a single agent with clinical potential against existing and possible future emerging CoV-associated diseases.Target Identification ::: Results/DiscussionDevelopment of wide-spectrum inhibitors is an attractive strategy against CoV-associated diseases; however, it entirely depends on the availability of a conserved target within the whole genus Coronavirus.", [["CoV", "ORGANISM", 145, 148], ["CoV", "ORGANISM", 287, 290], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 406, 417], ["future emerging CoV-associated diseases", "PROBLEM", 129, 168], ["wide-spectrum inhibitors", "TREATMENT", 228, 252], ["CoV-associated diseases", "PROBLEM", 287, 310], ["diseases", "OBSERVATION", 160, 168], ["diseases", "OBSERVATION", 302, 310], ["genus Coronavirus", "OBSERVATION", 400, 417]]], ["During the first round of target screening, all structural proteins (including S, E, M, HE, and N proteins) were excluded due to the considerable variations among different CoVs [1\u20133,33,34].", [["E", "GENE_OR_GENE_PRODUCT", 82, 83], ["HE", "GENE_OR_GENE_PRODUCT", 88, 90], ["CoVs", "SIMPLE_CHEMICAL", 173, 177], ["structural proteins", "PROTEIN", 48, 67], ["S", "PROTEIN", 79, 80], ["E", "PROTEIN", 82, 83], ["M", "PROTEIN", 85, 86], ["HE", "PROTEIN", 88, 90], ["N proteins", "PROTEIN", 96, 106], ["target screening", "TEST", 26, 42], ["all structural proteins", "TEST", 44, 67], ["S", "TEST", 79, 80], ["HE", "TEST", 88, 90], ["the considerable variations", "PROBLEM", 129, 156]]], ["Subsequently, the RNA-dependent RNA polymerase, RNA helicase, and Mpro constitute attractive potential nonstructural protein targets for consideration.", [["Mpro", "GENE_OR_GENE_PRODUCT", 66, 70], ["RNA-dependent RNA polymerase", "PROTEIN", 18, 46], ["RNA helicase", "PROTEIN", 48, 60], ["Mpro", "PROTEIN", 66, 70], ["the RNA", "TEST", 14, 21], ["RNA helicase", "TREATMENT", 48, 60], ["nonstructural protein targets", "OBSERVATION", 103, 132]]], ["However, no structural data were available for the former two proteins, increasing the difficulties for rational drug design and downstream modification of possible drug leads.Target Identification ::: Results/DiscussionThe pivotal roles played by Mpros in controlling viral replication and transcription through extensive processing of replicase polyproteins, together with the absence of closely related cellular homologues, identify the Mpro as a potentially important target for antiviral drug design [35].", [["cellular", "ANATOMY", 406, 414], ["Mpros", "GENE_OR_GENE_PRODUCT", 248, 253], ["cellular", "CELL", 406, 414], ["Mpro", "GENE_OR_GENE_PRODUCT", 440, 444], ["Mpros", "PROTEIN", 248, 253], ["replicase polyproteins", "PROTEIN", 337, 359], ["cellular homologues", "PROTEIN", 406, 425], ["Mpro", "PROTEIN", 440, 444], ["structural data", "TEST", 12, 27], ["rational drug design", "TREATMENT", 104, 124], ["viral replication", "TREATMENT", 269, 286], ["replicase polyproteins", "TREATMENT", 337, 359], ["antiviral drug design", "TREATMENT", 483, 504], ["possible", "UNCERTAINTY", 156, 164], ["drug leads", "OBSERVATION", 165, 175], ["replicase polyproteins", "OBSERVATION", 337, 359]]], ["However, pairwise BLAST of the primary sequences among CoV Mpros showed identities of only 38% in some cases.", [["CoV", "ORGANISM", 55, 58], ["CoV Mpros", "DNA", 55, 64], ["CoV Mpros", "SPECIES", 55, 64], ["the primary sequences", "TEST", 27, 48], ["CoV Mpros", "TEST", 55, 64], ["identities", "TEST", 72, 82]]], ["Since it is acknowledged that three-dimensional structures are more closely conserved than primary sequences, we decided to investigate the conservation among the CoV Mpro structures.", [["CoV", "ORGANISM", 163, 166], ["Mpro", "GENE_OR_GENE_PRODUCT", 167, 171], ["CoV Mpro structures", "DNA", 163, 182]]], ["As the Mpros showed comparatively high sequence similarity within each CoV group, representatives from every group were chosen for comparison.", [["Mpros", "GENE_OR_GENE_PRODUCT", 7, 12], ["Mpros", "DNA", 7, 12], ["the Mpros", "TEST", 3, 12]]], ["The structures of Mpros from TGEV (group I), HCoV-229E (group I), and SARS-CoV are available [36\u201338].", [["Mpros", "CHEMICAL", 18, 23], ["Mpros", "SIMPLE_CHEMICAL", 18, 23], ["TGEV", "ORGANISM", 29, 33], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 45, 54], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 70, 78], ["TGEV", "SPECIES", 29, 33], ["SARS-CoV", "SPECIES", 70, 78], ["HCoV", "TEST", 45, 49], ["SARS-CoV", "TEST", 70, 78]]], ["Although the crystal structure of IBV (group III) Mpro is currently under refinement by our group, it can nevertheless be used as an experiment-based model.", [["IBV", "ORGANISM", 34, 37], ["crystal", "OBSERVATION_MODIFIER", 13, 20], ["IBV", "OBSERVATION", 34, 37]]], ["As the structure of MHV Mpro (group II) was unavailable, and previous studies have shown that SARS-CoV is related to group II [10], we constructed a homology model for MHV Mpro based on the structure of SARS-CoV Mpro.", [["SARS", "DISEASE", 94, 98], ["MHV Mpro", "ORGANISM", 20, 28], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 94, 102], ["MHV", "ORGANISM", 168, 171], ["SARS-CoV Mpro", "ORGANISM", 203, 216], ["MHV Mpro", "PROTEIN", 20, 28], ["group II", "PROTEIN", 30, 38], ["MHV Mpro", "PROTEIN", 168, 176], ["SARS-CoV Mpro", "PROTEIN", 203, 216], ["MHV", "SPECIES", 20, 23], ["SARS-CoV", "SPECIES", 94, 102], ["MHV", "SPECIES", 168, 171], ["SARS-CoV", "SPECIES", 203, 211], ["previous studies", "TEST", 61, 77], ["SARS-CoV", "PROBLEM", 94, 102], ["MHV Mpro", "TREATMENT", 168, 176], ["SARS", "PROBLEM", 203, 207], ["CoV Mpro", "TREATMENT", 208, 216], ["MHV", "OBSERVATION_MODIFIER", 20, 23]]], ["Superposition of the crystal structures and homology model showed approximately 2 \u00c5 root mean square deviation for all 300 C\u03b1, but the most variable regions were the helical domain III and surface loops.", [["surface", "ANATOMY", 189, 196], ["C\u03b1", "PROTEIN", 123, 125], ["helical domain III", "PROTEIN", 166, 184], ["surface loops", "PROTEIN", 189, 202], ["homology model", "TEST", 44, 58], ["approximately", "OBSERVATION_MODIFIER", 66, 79], ["root", "OBSERVATION_MODIFIER", 84, 88], ["mean", "OBSERVATION_MODIFIER", 89, 93], ["square deviation", "OBSERVATION", 94, 110], ["surface loops", "OBSERVATION", 189, 202]]], ["The substrate-binding pockets located in a cleft between domains I and II, and especially the S4, S2, and S1 are highly conserved among CoV Mpros suggesting the possibility for wide-spectrum inhibitor design targeting this region in the Mpros of all CoVs.", [["S4", "GENE_OR_GENE_PRODUCT", 94, 96], ["S2", "GENE_OR_GENE_PRODUCT", 98, 100], ["S1", "GENE_OR_GENE_PRODUCT", 106, 108], ["CoV Mpros", "ORGANISM", 136, 145], ["CoVs", "GENE_OR_GENE_PRODUCT", 250, 254], ["substrate-binding pockets", "PROTEIN", 4, 29], ["I and II", "PROTEIN", 65, 73], ["S4", "PROTEIN", 94, 96], ["S2", "PROTEIN", 98, 100], ["S1", "PROTEIN", 106, 108], ["CoV Mpros", "PROTEIN", 136, 145], ["CoVs", "PROTEIN", 250, 254], ["The substrate-binding pockets", "PROBLEM", 0, 29], ["a cleft between domains I and II, and especially the S4, S2, and S1", "PROBLEM", 41, 108], ["wide-spectrum inhibitor design", "TREATMENT", 177, 207], ["binding pockets", "OBSERVATION", 14, 29], ["cleft", "OBSERVATION", 43, 48], ["S4", "ANATOMY_MODIFIER", 94, 96], ["S2", "ANATOMY", 98, 100], ["S1", "ANATOMY", 106, 108], ["suggesting the possibility for", "UNCERTAINTY", 146, 176], ["all CoVs", "ANATOMY", 246, 254]]], ["This hypothesis was further supported by enzyme activity assays (see Table 1).", [["enzyme activity assays", "TEST", 41, 63]]], ["Based on the assumption that the substrate-binding sites are highly conserved among CoV Mpros, a fluorescence-labeled substrate MCA-AVLQ\u2193SGFR-Lys(Dnp)-Lys-NH2 was synthesized to determine the kinetic parameters of TGEV, HCoV-229E, FIPV, MHV, IBV, and SARS-CoV Mpros.", [["SGFR-Lys", "CHEMICAL", 137, 145], ["Dnp", "CHEMICAL", 146, 149], ["Lys", "CHEMICAL", 151, 154], ["SGFR-Lys(Dnp)-Lys-NH2", "CHEMICAL", 137, 158], ["CoV", "ORGANISM", 84, 87], ["Mpros", "GENE_OR_GENE_PRODUCT", 88, 93], ["SGFR-Lys(Dnp)-Lys-NH2", "SIMPLE_CHEMICAL", 137, 158], ["TGEV", "ORGANISM", 214, 218], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 220, 229], ["FIPV", "GENE_OR_GENE_PRODUCT", 231, 235], ["MHV", "ORGANISM", 237, 240], ["IBV", "ORGANISM", 242, 245], ["SARS-CoV Mpros", "ORGANISM", 251, 265], ["substrate-binding sites", "DNA", 33, 56], ["CoV Mpros", "PROTEIN", 84, 93], ["MCA", "PROTEIN", 128, 131], ["AVLQ", "PROTEIN", 132, 136], ["SGFR", "PROTEIN", 137, 141], ["NH2", "PROTEIN", 155, 158], ["TGEV", "SPECIES", 214, 218], ["HCoV-229E", "SPECIES", 220, 229], ["MHV", "SPECIES", 237, 240], ["IBV", "SPECIES", 242, 245], ["SARS-CoV", "SPECIES", 251, 259], ["the substrate-binding sites", "PROBLEM", 29, 56], ["a fluorescence", "TEST", 95, 109], ["substrate MCA", "TEST", 118, 131], ["AVLQ", "TEST", 132, 136], ["SGFR", "TEST", 137, 141], ["Lys-NH2", "TREATMENT", 151, 158], ["TGEV", "TEST", 214, 218], ["HCoV", "TEST", 220, 224], ["FIPV", "TREATMENT", 231, 235], ["MHV", "TREATMENT", 237, 240], ["IBV", "TREATMENT", 242, 245], ["SARS", "PROBLEM", 251, 255]]], ["The substrate sequence was derived from residues P4\u2013P5\u2032 of the SARS-CoV Mpro N-terminal autoprocessing site, which has the sequence AVLQSGFRK.", [["N", "CHEMICAL", 77, 78], ["SARS-CoV Mpro N-terminal autoprocessing site", "DNA", 63, 107], ["AVLQSGFRK", "PROTEIN", 132, 141], ["SARS-CoV", "SPECIES", 63, 71], ["The substrate sequence", "TEST", 0, 22], ["the SARS", "TEST", 59, 67], ["CoV Mpro N-terminal autoprocessing site", "TREATMENT", 68, 107]]], ["IBV Mpro demonstrated an almost identical Km to that of SARS-CoV Mpro.", [["SARS", "DISEASE", 56, 60], ["IBV", "ORGANISM", 0, 3], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 56, 69], ["IBV", "SPECIES", 0, 3], ["SARS-CoV", "SPECIES", 56, 64], ["SARS", "PROBLEM", 56, 60], ["CoV Mpro", "TREATMENT", 61, 69]]], ["An interesting observation was that four other CoV proteases showed marginally stronger binding affinity to the substrate than SARS-CoV Mpro itself.", [["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 127, 140], ["CoV proteases", "PROTEIN", 47, 60], ["SARS-CoV", "SPECIES", 127, 135], ["four other CoV proteases", "TEST", 36, 60], ["marginally stronger binding affinity", "PROBLEM", 68, 104]]], ["These results further support the preliminary biochemical studies on conservation of substrates of CoV Mpros [39].First Round of Inhibitor Design: Michael Acceptor Inhibitors ::: Results/DiscussionThe structures of TGEV and SARS-CoV Mpros have previously been determined in complex with a substrate-analog chloromethyl ketone (CMK) inhibitor, Cbz-VNSTLQ-CMK.", [["SARS", "DISEASE", 224, 228], ["chloromethyl ketone", "CHEMICAL", 306, 325], ["Cbz-VNSTLQ-CMK", "CHEMICAL", 343, 357], ["chloromethyl ketone", "CHEMICAL", 306, 325], ["CMK", "CHEMICAL", 327, 330], ["Cbz-VNSTLQ-CMK", "CHEMICAL", 343, 357], ["CoV", "ORGANISM", 99, 102], ["TGEV", "ORGANISM", 215, 219], ["SARS-CoV Mpros", "ORGANISM", 224, 238], ["chloromethyl ketone", "SIMPLE_CHEMICAL", 306, 325], ["CMK", "SIMPLE_CHEMICAL", 327, 330], ["Cbz-VNSTLQ-CMK", "SIMPLE_CHEMICAL", 343, 357], ["TGEV", "SPECIES", 215, 219], ["SARS-CoV", "SPECIES", 224, 232], ["the preliminary biochemical studies", "TEST", 30, 65], ["CoV Mpros", "TEST", 99, 108], ["TGEV", "PROBLEM", 215, 219], ["SARS", "PROBLEM", 224, 228], ["a substrate-analog chloromethyl ketone (CMK) inhibitor", "TREATMENT", 287, 341]]], ["The sequence of this substrate-analog was derived from residues P6\u2013P1 of the N-terminal autoprocessing site of TGEV Mpro [36,38].", [["N-", "CHEMICAL", 77, 79], ["TGEV", "ORGANISM", 111, 115], ["N-terminal autoprocessing site", "PROTEIN", 77, 107], ["TGEV", "SPECIES", 111, 115], ["this substrate-analog", "TREATMENT", 16, 37], ["the N-terminal autoprocessing", "TREATMENT", 73, 102]]], ["However, the two protomers of SARS-CoV Mpro each exhibited an unexpected binding mode, possibly resulting from the comparatively weak binding of peptidyl elements derived from the substrate of TGEV Mpro and from the highly reactive electrophile CMK.", [["SARS", "DISEASE", 30, 34], ["Mpro", "CHEMICAL", 198, 202], ["CMK", "CHEMICAL", 245, 248], ["SARS-CoV Mpro", "ORGANISM", 30, 43], ["TGEV", "ORGANISM", 193, 197], ["Mpro", "GENE_OR_GENE_PRODUCT", 198, 202], ["CMK", "SIMPLE_CHEMICAL", 245, 248], ["peptidyl elements", "PROTEIN", 145, 162], ["TGEV Mpro", "PROTEIN", 193, 202], ["SARS-CoV", "SPECIES", 30, 38], ["TGEV", "SPECIES", 193, 197], ["SARS", "TEST", 30, 34], ["the comparatively weak binding of peptidyl elements", "PROBLEM", 111, 162], ["binding mode", "OBSERVATION", 73, 85], ["peptidyl elements", "OBSERVATION", 145, 162], ["highly", "OBSERVATION_MODIFIER", 216, 222], ["reactive", "OBSERVATION_MODIFIER", 223, 231], ["electrophile CMK", "OBSERVATION", 232, 248]]], ["This would suggest that nucleophilic attack might have occurred before a stable noncovalently bound enzyme-inhibitor complex was formed.", [["noncovalently bound enzyme-inhibitor complex", "PROTEIN", 80, 124], ["nucleophilic attack", "PROBLEM", 24, 43], ["a stable noncovalently bound enzyme-inhibitor complex", "PROBLEM", 71, 124], ["nucleophilic attack", "OBSERVATION", 24, 43], ["stable", "OBSERVATION_MODIFIER", 73, 79]]], ["Accordingly, the single binding mode in the TGEV Mpro complex was taken into account when designing possible broad-spectrum inhibitors on the basis of these structures and models.", [["TGEV", "ORGANISM", 44, 48], ["Mpro", "GENE_OR_GENE_PRODUCT", 49, 53], ["TGEV Mpro complex", "PROTEIN", 44, 61], ["TGEV", "SPECIES", 44, 48], ["broad-spectrum inhibitors", "TREATMENT", 109, 134]]], ["Although the CMK inhibitor is nonselective because of its high chemical reactivity and is susceptible to cleavage by gastric and enteric proteinases, it could provide structural insight into the substrate-binding pocket.", [["gastric", "ANATOMY", 117, 124], ["CMK", "GENE_OR_GENE_PRODUCT", 13, 16], ["gastric", "MULTI-TISSUE_STRUCTURE", 117, 124], ["enteric proteinases", "GENE_OR_GENE_PRODUCT", 129, 148], ["gastric and enteric proteinases", "PROTEIN", 117, 148], ["substrate-binding pocket", "PROTEIN", 195, 219], ["the CMK inhibitor", "TEST", 9, 26], ["its high chemical reactivity", "PROBLEM", 54, 82], ["gastric and enteric proteinases", "PROBLEM", 117, 148], ["gastric", "ANATOMY", 117, 124], ["enteric proteinases", "ANATOMY", 129, 148], ["binding pocket", "OBSERVATION", 205, 219]]], ["Superposition of the structures and model revealed that all these proteases have a His\u2013Cys catalytic dyad with relatively conserved orientations, in which His acts as a proton acceptor and Cys undergoes nucleophilic attack on the carbonyl carbon of the substrate.", [["Cys", "CHEMICAL", 189, 192], ["His\u2013Cys", "CHEMICAL", 83, 90], ["His", "CHEMICAL", 155, 158], ["Cys", "CHEMICAL", 189, 192], ["carbonyl carbon", "CHEMICAL", 230, 245], ["Cys", "AMINO_ACID", 189, 192], ["carbonyl carbon", "SIMPLE_CHEMICAL", 230, 245], ["proteases", "PROTEIN", 66, 75], ["His\u2013Cys catalytic dyad", "PROTEIN", 83, 105], ["a proton acceptor", "TREATMENT", 167, 184], ["nucleophilic attack", "PROBLEM", 203, 222], ["the carbonyl carbon of the substrate", "TREATMENT", 226, 262]]], ["It is widely accepted that increased inhibitor potency can be achieved provided that a covalent bond is formed between the active Cys residue and the designed compound, resembling the intermediate during substrate cleavage.", [["Cys", "CHEMICAL", 130, 133], ["increased inhibitor potency", "TREATMENT", 27, 54], ["a covalent bond", "TREATMENT", 85, 100], ["the active Cys residue", "PROBLEM", 119, 141], ["the designed compound", "PROBLEM", 146, 167], ["active", "OBSERVATION_MODIFIER", 123, 129], ["Cys residue", "OBSERVATION", 130, 141]]], ["The Michael acceptors, a class of conjugated carbonyl compounds, were successfully introduced to devise irreversible Cys protease inhibitors, including the antirhinovirus compound ruprintrivir (formerly designated AG7088) [40\u201342], and so the highly reactive electrophile CMK was replaced by a less reactive trans-\u03b1, \u03b2-unsaturated ethyl ester, which was expected to readily extend into the bulky S1\u2032 subsite of CoV Mpros.First Round of Inhibitor Design: Michael Acceptor Inhibitors ::: Results/DiscussionDuring our initial round of inhibitor design, we focused on the S1, S2, and S4 subsites crucial for substrate recognition and utilized a strategy for mimicking the substrate side chains of residues P4\u2013P1 to accommodate the corresponding subsites.", [["ruprintrivir", "CHEMICAL", 180, 192], ["[40\u201342]", "CHEMICAL", 222, 229], ["CMK", "CHEMICAL", 271, 274], ["trans-\u03b1, \u03b2-unsaturated ethyl ester", "CHEMICAL", 307, 341], ["carbonyl", "CHEMICAL", 45, 53], ["Cys", "CHEMICAL", 117, 120], ["ruprintrivir", "CHEMICAL", 180, 192], ["AG7088", "CHEMICAL", 214, 220], ["CMK", "CHEMICAL", 271, 274], ["trans-\u03b1, \u03b2-unsaturated ethyl ester", "CHEMICAL", 307, 341], ["Michael acceptors", "SIMPLE_CHEMICAL", 4, 21], ["conjugated carbonyl compounds", "SIMPLE_CHEMICAL", 34, 63], ["ruprintrivir", "SIMPLE_CHEMICAL", 180, 192], ["AG7088", "SIMPLE_CHEMICAL", 214, 220], ["CMK", "SIMPLE_CHEMICAL", 271, 274], ["trans-\u03b1, \u03b2-unsaturated ethyl ester", "SIMPLE_CHEMICAL", 307, 341], ["CoV", "ORGANISM", 410, 413], ["Michael Acceptor", "SIMPLE_CHEMICAL", 453, 469], ["S2", "GENE_OR_GENE_PRODUCT", 571, 573], ["bulky S1\u2032 subsite", "PROTEIN", 389, 406], ["CoV Mpros", "PROTEIN", 410, 419], ["S1, S2, and S4 subsites", "PROTEIN", 567, 590], ["conjugated carbonyl compounds", "TREATMENT", 34, 63], ["irreversible Cys protease inhibitors", "TREATMENT", 104, 140], ["the antirhinovirus compound ruprintrivir", "TREATMENT", 152, 192], ["\u03b2-unsaturated ethyl ester", "TREATMENT", 316, 341], ["inhibitor design", "TREATMENT", 531, 547], ["a strategy", "TREATMENT", 638, 648], ["mimicking the substrate side chains of residues P4\u2013P1", "TREATMENT", 653, 706], ["the corresponding subsites", "PROBLEM", 722, 748], ["reactive", "OBSERVATION_MODIFIER", 249, 257], ["electrophile CMK", "OBSERVATION", 258, 274], ["reactive", "OBSERVATION_MODIFIER", 298, 306], ["bulky", "OBSERVATION_MODIFIER", 389, 394], ["CoV Mpros", "OBSERVATION", 410, 419], ["S2", "ANATOMY", 571, 573]]], ["Since backbones of CoV Mpros constituting this area superimposed particularly well, except for a small segment located on the outer wall of S2, we concentrated on the variation of side chains forming these pockets.", [["outer wall", "ANATOMY", 126, 136], ["CoV", "ORGANISM", 19, 22], ["Mpros", "GENE_OR_GENE_PRODUCT", 23, 28], ["outer wall", "CELLULAR_COMPONENT", 126, 136], ["CoV Mpros", "PROTEIN", 19, 28], ["S2", "PROTEIN", 140, 142], ["side chains", "PROTEIN", 180, 191], ["CoV Mpros", "TREATMENT", 19, 28], ["a small segment", "PROBLEM", 95, 110], ["these pockets", "PROBLEM", 200, 213], ["CoV Mpros", "OBSERVATION", 19, 28], ["small", "OBSERVATION_MODIFIER", 97, 102], ["segment", "OBSERVATION_MODIFIER", 103, 110], ["outer", "ANATOMY_MODIFIER", 126, 131], ["wall", "ANATOMY_MODIFIER", 132, 136], ["S2", "ANATOMY", 140, 142], ["concentrated", "OBSERVATION_MODIFIER", 147, 159], ["side chains", "OBSERVATION_MODIFIER", 180, 191], ["pockets", "OBSERVATION_MODIFIER", 206, 213]]], ["In the TGEV Mpro complex structure [36], the side chains of 165-Glu, 162-His, 171-His, and 139-Phe (also conserved in other Mpros) are incorporated with other backbone elements to constitute the S1 site, which has an absolute requirement for Gln at the P1 position via two hydrogen bonds.", [["165-Glu", "CHEMICAL", 60, 67], ["162-His, 171-His, and 139-Phe", "CHEMICAL", 69, 98], ["Gln", "CHEMICAL", 242, 245], ["165-Glu, 162-His, 171-His, and 139-Phe", "CHEMICAL", 60, 98], ["Gln", "CHEMICAL", 242, 245], ["hydrogen", "CHEMICAL", 273, 281], ["TGEV", "ORGANISM", 7, 11], ["165-Glu", "SIMPLE_CHEMICAL", 60, 67], ["162-His", "SIMPLE_CHEMICAL", 69, 76], ["171-His", "SIMPLE_CHEMICAL", 78, 85], ["139-Phe", "AMINO_ACID", 91, 98], ["Gln", "AMINO_ACID", 242, 245], ["TGEV Mpro complex", "PROTEIN", 7, 24], ["Mpros", "PROTEIN", 124, 129], ["S1 site", "DNA", 195, 202], ["P1 position", "PROTEIN", 253, 264], ["TGEV", "SPECIES", 7, 11], ["TGEV", "SPECIES", 7, 11], ["the side chains", "TEST", 41, 56], ["Glu", "TEST", 64, 67], ["an absolute requirement", "PROBLEM", 214, 237], ["Gln at the P1 position", "TREATMENT", 242, 264], ["backbone elements", "OBSERVATION", 159, 176], ["S1", "ANATOMY", 195, 197], ["absolute requirement", "OBSERVATION", 217, 237], ["hydrogen bonds", "OBSERVATION", 273, 287]]], ["Modeling showed that a lactam with (S) stereochemistry at the \u03b1-carbon might preserve the hydrogen bonds essential for S1 recognition; moreover, a comparatively bulky lactam ring would create additional van der Waals interactions.", [["lactam", "CHEMICAL", 23, 29], ["\u03b1-carbon", "CHEMICAL", 62, 70], ["lactam", "CHEMICAL", 167, 173], ["lactam", "CHEMICAL", 23, 29], ["\u03b1-carbon", "CHEMICAL", 62, 70], ["hydrogen", "CHEMICAL", 90, 98], ["lactam", "CHEMICAL", 167, 173], ["(S) stereochemistry", "SIMPLE_CHEMICAL", 35, 54], ["\u03b1-carbon", "SIMPLE_CHEMICAL", 62, 70], ["S1", "PROTEIN", 119, 121], ["a lactam with (S) stereochemistry", "TREATMENT", 21, 54], ["S1 recognition", "PROBLEM", 119, 133], ["a comparatively bulky lactam ring", "TREATMENT", 145, 178], ["additional van der Waals interactions", "TREATMENT", 192, 229], ["hydrogen bonds", "OBSERVATION", 90, 104]]], ["The side chains of 164-Leu, 51-Ile, 41-His, and 53-Tyr, as well as the alkyl portion of side chains of 186-Asp and 47-Thr, are involved in forming a deep hydrophobic S2 subsite that can accommodate the relatively large side chain of Leu in TGEV Mpro.", [["164-Leu", "CHEMICAL", 19, 26], ["51-Ile, 41-His, and 53-Tyr", "CHEMICAL", 28, 54], ["alkyl", "CHEMICAL", 71, 76], ["186-Asp and 47-Thr", "CHEMICAL", 103, 121], ["Leu", "CHEMICAL", 233, 236], ["164-Leu, 51-Ile, 41-His", "CHEMICAL", 19, 42], ["53-Tyr", "CHEMICAL", 48, 54], ["Asp", "CHEMICAL", 107, 110], ["47-Thr", "CHEMICAL", 115, 121], ["Leu", "CHEMICAL", 233, 236], ["164-Leu", "SIMPLE_CHEMICAL", 19, 26], ["51-Ile", "SIMPLE_CHEMICAL", 28, 34], ["41-His", "SIMPLE_CHEMICAL", 36, 42], ["53-Tyr", "SIMPLE_CHEMICAL", 48, 54], ["186-Asp", "SIMPLE_CHEMICAL", 103, 110], ["47-Thr", "AMINO_ACID", 115, 121], ["Leu", "AMINO_ACID", 233, 236], ["TGEV", "ORGANISM", 240, 244], ["deep hydrophobic S2 subsite", "PROTEIN", 149, 176], ["TGEV Mpro", "SPECIES", 240, 249], ["The side chains", "TEST", 0, 15], ["Leu", "TEST", 23, 26], ["His", "TEST", 39, 42], ["Asp", "TEST", 107, 110], ["a deep hydrophobic S2 subsite", "PROBLEM", 147, 176], ["Leu in TGEV Mpro", "TREATMENT", 233, 249], ["alkyl", "ANATOMY_MODIFIER", 71, 76], ["deep", "ANATOMY_MODIFIER", 149, 153], ["hydrophobic S2 subsite", "OBSERVATION", 154, 176], ["relatively", "OBSERVATION_MODIFIER", 202, 212], ["large", "OBSERVATION_MODIFIER", 213, 218], ["TGEV Mpro", "OBSERVATION", 240, 249]]], ["This feature can also be observed in the HCoV-229E Mpro.", [["HCoV-229E Mpro", "CELL_LINE", 41, 55], ["HCoV-229E Mpro", "SPECIES", 41, 55], ["the HCoV", "TEST", 37, 45]]], ["Several conservative substitutions occur in other CoV Mpros (164-Leu \u2192 165-Met in SARS-CoV and MHV Mpros; 53-Tyr \u2192 50-Trp in IBV Mpro).", [["164-Leu", "CHEMICAL", 61, 68], ["Leu", "CHEMICAL", 65, 68], ["Tyr", "CHEMICAL", 109, 112], ["Trp", "CHEMICAL", 118, 121], ["CoV", "ORGANISM", 50, 53], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["SARS-CoV", "SPECIES", 82, 90], ["IBV", "SPECIES", 125, 128], ["Several conservative substitutions", "PROBLEM", 0, 34], ["CoV Mpros", "TEST", 50, 59], ["Leu \u2192", "TEST", 65, 70], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["MHV Mpros", "TEST", 95, 104], ["Trp in IBV Mpro", "TREATMENT", 118, 133], ["conservative substitutions", "OBSERVATION", 8, 34]]], ["Another minor difference was observed in SARS-CoV and MHV Mpros, where the outer wall segment is composed of a short 310-helix from residues 45\u201350, compared with a less regular structure in HCoV and TGEV Mpro.", [["outer wall", "ANATOMY", 75, 85], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 41, 49], ["MHV Mpros", "ORGANISM", 54, 63], ["HCoV", "CANCER", 190, 194], ["TGEV", "ORGANISM", 199, 203], ["MHV Mpros", "PROTEIN", 54, 63], ["HCoV", "PROTEIN", 190, 194], ["TGEV Mpro", "PROTEIN", 199, 208], ["SARS-CoV", "SPECIES", 41, 49], ["MHV", "SPECIES", 54, 57], ["HCoV", "SPECIES", 190, 194], ["TGEV", "SPECIES", 199, 203], ["SARS", "PROBLEM", 41, 45], ["MHV Mpros", "TREATMENT", 54, 63], ["TGEV Mpro", "TREATMENT", 199, 208], ["minor", "OBSERVATION_MODIFIER", 8, 13], ["difference", "OBSERVATION_MODIFIER", 14, 24], ["MHV Mpros", "OBSERVATION", 54, 63], ["outer", "ANATOMY_MODIFIER", 75, 80], ["wall", "ANATOMY_MODIFIER", 81, 85], ["segment", "ANATOMY_MODIFIER", 86, 93]]], ["With respect to the structure of IBV Mpro undergoing refinement, no clear electron density was observed in the corresponding stretch of residues 44\u201347.", [["Mpro", "CHEMICAL", 37, 41], ["residues 44\u201347", "CHEMICAL", 136, 150], ["IBV", "ORGANISM", 33, 36], ["electron", "SIMPLE_CHEMICAL", 74, 82], ["IBV", "SPECIES", 33, 36], ["clear electron density", "PROBLEM", 68, 90], ["IBV", "OBSERVATION", 33, 36], ["no", "UNCERTAINTY", 65, 67], ["density", "OBSERVATION", 83, 90]]], ["We reasoned that variations in the segment located on the outer wall of S2 should not significantly affect the hydrophobicity of this deep subsite.", [["outer wall", "ANATOMY", 58, 68], ["this deep subsite", "PROBLEM", 129, 146], ["variations", "OBSERVATION_MODIFIER", 17, 27], ["segment", "ANATOMY_MODIFIER", 35, 42], ["outer", "ANATOMY_MODIFIER", 58, 63], ["wall", "ANATOMY_MODIFIER", 64, 68], ["S2", "ANATOMY", 72, 74], ["hydrophobicity", "OBSERVATION_MODIFIER", 111, 125]]], ["This is supported by evidence wherein Leu is found at position P2 of substrates for all CoV Mpros.", [["Leu", "CHEMICAL", 38, 41], ["Leu", "CHEMICAL", 38, 41], ["Leu", "AMINO_ACID", 38, 41], ["CoV Mpros", "PROTEIN", 88, 97], ["all CoV Mpros", "TREATMENT", 84, 97], ["Leu", "OBSERVATION", 38, 41], ["CoV Mpros", "OBSERVATION", 88, 97]]], ["As P2 Phe is present in the C-terminal autocleavage site of SARS-CoV, phenyl was used as a smaller substituent to explore this subsite.", [["Phe", "CHEMICAL", 6, 9], ["SARS-CoV, phenyl", "CHEMICAL", 60, 76], ["Phe", "CHEMICAL", 6, 9], ["C", "CHEMICAL", 28, 29], ["phenyl", "CHEMICAL", 70, 76], ["Phe", "AMINO_ACID", 6, 9], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["phenyl", "SIMPLE_CHEMICAL", 70, 76], ["P2", "DNA", 3, 5], ["C-terminal autocleavage site", "DNA", 28, 56], ["SARS-CoV", "SPECIES", 60, 68], ["SARS", "PROBLEM", 60, 64], ["phenyl", "TREATMENT", 70, 76], ["a smaller substituent", "TREATMENT", 89, 110], ["this subsite", "PROBLEM", 122, 134], ["terminal", "ANATOMY_MODIFIER", 30, 38], ["SARS", "OBSERVATION", 60, 64]]], ["The side chain of Thr at P3 is solvent-exposed, so this site was expected to tolerate a wide range of functionality.", [["Thr", "CHEMICAL", 18, 21], ["Thr", "CHEMICAL", 18, 21], ["Thr", "AMINO_ACID", 18, 21], ["Thr at P3", "TREATMENT", 18, 27], ["side chain", "OBSERVATION_MODIFIER", 4, 14], ["Thr", "OBSERVATION", 18, 21], ["solvent", "OBSERVATION_MODIFIER", 31, 38]]], ["The side chains of 164-Leu, 166-Leu, 184-Tyr, and 191-Gln that form the S4 hydrophobic subsite of TGEV are conserved in other CoV Mpros, excluding the following conservative substitutions: 184-Tyr \u2192 184-Phe in HCoV Mpro; 164-Leu \u2192 165-Met, 184-Tyr \u2192 185-Phe in SARS-CoV.", [["164-Leu", "CHEMICAL", 19, 26], ["166-Leu, 184-Tyr", "CHEMICAL", 28, 44], ["191-Gln", "CHEMICAL", 50, 57], ["164-Leu, 166-Leu, 184-Tyr", "CHEMICAL", 19, 44], ["191-Gln", "CHEMICAL", 50, 57], ["Tyr", "CHEMICAL", 193, 196], ["Phe", "CHEMICAL", 203, 206], ["164-Leu \u2192 165-Met, 184-Tyr \u2192 185-Phe", "CHEMICAL", 221, 257], ["164-Leu", "SIMPLE_CHEMICAL", 19, 26], ["166-Leu", "AMINO_ACID", 28, 35], ["184-Tyr", "AMINO_ACID", 37, 44], ["191-Gln", "AMINO_ACID", 50, 57], ["TGEV", "ORGANISM", 98, 102], ["CoV Mpros", "ORGANISM", 126, 135], ["Phe", "AMINO_ACID", 203, 206], ["184-Tyr \u2192 185-Phe", "AMINO_ACID", 240, 257], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 261, 269], ["S4 hydrophobic subsite", "PROTEIN", 72, 94], ["CoV Mpros", "PROTEIN", 126, 135], ["TGEV", "SPECIES", 98, 102], ["SARS-CoV", "SPECIES", 261, 269], ["The side chains", "TEST", 0, 15], ["Leu", "TEST", 23, 26], ["Leu", "TEST", 32, 35], ["Tyr", "TEST", 41, 44], ["TGEV", "PROBLEM", 98, 102], ["conservative substitutions", "TEST", 161, 187], ["Tyr \u2192", "TEST", 193, 198], ["Phe", "TEST", 203, 206], ["Mpro", "TEST", 215, 219], ["Leu", "TEST", 225, 228], ["Met", "TEST", 235, 238], ["Tyr \u2192", "TEST", 244, 249], ["Phe in SARS", "TEST", 254, 265], ["CoV", "TEST", 266, 269]]], ["A tertiary butyloxycarbonyl was introduced at the P4 position as an N-terminal protecting group to enter into the S4 site.", [["butyloxycarbonyl", "CHEMICAL", 11, 27], ["tertiary butyloxycarbonyl", "CHEMICAL", 2, 27], ["N", "CHEMICAL", 68, 69], ["butyloxycarbonyl", "SIMPLE_CHEMICAL", 11, 27], ["N-terminal protecting group", "PROTEIN", 68, 95], ["S4 site", "DNA", 114, 121], ["A tertiary butyloxycarbonyl", "TREATMENT", 0, 27], ["an N-terminal protecting group", "TREATMENT", 65, 95], ["S4", "ANATOMY", 114, 116]]], ["Thus, by combining the modifications above, a novel compound designated as I2 (see Figure 1A) was designed and a series of analogs was synthesized for the inhibition assay (see Protocol S1).Kinetic Mechanism of Michael Acceptor Inhibitors ::: Results/DiscussionCovalent irreversible inactivation of CoV Mpros by Michael acceptor inhibitors proceeds according to the kinetic mechanism presented in the scheme below:Kinetic Mechanism of Michael Acceptor Inhibitors ::: Results/Discussion", [["Mpros", "CHEMICAL", 303, 308], ["Michael Acceptor", "SIMPLE_CHEMICAL", 211, 227], ["CoV Mpros", "SIMPLE_CHEMICAL", 299, 308], ["Michael acceptor inhibitors", "SIMPLE_CHEMICAL", 312, 339], ["Michael Acceptor", "SIMPLE_CHEMICAL", 435, 451], ["analogs", "TREATMENT", 123, 130], ["the inhibition assay", "TEST", 151, 171], ["Covalent irreversible inactivation of CoV Mpros", "TREATMENT", 261, 308], ["Michael acceptor inhibitors", "TREATMENT", 312, 339]]]]}